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Summary 
Alzheimer`s disease is the most common form of dementia.  It is characterised by the 
accumulation of amyloid plaques and neurofibrillary tangles in the brain.  Plaques mainly 
consist of the 40- or 42-amino-acid amyloid-β peptide (Aβ), which is derived through 
proteolysis of the amyloid precursor protein (APP) by β- and γ-secretase.  In contrast, α-
secretase prevents the formation of Aβ by cleaving APP within the Aβ domain.  There is 
strong evidence that ADAM10 (a disintegrin and metalloproteinase) acts as α-secretase in 
vivo whereas BACE1 (beta-site APP cleaving enzyme) acts as β-secretase. 
ADAM10 has a 444 nucleotide conserved 5`untranslated region (UTR) with potential 
upstream open reading frames (uORFs) and a guanine-cytosine (GC) content of 70%.  
Recently, our group could demonstrate that the 5’UTR of ADAM10 inhibits ADAM10 
translation. 
Since the protein expression of ADAM10 is repressed by its 5`UTR, the possible 
involvement of 5`UTR RNA-binding proteins in this process was examined in this work. 
Using Electrophoretic mobility shift assays (EMSAs) and UV crosslink experiments, I 
could show that proteins bind to the 5’UTR of ADAM10 and thus are potential candidates 
which might modify ADAM10 translation.  To identify these interacting proteins, a 
streptavidin-based affinity chromatography purification method coupled to mass 
spectrometry was established and a UTR-database search was performed.  Mass 
spectrometry analysis revealed several RNA-binding proteins as ADAM10 5`UTR 
interactors, including Unr, a protein involved in translational regulation and mRNA 
stability of certain transcripts.  A UTR-database search revealed Unr, as candidate RNA-
binding protein of the ADAM10 5`UTR. 
The interaction of Unr with the ADAM10 5`UTR was confirmed by EMSAs with 
recombinant Unr.  The formation of the ADAM10 5`UTR-Unr complex was visible in the 
gel through a delay in the running behaviour in comparison with the free RNA.  Deletion 
of an 83 purine-rich nucleotide stretch within the 5’UTR abolished the binding of 
recombinant Unr to the 5’UTR of ADAM10 and resulted in an increase of ADAM10 
expression.  Moreover, upon Unr knockdown reduced levels of ADAM10 as well as 
reduced ADAM10 mRNA were observed.  Due to the reduced ADAM10 protein levels, 
the ADAM10 dependent shedding of APP was reduced.  Overexpression of Unr resulted in 
a minor change of ADAM10 expression with no change in ADAM10 mRNA. 
Summary 
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In summary, this study demonstrated that the cytoplasmic protein Unr is able to bind 
to the 5’UTR of ADAM10.  Unr may contribute to the translational repression of 
ADAM10 protein expression and in addition to the stabilisation of the ADAM10 mRNA.  
Zusammenfassung 
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Zusammenfassung 
Die Alzheimer Krankheit ist die weltweit am häufigsten vorkommende Altersdemenz.  
Die Akkumulation von extrazellulären Amyloid-Plaques und von intrazellulären 
neurofibrillären Bündeln ist das charakteristische Merkmal der Alzheimer Krankheit.  
Amyloid-Plaques bestehen überwiegend aus dem 40-42 Aminosäuren langem Amyloid β-
Peptid (Aβ), das durch sequenzielle proteolytische Spaltung durch die β- und γ-Sekretase 
aus dem β-Amyloid-Vorläuferprotein (APP) entsteht.  Im Gegensatz dazu verhindert die α-
Sekretase die Bildung von Aβ durch Spaltung von APP in der Mitte der Aβ-Domäne.  
Verschiedene Studien deuten darauf hin, dass ADAM10 in vivo als α-Sekretase fungiert 
und BACE1 als β-Sekretase. 
ADAM10 hat eine 444 Nukleotide lange konservierte 5`untranslatierte Region 
(5`UTR) mit potenziellen uORFs und einem GC-Gehalt von 70%.  Kürzlich konnte unsere 
Gruppe zeigen, dass die 5`UTR von ADAM10 die Translationsrate von ADAM10 
inhibiert. 
Da die Proteinexpression von ADAM10 durch ihre 5`UTR inhibiert wird, sollte in 
dieser Arbeit die mögliche Beteiligung von RNA-bindenden Proteinen an diesem Prozess 
untersucht werden.  Mit Hilfe von Electrophoretic Mobility Shift Assays (EMSAs) und UV 
Crosslink Experimenten konnte ich zeigen, dass mehrere Proteine selektiv an die 5`UTR 
von ADAM10 binden.  Um die möglichen Bindekandidaten zu identifizieren, wurde eine 
auf Biotin-Streptavidin-basierende Affinitätschromatographie als Reinigungsmethode 
entwickelt und eine UTR-Datenbanksuche durchgeführt.  Mit Hilfe von 
Massenspektrometrieanalyse wurden mehrere potenzielle RNA-bindende Proteine, 
darunter Unr, als Bindekandidaten der ADAM10 5`UTR identifiziert.  Unr ist ein 
zytosolisches Protein, das an der translationellen Kontrolle verschiedener Proteine beteiligt 
ist.  Die UTR-Datenbanksuche bestätigte Unr als ADAM10 5`UTR bindendes Protein. 
Anhand von EMSAs mit rekombinantem Unr konnte die Bindung von Unr an die 
5`UTR von ADAM10 bestätigt werden.  Die Deletion einer 83 Nukleotide langen, Purin-
reichen Nukleotidsequenz in der 5`UTR verhindert die Bindung von rekombinantem Unr 
an die 5`UTR von ADAM10 und resultiert in einer erhöhten ADAM10 Expression.  Des 
Weiteren wurden Zellen hergestellt, in denen Unr herrunterreguliert ist.  In diesen Zellen 
werden sowohl reduzierte ADAM10 Proteinmengen als auch ADAM10 mRNA 
beobachtet.  Auf Grund des reduzierten ADAM10 Proteinspiegels ist die Spaltung von 
APP durch die α-Sekretase ADAM10 reduziert.  Die Überexpression von Unr resultiert in 
Zusammenfassung 
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einer minimalen Veränderung der ADAM10 Expression ohne Veränderung der ADAM10 
mRNA Mengen. 
Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass das zytosolische 
Protein Unr an die 5`UTR von ADAM10 binden kann.  Unr ist möglicherweise ein 
Translationshemmer für die ADAM10 Expression und ist wichtig für die Stabilität der 
ADAM10 mRNA. 
Introduction 
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1 Introduction 
1.1 Histopathology of Alzheimer’s disease 
Alzheimer's disease (AD) is the most common form of dementia among older people 
and affects the parts of the brain that control thought, memory and language (Figure 1.1) 
(Selkoe, 2001a). 
 
 
Figure 1.1 Representation of a cross-section of a brain as seen from the front. 
The cross-section on the left represents a normal brain and the one on the right represents a brain 
with AD. (Resource: American Health Assistance Foundation (http://www.ahaf.org/)) 
 
 
About 18 million people worldwide are currently affected by AD.  Since ageing is the 
major risk factor for AD, the number of people affected increases markedly with advanced 
age.  The disease usually begins after age of 60.  Of people over 65-year-olds only 5-10% 
develop AD symptoms, while for those over 85 years the probability increases to 30-50%.  
Thus, after the age of 65 the risk of AD doubles every five years (Evans et al., 1989; 
Kawas et al., 2000). 
Symptoms of AD include memory loss, language deterioration, impaired ability to 
mentally manipulate visual information, poor judgement, confusion, restlessness and mood 
swings (Parihar and Hemnani, 2004).  The early symptoms, which include forgetfulness 
and loss of concentration, are often missed because they resemble natural signs of ageing 
(Selkoe, 2001a). 
The disease is named after Dr. Alois Alzheimer, a German physician.  In 1906, Dr. 
Alois Alzheimer reported the first AD patient, Auguste D. (Figure 1.2).  Dr. Alzheimer for 
the first time described changes in the brain tissue of Auguste D. who had died of an 
unusual mental illness (Alzheimer, 1907). 
Introduction 
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Figure 1.2 Alois Alzheimer and Auguste D. (Maurer and Maurer, 1998). 
Photographs of Alois Alzheimer on the left and his patient Auguste D. on the right. 
 
 
The symptoms described were progressive memory impairment, disordered cognitive 
function, altered behaviour including paranoia, delusions, loss of social appropriateness 
and a progressive decline in language function (Alzheimer, 1907).  Post-mortem, the brain 
of the patient showed atrophy and “many fibrils” in the cell and “miliary foci” all over the 
cortex, especially in the upper layers, which were observed by silver staining.  These 
lesions, that Alzheimer reported more than 100 years ago, are the pathological hallmarks of 
AD, which today are described as neuronal cell loss, the intracellular accumulation of 
neurofibrillary tangles and the extracellular deposition of senile plaques. 
One of the hallmarks of AD is the presence of characteristic extracellular deposited 
senile plaques in the brains of patients (Figure 1.3).  They are usually found in brain 
regions such as hippocampus, amygdala, cortical and subcortical areas (LaFerla and Oddo, 
2005; Selkoe, 2001a; Selkoe, 2001b) and are primarily composed of the amyloid β-peptide 
(Aβ) (Glenner and Wong, 1984).  The Aβ peptide is liberated from a larger membrane 
protein, the amyloid precursor protein (APP).  The peptide is highly hydrophobic and 
aggregates to form oligomers and fibers.  It is secreted by all cells throughout the body, but 
is produced in particularly large amounts by neurons in the brain.  Analysis of the amyloid 
plaques found in the brains of AD patients revealed that they are mainly composed of 
peptides of either 40 or 42 amino acids.  The ratio of Aβ40 to Aβ42 is usually 9:1 (Haass 
and Selkoe, 2007).  The peptide ending at amino acid 42 (Aβ42) is more hydrophobic and 
thus particularly more prone to aggregation (Jarrett et al., 1993a; Jarrett et al., 1993b).  
Most plaques in the AD brain are diffuse plaques (Joachim et al., 1989; Selkoe, 1997).  
There are also less frequent neuritic plaques, in which dystrophic neurites are a prominent 
and commonplace feature.  Since diffuse plaques are also found frequently in healthy aged 
Introduction 
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brains, it is hypothesised that they are the precursor of neuritic plaques (LaFerla and Oddo, 
2005; Selkoe, 2001a; Selkoe, 2001b). 
 
Figure 1.3 Amyloid plaques and neurofibrillary tangles. 
The formation of amyloid plaques and neurofibrillary tangles contribute to the degradation of 
neurons in the brain and the subsequent symptoms of AD.  (Resource: American Health Assistance 
Foundation (http://www.ahaf.org/)) 
 
 
A second hallmark of AD brains is the presence of intraneuronal lesions called 
neurofibrillary tangles (Figure 1.3).  Neurofibrillary tangles are filamentous inclusions 
composed of hyperphosphorylated forms of the microtubule associated protein tau 
(Grundke-Iqbal et al., 1986), which assembles into arrays of paired helical filaments 
(PHF).  Normally, the tau protein is a soluble protein that is involved in the assembly and 
stabilisation of microtubules (Xie et al., 1998).  On the other hand, the pathological tau 
protein shows altered solubility properties, is abnormally phosphorylated, has less affinity 
for microtubules and forms filamentous structures (Goedert et al., 1992; Grundke-Iqbal et 
al., 1986).  Due to the alterations of the cellular tau protein, PHFs are formed that appear 
as intraneuronal tangles at autopsy (Johnson and Hartigan, 1999).  In other 
neurodegenerative disorders, such as frontal temporal dementia or Pick’s disease, 
neurofibrillary tangles are also observed (Koo et al., 1999; Lee et al., 2001; Morris et al., 
2001).  As tangles are a defined characteristic of a large number of neurodegenerative 
diseases, they are thought to be a secondary consequence of a primary neuronal injury and 
thus, an indication of disease progression (David et al., 2002). 
Additional pathogenic alterations found in the brains of AD patients are microgliosis, 
astrocytosis, selective neuronal degeneration, neuronal loss and multiple neurotransmitter 
deficits (Ding et al., 1992; Norris et al., 2005). 
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1.2 Molecular biology of Alzheimer`s disease 
1.2.1 Amyloid precursor protein processing 
In 1987, APP was cloned by using the information obtained through isolation and 
sequencing of Aβ (Kang et al., 1987).  The APP gene is located on chromosome 21 and 
encodes a type I transmembrane glycoprotein of 770 amino acids (Esch et al., 1990; Kang 
et al., 1987).  The gene is alternatively spliced to encode for the APP protein variants of 
695 and 751 amino acids.  The APP splice variants of 770 and 751 amino acids are 
ubiquitously expressed (Selkoe, 2004).  The 695 amino acid isoform is expressed at higher 
levels in neurons in comparison to the two longer splice variants (Rohan de Silva et al., 
1997). 
Three different enzymes termed α-, β-, and γ-secretase process APP (Haass and 
Steiner, 2002; Kaether and Haass, 2004; Walter et al., 2001).  Cleavage of APP within the 
ectodomain by either α- or β-secretase generates the soluble APPα or APPβ and the 
membrane-bound APP C-terminal fragments, APP-CTFα (83 amino acids) or CTFβ (99 
amino acids), respectively.  The membrane bound cleavage products of α- and β-secretase 
(APP-CTFα and -CTFβ) are direct substrates for γ-secretase.  γ-secretase generates the 
APP intracellular domain (AICD) (Sastre et al., 2001) and p3 (Haass et al., 1992a) by 
intramembrane cleavage of APP-CTFα.  The cleavage of APP-CTFβ by γ-secretase yields 
AICD and Aβ that accumulates as amyloid deposits in senile plaques of aged individuals 
and patients with AD (Haass and Selkoe, 1993).  In Figure 1.4, a schematic representation 
of APP processing is shown. 
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Figure 1.4 Schematic representation of APP processing (according to Walter et al. 2001). 
In the non-amyloidogenic pathway, α-secretase cleaves APP in the middle of the Aβ domain to 
generate extracellular APPsα, thereby preventing the formation of Aβ generation.  The resulting 
APP-CTFα is subsequently cleaved by γ-secretase to yield p3 and AICD.  In the amyloidogenic 
pathway, APP is first cleaved by β-secretase to generate APPsβ.  The membrane-bound APP-CTFβ 
is then cleaved by γ-secretase.  The released Aβ forms extracellular aggregates, which lead to 
amyloid plaque formation. 
 
 
As the α-secretase cleaves APP between residues 16 and 17 of the Aβ domain and thus 
precludes Aβ generation, this process is referred to as the non-amyloidogenic pathway.  On 
the other hand, β-secretase cleaves APP at the beginning of the Aβ domain resulting in Aβ 
peptide generation.  Therefore, this process is referred to as the amyloidogenic pathway. 
 
1.3 Genetics of Alzheimer’s disease 
The majority of AD cases are sporadic, while 5-10% of the cases are genetically 
inherited as familial AD (FAD) (Selkoe, 2001a).  The onset of age of the disease is earlier 
in FAD than in sporadic AD.  Three FAD causing genes, APP and presenilin (PS) 1 and 
PS2, have been revealed by genetic analysis of pedigrees with FAD (Goate et al., 1991; 
Non-amyloidogenic processing
α-secretase
APP
N
C CTFα
APPsα
p3
AICD
γ-secretase
Amyloidogenic processing
AICD
APPsβ
N
C
γ-secretase
Aβ
CTFβ
β-secretase
APP
Introduction 
16 
Levy-Lahad et al., 1995b; Levy-Lahad et al., 1995c; Rogaev et al., 1995; Sherrington et 
al., 1995; St George-Hyslop et al., 1992).  Mutations in the PS1 gene cause most of the 
FAD cases, whereas APP and PS2 mutations are rather rare.  To date, 185 missense 
mutations are found in PS1 and 13 in PS2 (Alzheimer Disease and Frontotemporal 
Dementia Mutation Database: http://www.molgen.ua.ac.be/ADMutations) (Cruts et al., 
1998).  For all tested missense mutations, the ratio of Aβ42 to Aβ40 is increased.  For 
APP, so far, 33 missense mutations are found (Alzheimer Disease and Frontotemporal 
Dementia Mutation Database: http://www.molgen.ua.ac.be/ADMutations) (Cruts et al., 
1998).  Interestingly, all the FAD missense mutations found in APP are located near to the 
three secretase-cleavage sites suggesting that they cause AD by an alteration of the APP 
cleavage.  Predominantly the mutations localize close to the γ-secretase cleavage site and 
cause an increase in the production of Aβ42 peptides (Haass et al., 1994; Suzuki et al., 
1994).  There is also a rare mutation in a Swedish family that localizes to the β-secretase 
cleavage site.  This mutation causes an increase in the production of all Aβ peptides (Cai et 
al., 1993; Citron et al., 1992).  Recently, the APP mutation A673T was identified that 
protects against AD (Jonsson et al., 2012).  This mutation is close by the β-secretase 
cleavage site and reduces the formation of Aβ (Jonsson et al., 2012).  Mutations in the 
vicinity of the α-secretase cleavage site do not influence the processing of APP but rather 
alter the aggregation properties of Aβ (Selkoe, 2001a).  Furthermore, individuals with 
Down`s syndrome, harbouring an extra copy of chromosome 21 containing the APP gene, 
invariably develop dementia and AD-like pathology (Head and Lott, 2004). 
In contrary to the FAD cases, the reasons for the development of sporadic AD, which 
forms the majority of all AD cases, are unclear.  However, a major genetic risk factor for 
late-onset AD, the ε4 allele of apolipoprotein E, has been identified (Levy-Lahad et al., 
1995a).  Genetic analysis revealed that the likelihood of developing AD will increase with 
the inheritance of one or two ε4 alleles in comparison to subjects harbouring ε2 and/or ε3 
alleles (Corder et al., 1993).  Recently, other risk loci within CLU, PICALM, CR1 and 
SORL1 were identified (Harold et al., 2009; Lambert et al., 2009; Lee et al., 2007).  On 
the other hand, the greatest risk factor of AD is ageing.  However, the mechanism how 
ageing contributes to Aβ deposition in the brain is not well established.  The cause of 
sporadic AD might be a deficiency in Aβ degradation (Yasojima et al., 2001a; Yasojima et 
al., 2001b) or an increase in β-secretase cleavage of APP (Holsinger et al., 2002; Yang et 
al., 2003).  These observations suggest that the balance between generation and clearance 
of Aβ is altered by ageing.  Moreover, the difference in the levels of alteration of Aβ 
Introduction 
17 
generation and clearance may account for the difference in the onset age of the disease.  
The imbalance between Aβ generation and clearance may result from an alteration of gene 
expression or from unknown factors involved in these processes.  Such alteration could 
also cause an acceleration of the Aβ aggregation rate in the brain. 
In Figure 1.5, the sequence of pathogenic events leading to AD is represented by the 
amyloid cascade hypothesis (Hardy and Selkoe, 2002). 
 
Missense mutations in APP, PS1 or PS2 genes or sporadic AD
Increased Aβ42 production and accumulation
Aβ oligomerization and deposition of diffuse plaques
Subtle effects of Aβ oligomers on synapses
Progressive synaptic and neuritic injury Microglia and astrocytic activation
Altered neuronal ionic homeostasis; oxidative injury
Altered kinases/phospatase activities Tangles
Widespread neuronal/neuritic dysfunction and cell death with transmitter deficits
DEMENTIA  
Figure 1.5 Amyloid cascade hypothesis (adopted from Hardy and Selkoe, 2002). 
The sequence of pathogenic events leading to AD proposed by the amyloid cascade hypothesis.  
Aβ may directly injure the synapses and neurites of brain neurons, in addition to activating 
microglia and astrocytes (Haass and Selkoe, 2007; Hardy and Selkoe, 2002). 
 
 
1.4 β-secretase 
The β-secretase BACE1 (beta-site APP cleaving enzyme), also known as Asp2 or 
memapsin2, was discovered in 1999 independently by a number of different groups 
(Hussain et al., 1999; Lin et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 
1999).  BACE1 is a 501-amino-acid type I transmembrane protease belonging to the pepsin 
and retroviral aspartic protease family.  It has a large ectodomain containing the dual active 
site motif (D-T/S-G-T/S), a transmembrane domain and a short cytoplasmic tail (Figure 
1.6) (Vassar et al., 2009; Walter et al., 2001; Willem et al., 2009).   
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Figure 1.6 Schematic view of BACE1 (Walter et al., 2001). 
The signal peptide (SP) is shown in yellow, the prodomain (pro) in red, the aspartyl protease site 
motifs (DTGS and DSGT) in the luminal/ extracellular domain by stars and the furin cleavage site 
by an arrow.  In the amino acid sequence of the cytoplasmic tail, given in single-letter code, the 
phosphorylation site is shown in red and the dileucine motive in light blue. 
 
 
BACE1 is synthesized in the endoplasmic reticulum (ER) as an immature proenzyme 
with a molecular weight of 50 kDa.  Mature BACE1 has a molecular weight of 70 kDa.  
Maturation involves disulphide bridge formation, N-glycosylation, carbohydrate 
sulphation, propeptide removal and palmitoylation (Benjannet et al., 2001; Bennett et al., 
2000b; Capell et al., 2000; Creemers et al., 2001; Haniu et al., 2000; Huse et al., 2000). 
Even though it is not well understood whether BACE1 in principal exists as a 
monomeric enzyme or a dimer, there is evidence that a high molecular complex variant of 
BACE1 has a higher β-secretase activity than the monomer (Schmechel et al., 2004; 
Westmeyer et al., 2004).  BACE1 has an acidic pH optimum, and the enzyme is located in 
the Golgi apparatus, the endosomes, and at the cell membrane (Esler and Wolfe, 2001; 
Haass et al., 1992b; Koo and Squazzo, 1994; Vassar et al., 1999).  It was shown that 
BACE1 is internalized from the plasma membrane to endosomes.  This internalization 
process is mainly driven by the dileucine motive in the C-terminus (Figure 1.6) (Huse et 
al., 2000; Pastorino et al., 2002).  From the endosomes, BACE1 is recycled to the Golgi 
apparatus.  For this process the phosphorylation of a single serine residue (S498) in the C-
terminus is required (Figure 1.6) (Walter et al., 2000).  In human cortical neurons, BACE1 
co-localizes with its cleavage product APPsβ and the putative α-secretase ADAM10 
(Marcinkiewicz and Seidah, 2000; Sennvik et al., 2004). 
There is a close homologue to BACE1, BACE2, which does not contribute to the 
amyloidogenic processing of APP.  BACE2 seems to have α-secretase-like properties 
(Farzan et al., 2000; Fluhrer et al., 2002; Hussain et al., 2000; Yan et al., 2001) and is 
preferentially expressed in non-neuronal cells (Bennett et al., 2000a). 
Strong support for the pivotal (and exclusive) role of BACE1 as β-secretase comes 
from BACE1 knockout mice which show a complete absence of Aβ generation in their 
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brains, suggesting that BACE1 is the only protease mediating β-secretase activity (Cai et 
al., 2001; Luo et al., 2001; Roberds et al., 2001).  Initial reports indicated that BACE1 
knockout mice develop normally, are healthy, fertile and appear to have no obvious 
morphological phenotype (Cai et al., 2001; Luo et al., 2003; Luo et al., 2001; Roberds et 
al., 2001).  However, recent studies have shown that they are not completely normal.  
Behavioural assays revealed memory impairment and changes in spontaneous activity 
(Dominguez et al., 2005; Harrison et al., 2003; Laird et al., 2005; Ohno et al., 2004).  
Moreover, close analysis of BACE1 knockout mice revealed an important morphological 
phenotype.  They show severe hypomyelination of the peripheral nervous system (PNS) 
similar to neuregulin-1 (NRG-1) heterozygous mice (Hu et al., 2006; Willem et al., 2006).  
It could be shown that NRG-1 is a physiological substrate of BACE1.  BACE1 participates 
in the proteolytic processing of NRG-1 (Hu et al., 2006; Willem et al., 2006), a ligand for 
members of the ErbB family of receptor-tyrosine kinases.  Since in BACE1 knockout mice 
NRG-1 cannot be cleaved by BACE1, full-length NRG-1 accumulates and failure of NRG-
1 signalling causes reduced myelin sheath thickness of axons of both peripheral sciatic 
nerves (Hu et al., 2006; Willem et al., 2006) and central optic nerves (Hu et al., 2006).  
Moreover, this abrogated cleavage of NRG-1 also impairs remyelination of injured sciatic 
nerves (Hu et al., 2008). 
Besides APP and NRG-1, BACE1 was found to process the Golgi-localized 
membrane-bound α2,6-sialyltransferase (Kitazume et al., 2001), the P-selectin 
glycoprotein ligand-1 (PSLG-1) (Lichtenthaler et al., 2003), the APP like proteins APLP1 
and APLP2 (Eggert et al., 2004; Li and Sudhof, 2004; Pastorino et al., 2004), the low-
density lipoprotein receptor-related protein (LRP) (von Arnim et al., 2005), the voltage-
gated sodium channel (Nav1) β2 subunit (Navβ2) (Kim et al., 2005; Wong et al., 2005), and 
neuregulin-3 (NRG-3) (Hu et al., 2008).  Recently, Kuhn et al. identified 34 mostly novel 
substrates in primary neurons by secretome protein enrichment with click sugars (SPECS) 
(Kuhn et al., 2012).  Seizure protein 6, NCAM-L1, CHL1 and contactin-2, four of the 
identified substrates, were validated in BACE1 inhibitor-treated and BACE1 knockout 
mice (Kuhn et al., 2012).  In an independent study, Zhou et al. identified several putative 
BACE1 substrates in primary neuronal cultures by a quantitative proteomic approach 
(Zhou et al., 2012).  The adhesion molecules NCAM-L1 and CHL1 were confirmed in cell 
culture, in BACE1 inhibitor-treated and BACE1 knockout mice (Zhou et al., 2012). 
BACE1 is located on chromosome 11.  So far no AD-causing mutation has been 
identified, but polymorphisms in the BACE1 gene seem to influence the risk for AD 
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(Kirschling et al., 2003).  It has been shown that β-secretase mRNA is ubiquitously 
expressed with its highest levels in the brain and pancreas (Vassar et al., 1999; Yan et al., 
1999).  However, the BACE1 activity in the pancreas is low due to BACE1 variants with 
reduced proteolytic activity which are generated from alternative spliced transcripts 
(Mowrer and Wolfe, 2008).  Interestingly, several studies showed that levels of BACE1 
protein and activity are elevated approximately 2-fold in AD brain without a parallel 
increase in mRNA expression (Fukumoto et al., 2002; Holsinger et al., 2002; Li and 
Sudhof, 2004; Preece et al., 2003; Yang et al., 2003). 
 
1.5 γ-secretase 
γ-secretase is an unusual aspartyl protease occurring as high molecular weight 
complex that catalyses intramembrane proteolysis of a variety of substrates apart from APP 
(Haass, 2004; Steiner, 2004).  The Notch (1-4) receptors, which are essential for cell 
differentiation, are very important and well-studied substrates of γ-secretase (Berezovska 
et al., 1999; Davis et al., 1998; De Strooper et al., 1999; Donoviel et al., 1999; Herreman 
et al., 1999; Herreman et al., 2000; Levitan and Greenwald, 1998; Nakajima et al., 2000; 
Qian et al., 1998; Struhl and Greenwald, 2001; Wong et al., 1997).  Notch functions as a 
receptor at the cell surface and mediates cell-cell signalling interactions to specify cell 
fates during development (Bray, 2006).  Apart from APP and Notch, there is a growing 
number of type I transmembrane proteins that have been identified as substrates of γ-
secretase such as APLP1 and APLP2 (Scheinfeld et al., 2002), CD44 (Cluster of 
differentiation 44) (Lammich et al., 2002; Murakami et al., 2003), N- and E-cadherin (Baki 
et al., 2001; Georgakopoulos et al., 1999; Marambaud et al., 2002), Delta and Jagged 
(Ikeuchi and Sisodia, 2003; LaVoie and Selkoe, 2003) and ErbB4 (Ni et al., 2001).  
Altogether, around 90 substrates have been described for γ-secretase until today (Lleo and 
Saura, 2011). 
γ-secretase is composed of the four core components presenilin (PS1 or PS2), nicastrin 
(Nct), anterior pharynx-defective phenotype 1 (Aph1) and presenilin enhancer 2 (Pen2) 
(Haass, 2004).  Edbauer and colleagues showed that when all four components were 
expressed together in yeast, which has no homologues of γ-secretase components and thus 
lacks γ-secretase activity, active γ-secretase was reconstituted (Edbauer et al., 2003). This 
suggests that these four components are necessary and sufficient for the activity of the 
enzyme. 
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1.5.1 Presenilin 
The genes encoding PS1 and PS2 are located on chromosome 14 and 1, respectively 
(Levy-Lahad et al., 1995b; Levy-Lahad et al., 1995c; Sherrington et al., 1995).  They are 
related multipass transmembrane proteins that share about 63% of sequence identity.  PS1 
and PS2 possess nine membrane-spanning segments (Henricson et al., 2005; Kaether et al., 
2004; Laudon et al., 2005; Oh and Turner, 2005a; Oh and Turner, 2005b) and a large 
cytoplasmic loop located between transmembrane domain 6 and 7 (Laudon et al., 2005; Li 
and Greenwald, 1998; Periz and Fortini, 2004). 
PS1 or PS2 are the catalytic subunit of the γ-secretase complex and provide the two 
critical aspartyl residues (Kimberly et al., 2000; Wolfe et al., 1999).  PS1 and PS2 are 
synthesized as a holoprotein of 50 kDa.  To generate the functional γ-secretase, PS1 or PS2 
undergo endoproteolysis within the large cytoplasmic loop to generate a 30 kDa N- and a 
20 kDa C-terminal fragment (NTF and CTF) in the cell (Fukumori et al., 2010; Thinakaran 
et al., 1996).  The NTF and CTF of PS1 or PS2 form a heterodimer (Capell et al., 1998; 
Saura et al., 1999; Yu et al., 1998) which are more stable than the holoprotein (Ratovitski 
et al., 1997; Steiner et al., 1998). 
The following lines of evidence demonstrate that PS is the catalytic subunit of the γ-
secretase complex: (1) The two crucial aspartate residues (Asp) are required for γ-secretase 
activity.  Substitution of either of the two aspartate residues buried within the 6th and 7th 
transmembrane domains of PS abolished γ-secretase activity (Wolfe et al., 1999; Yu et al., 
2000a).  (2) γ-secretase activity was severely diminished in cells derived from PS1 
knockout mice (De Strooper et al., 1998) and completely abolished in PS1 and PS2 
deficient embryonic stem cells (Herreman et al., 2000; Zhang et al., 2000).  (3) γ-secretase 
inhibitors can be directly crosslinked to PS (Esler et al., 2000; Li et al., 2000). 
 
1.5.2 Nicastrin 
Nct, as well as Aph1 and Pen2 proteins, associate with presenilin heterodimers and are 
required for protease activity.  Nct is a type I integral membrane glycoprotein comprising 
709 amino acid residues in humans with a predicted size of 80 kDa for the native protein.  
It undergoes complex glycosylation and sialylation within the secretory pathway to yield 
the mature form of around 120 kDa, which exists in the active γ-secretase complex 
(Edbauer et al., 2002; Leem et al., 2002; Tomita et al., 2002; Yang et al., 2002; Yu et al., 
2000b).  Shah and colleagues showed that Nct functions as a γ-secretase substrate receptor 
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(Shah et al., 2005).  It was shown that the ectodomain of Nct can bind to ectodomain-
shedded APP and Notch before γ-secretase cleavage occurs. 
 
1.5.3 Aph1 
By genetic screening for mutants that enhance the Notch signalling defect phenotype 
in C.elegans, Aph1 was identified (Francis et al., 2002; Goutte et al., 2002).  Aph1 is a 
multitransmembrane protein that spans the membrane seven times (Fortna et al., 2004).  It 
was shown that Aph1 interacts with PS NTF/CTF heterodimers and Nct in mammalian 
cells and in vivo (Lee et al., 2002).  In humans, two homologs of Aph1 genes, Aph1a and 
Aph1b, were identified.  Furthermore, for Aph1a two splice variants are reported, Aph1aL 
and Aph1aS.  It was shown that the two splice variants of Aph1a as well as Aph1b are not 
found in the same γ-secretase complex (Shirotani et al., 2004).  PS1 and PS2 are also in 
separate complexes, resulting in the formation of 6 different proteolytically active γ-
secretase complexes with every possible combination of PS and Aph1 variants in human 
cells (Hebert et al., 2004; Shirotani et al., 2004).  In mice, there are eight complex 
possibilities, as mice contain a third Aph1 homolog, Aph1c (Hebert et al., 2004).  So far, it 
is not well understood whether there exist any differences on the γ- secretase activity or 
any substrate preference of an individual γ-secretase complex.  It has been demonstrated 
that the absence of Aph1 causes a decrease in the levels of the other γ-secretase complex 
components (Ma et al., 2005; Serneels et al., 2005; Shirotani et al., 2004; Takasugi et al., 
2003), suggesting that Aph1 stabilises the γ-secretase complex.  However, the Aph1 
function for cleavage within an assembled complex is still unclear and further studies are 
required to elucidate the function of Aph1. 
 
1.5.4 Pen2 
As Aph1, Pen2 was identified by genetic screening for mutants that enhance the Notch 
signalling defect phenotype in C.elegans (Francis et al., 2002; Goutte et al., 2002).  Pen2 is 
the smallest subunit of the γ-secretase complex with 101 amino acids (Francis et al., 2002; 
Steiner et al., 2002).  It encodes a membrane protein of about 10 kDa that spans the 
membrane twice.  Pen2 adopts a hairpin orientation in the membrane with its N- and C-
terminal domains facing the luminal/extracellular space (Crystal et al., 2003).  It was 
shown that Pen2 is involved in the initiation of PS endoproteolysis (Takasugi et al., 2003) 
and that it is necessary to stabilise the NTF and CTF of PS within the γ-secretase complex 
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(Hasegawa et al., 2004; Prokop et al., 2005; Prokop et al., 2004).  Whether and how Pen2 
contributes to the catalytic function of γ-secretase is still unclear. 
 
1.5.5 Assembly of the γ-secretase complex 
How the γ-secretase complex is assembled and transported is not understood in full 
detail.  It was shown that the four components of the γ-secretase undergo stepwise 
assembly in the ER and co-operatively exit the ER (Capell et al., 2005; Kim et al., 2004).  
Complex formation in the ER begins with binding of Aph1 to the transmembrane domain 
(TMD) of immature Nct.  This immature Nct-Aph1 heterodimer then binds to PS 
holoprotein in the ER to form a ternary complex.  In the final step of γ-secretase assembly 
in the ER, Pen2 binds to PS resulting in endoproteolytic cleavage of PS and structural 
changes in the Nct ectodomain (Dries and Yu, 2008).  γ-secretase is then transported 
through the Golgi, where Nct is complex glycosylated and transported to the plasma 
membrane and the endosomal/lysosomal system.  The fully assembled complex is known 
to exert its biological function in the late secretory pathway (De Strooper, 2003). 
The non-assembled complex components appear to be unstable and/or to be retained within 
the ER.  The following lines of evidence suggest this: (1) Decreased Nct expression by 
RNAi is accompanied by reduced PS1, Aph1a-L and Pen2 expression (Steiner et al., 
2002).  (2) Decreased Pen2 expression by RNAi leads to loss of PS1 NTF and CTF and 
accumulation of immature Nct (Crystal et al., 2003; Prokop et al., 2004; Takasugi et al., 
2003).  (3) Presenilin knockout cells have only immature Nct and Pen2 is lost (Steiner et 
al., 2002).  In addition it was shown that in the absence of PS Nct is retained in the ER 
(Edbauer et al., 2002; Periz and Fortini, 2004).  Retention of PS1 was shown to be due to a 
retention signal in the C-terminus (Kaether et al., 2004).  Also non-assembled Pen2 was 
shown to accumulate in the ER where it is degraded by proteosomal degradation (Bergman 
et al., 2004; Crystal et al., 2004). 
Kaether and colleagues proposed a model for γ-secretase complex assembly and trafficking 
(Kaether et al., 2004).  According to this model the assembly of γ-secretase is governed by 
similar mechanisms that govern the assembly of complexes like ion channels and cell 
surface receptors.  Here control mechanisms ensure that only fully assembled complexes 
leave the ER and travel to the cell surface.  Quality control in the ER is crucial to prevent 
export of non-functioning or, worse, malfunctioning proteins.  Retention of monomeric 
subunits is achieved by exposing ER-retention signals that can be cytosolic (Zerangue et 
al., 1999) or within transmembrane domains (TMDs) (Bonifacino et al., 1990; Bonifacino 
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et al., 1991; Hennecke and Cosson, 1993; Sato et al., 2004).  Upon complex assembly 
these retention signals are masked and ER-export is permitted. 
 
1.6 α-secretase 
ADAMs are membrane proteins containing a disintegrin and metalloprotease domain, 
which are widely distributed and play important roles in many cellular events (Wolfsberg 
et al., 1995).  The domain structure of the ADAMs consists of a pro-domain, a 
metalloprotease domain, a disintegrin and cysteine-rich domain, an EGF-like domain, a 
transmembrane domain and a cytoplasmic tail (Figure 1.7). 
 
 
 
 
Figure 1.7 Representation of domain structure of a typical ADAM (Allinson et al., 2003). 
The signal peptide (SP) is shown in yellow, the prodomain (pro) in red, the furin cleavage site by 
an arrow, the metalloprotease domain in dark blue, the disintegrin domain in green, the cysteine-
rich domain in orange, the EGF-like domain in purple, the hydrophobic transmembrane domain in 
light blue and the cytoplasmic tail in blue. 
 
 
At least 17 individual members of the ADAM family are expressed in the brain 
(Karkkainen et al., 2000).  They cleave a variety of different substrates including adhesion 
molecules, cytokines, growth factors and growth factor receptors (Pruessmeyer and 
Ludwig, 2009).  By the work of several groups, ADAMs 9, 10 and 17 have been shown to 
be putative α-secretases for the cleavage of APP (Buxbaum et al., 1998; Koike et al., 1999; 
Lammich et al., 1999). 
 
1.6.1 ADAM9 
ADAM9, also known as meltrin γ or MDC9, is a ubiquitously expressed 84 kDa 
glycoprotein.  It was shown that ADAM9 mRNA is highly expressed in developing 
mesenchyme, heart and brain (Weskamp et al., 2002).  In adult tissue, it is ubiquitously 
expressed including the heart, brain, placenta, lung, skeletal muscle, digestive system and 
reproductive system (Weskamp et al., 1996).  ADAM9 is involved in various cellular 
processes.  The heparin-binding EGF-like growth factor (HB-EGF), for example, is 
processed by ADAM9 upon TPA stimulation (Izumi et al., 1998).  In addition, it was 
shown that in COS cells co-expression of APP and ADAM9 leads to APP processing by 
ADAM9 (Hotoda et al., 2002; Koike et al., 1999).  ADAM9 knockout mice developed 
normally, were viable and fertile, and did not show any abnormality.  Isolated fibroblasts 
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or hippocampal neurons derived from these mice still show shedding of HB-EGF and APP, 
suggesting a redundant role of ADAM9 (Weskamp et al., 2002). 
 
1.6.2 ADAM17 
ADAM17, also known as TACE (Tumor necrosis factor-α converting enzyme), was 
identified as being responsible for the shedding of the cytokine proTNF-α (Black et al., 
1997; Moss et al., 1997).  ADAM17 is widely expressed with high levels of expression in 
the heart, placenta, testis, ovary, lung and spleen (Black et al., 1997; Sahin et al., 2004).  In 
the brain the expression of ADAM17 is more or less limited to the endothelia and glia 
(Goddard et al., 2001).  The expression pattern in the brain is more consistent with a role 
for ADAM10 and ADAM9 than ADAM17 as the APP α-secretase, although expression 
analysis is not a completely reliable indicator of where an enzyme might function (even 
low levels of an ADAM may be completely sufficient for its physiological activity) 
(Karkkainen et al., 2000).  Mice lacking ADAM17 are perinatal lethal with multiple 
defects in various organs which closely resemble those seen in mice lacking EGFR, TGF 
or HB-EGF (Mann et al., 1993; Miettinen et al., 1995; Peschon et al., 1998).  Concerning 
Notch, mice lacking ADAM17 do not show any apparent phenotype related to Notch or 
Notch ligand loss (Peschon et al., 1998).  It was shown that the absence of ADAM17 
abolished regulated (PMA-stimulated), but not constitutive α-secretase activity in mouse 
embryonic fibroblasts (Buxbaum et al., 1998).  Apart from APP and TNFα, a substantial 
number of other substrates for ADAM17 have been identified, including EGFR ligands 
(Sahin et al., 2004; Sunnarborg et al., 2002), p75 TNFR (Peschon et al., 1998), IL6R 
(Matthews et al., 2003), prion protein (Vincent et al., 2001), VCAM-1 (Garton et al., 
2001) and ErbB4 (Rio et al., 2000). 
 
1.6.3 ADAM10 
ADAM10 was originally purified as a myelin-associated metalloprotease from brain 
myelin membranes.  A preliminary characterization showed that it efficiently degrades 
myelin basic protein (MBP) in brain extracts (Chantry et al., 1989).  Peptide sequences 
obtained from the purified protein later allowed cloning of ADAM10 cDNA from a bovine 
cDNA library (Howard et al., 1996).  Subsequently, it became clear that ADAM10 is the 
mammalian homologue of Drosophila Kuzbanian (Kuz), which in turn has an essential role 
in Notch signalling (Pan and Rubin, 1997). 
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ADAM10 was found to be expressed ubiquitously in embryos, including the 
dermatome, myotome of the somites, epidermis, gut endoderm, epithelial tissues of the 
kidney, liver, heart and neural crest cells of chicks (Hall and Erickson, 2003).  ADAM10 is 
also highly expressed in a variety of adult tissues as shown by Western blotting (Sahin et 
al., 2004).  In adult brains, ADAM10 was found to be widely expressed throughout the 
brain, including neurons.  This is consistent with a putative role of this gene as an α-
secretase for APP (Bernstein et al., 2003; Karkkainen et al., 2000).  Interestingly, it was 
reported that ADAM10 protein levels are decreased in platelets of AD patients (Colciaghi 
et al., 2002).  Additionally, a decrease in APPsα release was found by these platelets as 
well as in the cerebrospinal fluid of sporadic AD patients and AD patients carrying the 
Swedish mutation (Colciaghi et al., 2002; Fellgiebel et al., 2009; Sennvik et al., 2000).  
Overexpression of ADAM10 in HEK cells leads to an increased α-secretase activity, and 
endogenous α-secretase activity in these cells is inhibited by introducing a dominant 
negative form of ADAM10 (Lammich et al., 1999).  ADAM10 knockout mice are lethal 
around embryonic day 9.5 (Hartmann et al., 2002) with multiple malformations strikingly 
similar to that of a complex Notch deficiency as seen in PS1/PS2 or notch1/notch4 double 
mutant mice (Herreman et al., 1999; Krebs et al., 2000).  Due to the early embryonic 
lethality of ADAM10 knockout mice at a stage preceding neuronal development, APP 
processing can only be analysed in immortalized cell lines derived from ADAM10 
knockout embryos.  The results might therefore not directly reflect the actual contribution 
of ADAM10 in APP cleavage in the brain.  Nevertheless, the data clearly showed that α-
secretase activity was preserved in some ADAM10 knockout cell lines (Hartmann et al., 
2002).  It remains to be determined whether there is compensation by, or redundancy 
between, different ADAMs or other enzymes in the processing of APP (Asai et al., 2003) 
or whether different ADAMs have major roles in APP processing in distinct cells and 
tissues. 
A study by Postina and colleagues showed that overexpression of ADAM10 in 
neurons alleviates amyloid plaque formation and hippocampal defects in an AD mouse 
model (Postina et al., 2004).  Overexpression of inactive ADAM10 however could 
increase the Aβ plaque load in an AD mouse model (Postina et al., 2004).  This study 
suggests that an increase of ADAM10 activity may be therapeutically desirable.  To learn 
more about the function of ADAM10 during development and in adults as well as in APP 
processing in the brain, it will be critical to generate mice carrying a conditional mutation 
in this gene.  Therefore, Jorissen and colleagues recently generated conditional ADAM10 
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knockout mice, limiting ADAM10 inactivation to neural progenitor cells (NPC) and NPC-
derived neurons and glial cells (Jorissen et al., 2010).  In these mice, Notch1 processing is 
affected, leading to downregulation of several Notch-regulated genes in the brain of these 
mice.  In addition, the α-secretase-mediated processing of APP was largely reduced in the 
neurons of these mice, demonstrating that ADAM10 represents the most important α-
secretase in brain.  These results were confirmed in primary neurons by another recently 
published study (Kuhn et al., 2010).  Using RNAi-mediated knockdown of ADAM10 in 
different cell lines and primary murine neurons, α-secretase cleavage of APP was 
completely suppressed.  RNAi-mediated knockdown of ADAM9 and ADAM17, however, 
has no effect on α-secretase cleavage (Kuhn et al., 2010). 
Apart from processing APP and the Notch receptor, ADAM10 has also been 
implicated in regulating neuronal repulsion through cleaving ephrinA2 (Hattori et al., 
2000), and in the processing of various other cell surface molecules, including CD44 
(Murai et al., 2004), type IV collagen (Millichip et al., 1998), L1 adhesion molecule 
(Mechtersheimer et al., 2001), interleukin-6 receptor (Matthews et al., 2003), CXC 
chemokine fractalkine (Hundhausen et al., 2003), neurotensin receptor-3 (Navarro et al., 
2002), prion protein (Vincent et al., 2001), betacellulin, EGF (Sahin et al., 2004) and 
BACE1 (Hussain et al., 2003).  For most of these putative candidate ADAM10 substrates, 
the physiological relevance of the processing during development remains to be 
determined in vivo. 
 
1.7 Translational control 
1.7.1 Translational control of APP 
Interestingly, several studies have already shown that the APP mRNA is subjected to 
extensive regulation at the post-transcriptional level.  Studies in mammalian cell lines and 
primary neuronal cultures have indicated that RNA-binding proteins interact with 
regulatory regions of APP mRNA and modulate the expression of APP (Ruberti et al., 
2010).  The 5`UTR of APP contains several elements that control the translation of APP 
mRNA.  These include an internal ribosome entry site (IRES) (Beaudoin et al., 2008), an 
interleukin-1 (IL-1) translation enhancer element (Rogers et al., 1999) and an iron-
response element (IRE) (Cho et al., 2010; Rogers et al., 2002), similar to the originally 
identified IRE that regulates the translation of the L- and H-ferritin mRNAs in response to 
intracellular iron levels (Hentze et al., 1987; Klausner et al., 1993).  Furthermore, the APP 
coding sequence contains a guanine-rich (G-rich), G-quartet-like sequence that interacts 
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with either hnRNP C or FMRP (Lee et al., 2010; Westmark and Malter, 2007).  The RNA-
binding proteins hnRNP C and FMRP associate with the same APP mRNA coding region 
element and influence APP translation competitively and in opposite directions (Lee et al., 
2010).  Silencing hnRNP C increased FMRP binding to APP mRNA and repressed APP 
translation, while silencing FMRP enhanced hnRNP C binding and promoted translation of 
APP (Lee et al., 2010).  The repression of APP translation is linked to the recruitment of 
the FMRP-APP mRNA complex to processing bodies (PBs) and hnRNP C blocks the 
recruitment of APP mRNA to PBs (Lee et al., 2010).  Interestingly, it appears that hnRNP 
C not only regulates the translation of APP mRNA, but also increases its stability by 
binding to a highly conserved 29 nucleotides (nt) element within the 3`UTR, 
approximately 200 nt downstream of the stop codon (Rajagopalan et al., 1998; Zaidi et al., 
1994; Zaidi and Malter, 1994; Zaidi and Malter, 1995).  The same 29 nt sequence is also 
target of the RNA-binding protein nucleolin (Ceman et al., 1999; Zaidi et al., 1994; Zaidi 
and Malter, 1994; Zaidi and Malter, 1995).  While the 29 nt sequence appears to 
destabilize the APP mRNA, another sequence located in the first 52 bases downstream of 
the stop codon seems to have the opposite effect and increases stability (Broytman et al., 
2009).  The 52 nt stabilizing element is recognized by six cytosolic proteins YB1, La/SS-
B, EF1α, nucleolin, Rck/p54 and PAI/RBP1 (Broytman et al., 2009).  Whether these 
proteins are present in a single complex or bind APP mRNA independently is unknown.  
The identified proteins may interact with each other or within a complex through both 
RNA dependent or independent interactions. 
The described examples show that there is extensive evidence that APP expression is 
potently regulated by post-transcriptional mechanisms as APP mRNA stabilization and 
APP translation, indicating that the regulation of APP mRNA metabolism is an important 
event in AD pathophysiology (Beaudoin et al., 2008; Hebert et al., 2009; Patel et al., 2008; 
Rajagopalan et al., 1998; Rogers et al., 2002; Westmark and Malter, 2001a; Westmark and 
Malter, 2001b; Westmark and Malter, 2007). 
 
1.7.2 Translational control of BACE1 
So far, several independent studies have reported that expression of BACE1 is 
regulated by different translational control mechanisms such as microRNA (miRNA), 
noncoding antisense transcript and translational repression via the 5`UTR (depicted in 
Figure 1.8). 
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Figure 1.8 Translational control of BACE1 mRNA (adapted from Willem et al, 
2009) 
BACE1 expression is regulated by different post-transcriptional mechanisms which are depicted in 
this image. The 5`cap is shown in orange.  uORFs (green), RNA binding proteins (red) and 
secondary structures are depicted in the 5`UTR.  miRNA binding sites and RNA binding proteins 
in the 3`UTR are shown in light blue and red, respectively.  The antisense transcript (brown) is 
shown below the BACE1 ORF. 
 
 
miRNAs are small non-coding RNA molecules and function via base-pairing with 
complementary sequences within mRNAs, usually resulting in translational repression or 
target degradation (Bartel, 2009; Kusenda et al., 2006).  Hebert et al. showed that lowered 
levels of miR-9 and loss of miR-29a/b correlates with increased BACE1 expression 
(Hebert et al., 2008).  Consistent with these findings, it was shown that overexpression of 
miR29c downregulates BACE1 protein levels (Zong et al., 2011).  Another study by Wang 
et al. suggests that decreased miR-107 level tend to upregulate BACE1 expression (Wang 
et al., 2008).  Boissonneault and collegues demonstrated that miR-298 and miR-328 
recognize specific elements in the BACE1 3`UTR and thereby downregulate BACE1 
expression in cultured neuronal cells (Boissonneault et al., 2009).  Moreover, Zhu et al. 
showed that inhibition of miR-195 results in increased BACE1 protein level (Zhu et al., 
2012).  Recently, it was suggested that miR-124 plays an essential role in the control of 
BACE1 expression (Fang et al., 2012). 
Besides the regulation via miRNAs, BACE1 mRNA and protein expression is 
regulated via a conserved noncoding antisense transcript for BACE1 (BACE1-AS) 
(Faghihi et al., 2008).  Faghihi et al. showed that BACE1-AS forms a RNA duplex with 
BACE1 which may alter secondary and tertiary structures thereby stabilizing BACE1 
mRNA (Faghihi et al., 2008).  Through downregulation of BACE1-AS the formed RNA 
duplex between BACE1 and BACE1-AS is disrupted and thereby the stability of BACE1 
mRNA is decreased and protein levels are downregulated (Faghihi et al., 2008).  
Consistent with these findings, it was shown that the concentration of BACE1-AS 
transcripts is elevated in AD patients as well as APP transgenic mice (Faghihi et al., 2008). 
BACE1 ORF AAAAAA
antisense transcript 3`UTR5`UTR
miRNA
binding sites
uORFs
secondary 
structuresRNA 
binding 
proteins
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Finally, several studies independently showed that the 5`UTR of BACE1 represses the 
translation of BACE1 mRNA, but not the transcription (De Pietri Tonelli et al., 2004; 
Lammich et al., 2004; Mihailovich et al., 2007; O'Connor et al., 2008; Rogers et al., 2004; 
Zhou and Song, 2006).  Previously, we and other groups could show that the expression of 
BACE1 is controlled via its 5’UTR (De Pietri Tonelli et al., 2004; Lammich et al., 2004; 
Rogers et al., 2004).  BACE1 mRNA has a 446 nucleotides long GC-rich (70%) 5`UTR 
with three uORFs.  It could be shown that the complex secondary structure and the second 
uORFs are involved in the translational repression of BACE1 expression (Lammich et al., 
2004; Mihailovich et al., 2007; O'Connor et al., 2008; Zhou and Song, 2006).  In general, 
complex secondary structures, the presence of uORF and the binding of trans-activating 
factors to the 5’UTR are responsible for modulating the translational efficiency (Gebauer 
and Hentze, 2004).  However, until now little is known about the factors that influence the 
BACE1 expression via its 5`UTR.  So far, only O’Connor and colleagues determined that 
energy deprivation results in increased efficiency of BACE1 mRNA translation (O'Connor 
et al., 2008).  They showed that this increase in BACE1 expression was due to the 
phosphorylation of the translation initiation factor eIF2α (O'Connor et al., 2008).  Upon 
phosphorylation of eIF2α, the concentration of the ternary complex consisting of eIF2, 
GTP and Met-tRNAiMet, which is required for translation initiation, is reduced (Sonenberg 
and Hinnebusch, 2009).  Thus, in the wake of eIF2α phosphorylation, the scanning 40S 
ribosomal subunit more likely bypasses secondary structures (Lu et al., 2004; Vattem and 
Wek, 2004).  Upon binding of the 60S ribosomal subunit, the production of the protein is 
then increased (Clemens, 2001; Holcik and Sonenberg, 2005).  Under normal conditions, 
reinitiating ribosomes rebind the ternary complex and reinitiate at uORFs (Sonenberg and 
Hinnebusch, 2009).  The observed increase in BACE1 translation is similar to the 
translation of GCN4 and ATF4 (Hinnebusch, 1997; Vattem and Wek, 2004). 
 
1.7.3 Translational control of ADAM10 
For ADAM10, it was reported that its expression could be repressed under hypoxia in 
the human neuroblastoma SH-SY5Y cells by post-transcriptional mechanisms (Marshall et 
al., 2006; Webster et al., 2004).  Under hypoxic conditions ADAM10 protein levels were 
decreased by approximately 60%, resulting in a decrease of APPsα production.  In 
contrast, no change in the expression of the ADAM10 mRNA could be detected (Marshall 
et al., 2006).  The protein levels of BACE1 were unchanged.  In addition, ADAM10 
expression is regulated by miRNAs.  Bai et al. showed that the liver-specific miR-122 
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represses ADAM10 expression (Bai et al., 2009).  Recently, a computational approach 
predicted several miRNA binding sites for the ADAM10 3`UTR (Augustin et al., 2012).  
Expression of miR103, miR107 and miR1306 reduced the activity of a luciferase reporter 
containing the ADAM10 3`UTR (Augustin et al., 2012).  Besides the miRNAs, nELAV 
was shown to bind to the 3`UTR of ADAM10 (Amadio et al., 2009).  Reduction of 
nELAV results in decreased ADAM10 protein levels (Amadio et al., 2009). 
Finally, Lammich and colleagues could show that the 5`UTR of ADAM10 represses 
the translation of ADAM10 mRNA, but not the transcription (Figure 1.9) (Lammich et al., 
2010).  This was shown by transfection of HEK293 cells with ADAM10 with and without 
5`UTR.  Expression levels of ADAM10 in these cells were analysed by immunoblotting 
(Figure 1.9A).  Deletion of the 5`UTR resulted in a 3-fold increase of ADAM10 expression 
(Figure 1.9B).  In addition, analysis of mRNA levels demonstrated that the observed effect 
on protein expression is independent from an increase in transcription (Figure 1.9C).  
Moreover, the two potential uORFs within 444-nucleotide-long, GC-rich 5`UTR of 
ADAM10 had no influence on the translation of ADAM10 mRNA (Lammich et al., 2010). 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Translational regulation of ADAM10 expression (Lammich et al., 2010). 
(A) HEK293 cells were transiently transfected with ADAM10 or ADAM10 containing the 5`UTR 
together with GFP as transfection control.  The upper Western blot shows immature (im) ADAM10 
expression, the middle β-Actin expression and the lower GFP expression.  (B) Western blots were 
quantified and ADAM10 protein was normalised to GFP and β-actin levels.  The signal for 
ADAM10 containing the 5′UTR was set to 1.  (C) The ADAM10 mRNA of the transfected cells 
was quantified by RT-PCR.  ADAM10 mRNA levels were normalised to GAPDH mRNA levels 
using the 2-∆∆Ct method.  The result obtained for ADAM10 with 5`UTR mRNA was set to 1.  
Values are expressed as the mean ± standard deviation of 6 independent experiments made in 
triplicates. 
 
 
Complex secondary structures in the 5`UTR of ADAM10 and/or RNA-binding 
proteins might be responsible for the translational repression of ADAM10 expression.  
Recently, it could be shown that the ADAM10 expression is inhibited by a G-quadruplex 
A B C
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secondary structure near the 5`end of the ADAM10 5`UTR (Lammich et al., 2011).  G-
quadruplex structures can block the formation or scanning of the preinitiation complex 
(Huppert et al., 2008).  So far no further factors that influence the ADAM10 expression via 
its 5`UTR have been identified.  However, the inhibition by the G-quadruplex could be 
modulated by RNA-binding proteins (Khateb et al., 2004; Menon et al., 2008). 
 
1.8 Aim of the study 
Several studies showed that in AD patients BACE1 levels were elevated by a factor of 
2.7 in comparison to brains of patients having no AD (Fukumoto et al., 2002; Holsinger et 
al., 2002; Yang et al., 2003), although mRNA levels were not increased (Holsinger et al., 
2002; Preece et al., 2003; Yasojima et al., 2001b).  In addition, it was demonstrated that 
ADAM10 expression is also regulated by translational control mechanisms (Lammich et 
al., 2010; Lammich et al., 2011). 
For BACE1, it could be shown that a complex secondary structure and the second 
uORF are involved in the translational repression of BACE1 expression (Lammich et al., 
2004; Mihailovich et al., 2007; O'Connor et al., 2008; Zhou and Song, 2006).  
Furthermore, deletion of the first half of the BACE1 5`UTR revealed a striking increase in 
BACE1 protein expression (Lammich et al., 2004).   
Furthermore, Lammich and colleagues could show that the 5`UTR of ADAM10 
inhibits the translation of the ADAM10 mRNA (Lammich et al., 2010).  Again, in the 
absence of the 5`UTR, ADAM10 protein levels were significantly increased while mRNA 
levels were not changed.  Stepwise deletion of the first half of the ADAM10 5`UTR 
revealed a striking increase in ADAM10 protein expression, suggesting that this part of the 
5`UTR contains inhibitory elements for translation.  Moreover, a G-quadruplex secondary 
structure in the first half of the ADAM10 5`UTR was identified, which inhibits ADAM10 
translation (Lammich et al., 2011). 
These data demonstrate translational repression as a new mechanism controlling 
ADAM10 and BACE1 expression.  RNA-binding proteins could be involved in 
translational control of certain genes by interacting with secondary structures or specific 
sequences within the 5`UTR (Derrigo et al., 2000; Gray and Hentze, 1994; Gray and 
Wickens, 1998; Melefors and Hentze, 1993; Mignone et al., 2002; Sonenberg, 1994; 
Wilkie et al., 2003).  The observed effects on the protein expression might thus be 
explained by proteins that bind to the 5`UTR and modulate ADAM10 and/or BACE1 
translation.  Such proteins binding to the 5`UTR of ADAM10 and/ or BACE1 can e.g. 
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inhibit the early steps of the translation process or modulate higher-ordered structures that 
influence translation efficiency (Khateb et al., 2007; Menon et al., 2008; Muckenthaler et 
al., 1998). 
Since ADAM10 plays a crucial role in the pathogenesis of AD, the goal of this PhD 
thesis was to identify proteins which may affect ADAM10 translation via binding to their 
5`UTR.  Such proteins may be important during development and may be misregulated 
during ageing and in AD.  Thus, these proteins could provide novel therapeutic targets for 
AD treatment.  Given that BACE1 expression plays also a crucial role in the pathogenesis 
of AD and that there was also a interest in the regulation of BACE1 expression in our 
research group, the BACE1 5`UTR was included in some of the experiments. 
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2 Materials and Methods 
2.1 Devices and materials 
2.1.1 Molecular biology 
PCR machine (Mastercycler personal, Mastercyclergradient) Eppendorf 
Real-Time PCR System (7500 Fast)     Applied Biosystems 
MicroAmpTM (Optical Adhesive Film)    Applied Biosystems 
Photometer (Smart SpecTM 3000)     Bio-Rad 
Benchtop room temperature centrifuge (Biofuge pico)  Heraeus 
Benchtop 4°C centrifuge (Biofuge fresco, Fresco 17)  Heraeus, Thermo 
4°C centrifuge (Megafuge 1.0R, Multifuge 3 L-R)   Heraeus 
Centrifuge (AvantiTM J-20XP, J-25)     Beckman Coulter 
 Rotors: Type JA-10, JA-20, JA-25.50)   Beckman 
Ultracentrifuge (OptimaTM LE-80K)     Beckman Coulter 
 Rotors: 50 Ti, 70 Ti, 70.1 Ti     Beckman 
Ultracentrifuge (OptimaTM MAX-E Ultracentrifuge)  Beckman Coulter 
 Rotor: TLA 55      Beckman 
37°C incubator (Function Line)     Heraeus 
Freezer -20°C        Elektrolux 
Fridge 4°C        Elektrolux 
Autoclave (Tuttnauer 3850 EL)     Systec 
Water deionizing machine (Milli-Q academic)   Millipore 
Pipettier (Accu-Jet®)       Brand 
Disposable pipettes (25 ml, 10 ml, 5 ml, 2 ml)   Corning, Sarstedt 
Pipette tips (1 ml, 200 µl, 10 µl)     Sarstedt 
Filter pipette tips (1 ml, 300 µl, 100 µl, 20 µl, 10 µl)  Sarstedt 
Disposable tubes (50 ml, 15 ml, 2 ml, 1.5 ml, 0.5 ml, 0.2 ml) Sarstedt 
Waterbath (Typ 1002)      GFL 
Heating blocks       Liebisch 
Shaker (KM-2)       Edmund Bühler 
Bacterial culture shaker (Certomat BS-1)    B. Braun Biotech 
Agarose gel electrophoresis chambers    Peqlab, 
  Owl Separation Systems 
Microwave        Bosch 
Rotator (Roto-Shake GenieTM)     Scientific Industries 
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Thermo-shaker (Thermomixer compact)    Eppendorf 
Magnet stirrer (RCT basic, KMO 2 basic)    IKA Labortechnik 
pH-Meter (Inolab pH Level 1)     WTW 
Scale (Analytical plus 200g – 0.0001 g)    Ohaus 
Scale (Precision standard 2000 g – 0.01 g)    Ohaus 
Disposable cuvette (Polystyrol / Polystyrene, 10 x 4 x 45 mm) Sarstedt 
Quarz spectrophotometer cuvette (10 mm)    Hellma/Bio-Rad Labs 
Vortexer (Vortex Genie 2)      Scientific Industries 
Gel analysis device:       MS Laborgeräte 
UV lamp (White/Ultraviolet Transilluminator (UVP)) 
Camera (CCD Video Camera Module) 
Software (Quickstore plus II) 
Printer (P91, Mitsubishi) 
 
2.1.2 Protein analysis 
Plate reader (PowerWaveXS)     BioTek Instruments 
Gen5TM software       BioTek Instruments 
Power supplies (PowerPac 300, PowerPacTM basic)   Bio-Rad 
Gel apparatus (Mini-PROTEAN® Cell)    Bio-Rad 
Gel apparatus (X Cell Sure LockTM Mini Cell)   Invitrogen 
Blotting device (Mini Trans-Blot® Cell)    Bio-Rad 
Film developing device (Cawomat 2000 IR)   Cawo 
Slab Gel Dryer SGD2000      Savant 
Gel and blot documentation system (FluorChemTM 8900)  AlphaInnotech 
Luminescent Image Analyser (FujiFilm LAS4000)   FujiFilm 
Scanner (V200 Photo)      Epson 
 
2.1.3 Cell culture 
Clean bench (Hera Safe HS12)     Heraeus 
Bunsen burner (gasprofi 2SCS)     WLD-TEC 
Vacuum pump       Vaccubrand 
CO2-incubator (Hera cell)      Heraeus 
Centrifuge (Megafuge 1.0)      Heraeus 
Waterbath (Typ 1003)      GFL 
Methods 
37 
Microscope (Wilovert S)      Hund 
Sterile disposable pipettes (2 ml, 5 ml, 10 ml, 25 ml)  Sarstedt, Corning 
Sterile disposable tubes (15 ml, 50 ml)    Sarstedt 
Glass Pasteur pipettes      VWR International 
Culture dishes (92 x 17 mm, 60 x 15 mm, 6 well, 24 well)  Nunc 
N2-tank (Chronos)       Messer 
Freezer -80°C (Hera freeze)      Thermo 
 
2.2 Enzymes, Kits and Chemicals 
All general chemicals were, unless otherwise stated, purchased from Merck KGaA, 
Darmstadt, Carl Roth GmbH & Co.KG, Karlsruhe or Sigma-Aldrich Chemie GmbH, 
Taufkirchen. 
 
2.2.1 Molecular biology 
Agarose        Invitrogen 
Bacto-Agar        Becton, Dickson 
Bacto-Trypton       Becton, Dickson 
Yeast-extract        Becton, Dickson 
Triton-X100        USB 
RibomaxTM Large Scale RNA Production System – T7  Promega 
Biotin-14-CTP       Invitrogen 
GlycoBlueTM Coprecipitant      Ambion 
RNase Inhibitor Cloned      Ambion 
Ribonuclease Inhibitor      Fermentas 
BrightStarTM Biotinylated RNA CenturyTM Size Markers  Ambion 
BrightStar® BioDetectTM Nonisotopic Detection System  Ambion 
Streptavidin agarose       Invitrogen 
MAXIscript® In vitro Transcription Kit – T7   Ambion 
MEGAscript® High-Yield Transcription Kit   Ambion 
Ribo m7G Cap Analog      Promega 
Quick Spin Columns       Roche 
(G-50 Sephadex Columns for Radiolabelled RNA Purification) 
µMACSTM Streptavidin Kit      Miltenyi Biotec 
RNeasy® Mini Kit       Qiagen 
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RNase-Free DNase Set      Qiagen 
SuperScriptTM First-Strand Synthesis System for RT-PCR  Invitrogen 
Taq DNA polymerase      Roche 
GoTaq® DNA Polymerase      Promega 
PCR Nucleotide Mix       Roche 
2x Power SYBR Green PCR Master Mix     Applied Biosystems 
2x TaqMan Buffer       Applied Biosystems 
20x TaqMan Gene Expression Assay Mix    Applied Biosystems 
Glutathione Sepharose 4B      GE Healthcare 
Ni-NTA agarose       Qiagen 
NucleoSpin Plasmid       Macherey-Nagel 
NucleoBond plasmid purification (AX500)    Macherey-Nagel 
NucleoBond Xtra Midi      Macherey-Nagel 
NucleoSpin Extract II (PCR Clean-up, Gel Extraction)  Macherey-Nagel 
DNA molecular weight marker (100 bp, 1 kb)   Invitrogen 
Pwo PCR-system       Roche 
T4 ligase and 10x T4 ligase buffer     Fermentas 
Restriction endonucleases      NEB, Fermentas 
 
2.2.2 Protein biochemistry 
APS         Merck, Sigma 
TEMED        Roth 
Protease Inhibitor Cocktail      Sigma 
Bio-Rad Protein Assay (Bradford)     Bio-Rad 
BC Assay Reagent A + B      Interchim 
BSA standard        Interchim 
96 well plates for protein assay     Nunc 
DTT         Biomol 
PMSF         Sigma 
Tropix® I-Block       Applied Biosystems 
SDS         Serva 
See-Blue® Plus2 Pre-Stained Standard    Invitrogen 
Novex® Tricine Gels       Invitrogen 
PVDF transfer membrane (Immobilion-P)    Millipore 
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Nitrocellulose transfer membrane (Protan®)    Schleicher & Schuell 
Whatman paper       Schleicher & Schuell 
ECL Western blotting Detection Reagents    GE Healthcare 
ECL Plus Western blotting Detection Reagents   GE Healthcare 
Tropix® CDP Star®       Applied Biosystems 
Super RX, Fuji Medical X-ray Film     Fujifilm 
Spectra/Por 6 Regenerated Cellulose Dialysis Membranes 
(MWCO 10000)       Spectrum Laboratories 
SilverQuestTM Silver Staining Kit     Invitrogen 
96-well MULTI-SPOT® Human (6E10) Abeta Triplex Assay MSD 
 
2.2.3 Cell culture 
DMEM + GlutaMAXTM-I, high glucose without pyruvate  Gibco Invitrogen 
Foetal Bovine Serum       PAA 
OPTI-MEM®I + GlutaMAXTM-I (1x)    Gibco Invitrogen 
Penicillin/Streptavidin (100x, 5 mg/ml)    PAA 
L-Glutamine (100x, 200 mM)     PAA 
ZeocinTM (100 mg/ml)      Gibco Invitrogen 
Trypsin-EDTA (1x)       Gibco Invitrogen 
LipofectamineTM 2000      Invitrogen 
 
2.2.4 Vectors 
2.2.5 Eukaryotic expression vectors 
pcDNA6/V5-HisA       Invitrogen 
pcDNA4/Myc-HisA       Invitrogen 
pcDNA3.1(+) Zeo       Invitrogen 
psiCHECK-2        Promega 
BSENU6        Ambion 
pEGFP-N1        Clontech 
 
2.2.6 Prokaryotic expression vectors 
pGex-5X-1        GE Healthcare 
pGEM-3Z        Promega 
pET28a        Novagen 
Methods 
40 
2.3 Oligonucleotides 
All oligonucleotides were made by Thermo Electron GmbH and were all of an HPLC-
purified grade (oligonucleotides are listed in Tables 2.1, 2.3 and 2.5). 
 
2.4 Plasmids 
Construct Oligonucleotide Vector Restriction 
site  
 
ADAM10 5`UTR 5`cgc gct agc gcg gcg gca ggc cta g`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§1 
ADAM10 5`UTR 5`cgc aag ctt gcg gcg gca ggc cta g`3 
5`ctc gaa ttc ctg ccg ccg ccg ccg`3 
pGEM-3Z HindIII / 
Eco RI 
§3 
ADAM10 5`UTR 5`cgc gaa ttc gcg gcg gca ggc cta g`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pGEM-3Z EcoRI / 
HindIII 
§3 
∆251-432 
ADAM10 5`UTR 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`aag ctt ggg acc tcc ctc ccc ctc gt`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§3 
∆1-259 
ADAM10 5`UTR 
5`cgc gct agc gga gct agg agc gtt`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§3 
∆1-215 
ADAM10 5`UTR 
5`cgc gct agc gga gga agg aaa cga`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§3 
∆1-175 
ADAM10 5`UTR 
5`cgc gct agc gag aga ggg acc`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§3 
∆1-155 
ADAM10 5`UTR 
5`cgc gct agc tga gtt tcg aag gag`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§3 
∆164-246 
ADAM10 5`UTR 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`aaa cag gga gaa act cag acc tcc gcc tcc`3 
5`ctg agt ttc tcc ctg ttt tgg agg agc tag gag cg`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§1 
∆164-201 
ADAM10 5`UTR 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`ccg ctt tcc gaa act cag acc tcc gcc tcc`3 
5`ctg agt ttc gga aag cgg gga aag gag aag g`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§1 
∆204-246 
ADAM10 5`UTR 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`cca aaa cag gga cct tcc ctt gct cgt tcc`3 
5`aag gga agg tcc ctg ttt tgg agg agc tag gag cg`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§1 
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Construct Oligonucleotide Vector Restriction 
site  
 
∆1-163/247-432 
ADAM10 5`UTR 
5`cgc aag ctt cct ccc tcc ccc tcg ttc`3 
5`cgc gct agc gag gga ggg ggg gag ag`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§1 
 
5`UTR ADAM10 5`cgc gct agc gcg gcg gca ggc cta g`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
XhoI 
§1 
∆164-204 5`UTR 
ADAM10 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`ccg ctt tcc gaa act cag acc tcc gcc tcc`3 
5`ctg agt ttc gga aag cgg gga aag gag gaa gg`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
XhoI 
§1 
∆204-246 5`UTR 
ADAM10 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`cca aaa cag gga cct tcc ctt gct cgt tcc`3 
5`aag gga agg tcc ctg ttt tgg agg agc tag gag cg`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
XhoI 
§1 
∆164-246 5`UTR 
ADAM10 
5`cgc gct agc gcg gcg gca ggc cta g`3 
5`aaa cag gga gaa act cag acc tcc gcc tcc`3 
5`ctg agt ttc tcc ctg ttt tgg agg agc tag gag cg`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
XhoI 
§1 
∆1-215 5`UTR 
ADAM10 
5`cgc gct agc gga gga agg aaa cga`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
XhoI 
§1 
∆1-259 5`UTR 
ADAM10 
5`cgc gct agc gga gct agg agc gtt`3 
5`ctc aag ctt ctg ccg ccg ccg ccg`3 
pcDNA6/ 
V5-HisA 
NheI / 
XhoI 
§1 
UNR 5`cgc gga tcc gcc acc atg agc ttt gat cca aac ctt 
ctc`3 
5`cgc ctc gag gtc aat gac acc agc ttg acg g`3 
pcDNA4/ 
myc-HisA 
BamHI/ 
XhoI 
§4 
 
UNR 5`cgc ggg atc ccc atg agc ttt gat cca aac ctt ctc 
c`3 
5`cgc ctc gag tta gtc aat gac acc agc ttg acg`3 
pGEX5X-1 BamHI/ 
XhoI 
§4 
 
UNR 5`cgc ctc gag atg agc ttt gat cca aac ctt ctc`3 
5`cac gcg gcc gcg tca atg aca cca gct tga cgg`3 
psiCHECK XhoI / 
NotI 
§2, 5 
Unr KD 5`G aga ccg acg tga caa att aTT CAA GAG Ata 
at ttg tca cgt cgg tct Ctt ttt ctg ca`3 
5`C tct ggc tgc act gtt taa taA GTT CTC Tatta 
aac agt gca gcc aga G aaaaa g`5 
BSENU6 PmeI / 
PstI 
§2 
APAF-1 5`UTR  5`cgc gct agc aag aag agg tag cga gtg g`3 
5`cgc aag ctt ctt ccc tca gat ctt tct c`3 
pcDNA6/ 
V5-HisA 
NheI / 
HindIII 
§6 
 
Methods 
42 
Construct Oligonucleotide Vector Restriction 
site  
 
hnRNP A1 5`cgc gaa ttc atg tct aag tca gag tct c`3 
5`cgc ctc gag tta aaa tct tct gcc act gcc`3 
pET28a EcoRI / 
XhoI 
§6 
hnRNP B1 5`cgc gaa ttc atg gag aaa act tta gaa ac`3 
5`cgc ctc gag tca gta tcg gct cct ccc acc`3 
pET28a EcoRI / 
XhoI 
§6 
Table 2.1 Overview of the constructs and the vectors as well as the restriction 
enzyme sites, which were used to clone the constructs into the respective vector. 
§1 These constructs were generated by Dr. Dominik Büll 
§2 These constructs were generated by Dr. Sven Lammich 
§3 Template: pcDNA6/V5-HisA ADAM10 5`UTR 
§4 Template: IRATp970F0251D6 from RZPD 
§5 Template: pcDNA4/myc-HisA UNR 
§6 Template: cDNA library provided by Dr. Sven Lammich 
 
2.5 Antibodies 
2.5.1 Primary antibodies 
Anti-ADAM10, C-terminus, polyclonal antibody  1:1000  Millipore 
Anti-ADAM10, polyclonal antibody    1:7500  Calbiochem 
Anti-CSDE1 (UNR)      1:2000  Sigma 
b-Myb        1:200  Hybridoma Bank 
Histone H3 antibody – ChIP Grade (ab1791)  1:5000  Biozol, Abcam 
Rabbit serum 23 anti-Unr (Jacquemin-Sablon et al., 1994) 
Anti-Actin, monoclonal antibody    1:2000  Sigma 
Anti-α-tubulin, monoclonal antibody   1:1000  Sigma 
β-Amyloid, 1-16 (6E10) monoclonal antibody  1:1000  Signet 
mouse anti-APP A4, monoclonal antibody (22C11)  1:2000  Chemicon 
APP-CT       1:1000  Sigma 
192wt, polyclonal antibody     1 µg/ml Elan 
Pharmaceuticals 
2D8, monoclonal antibody     1 µg/ml E. Kremmer 
7C2 (UNR) , monoclonal antibody    1 µg/ml E. Kremmer 
Anti-Calnexin, polyclonal antibody    1:5000  Stressgen 
Anti-V5, monoclonal antibody    1:5000  Invitrogen 
Anti-GFP, monoclonal antibody    1:2000  Clontech 
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2.5.2 Secondary antibodies 
Anti-mouse-HRP      1:10000 Promega 
Anti-rabbit-HRP      1:10000 Promega 
Anti-rat       1:5000  Santa Cruz 
 
2.6 DNA techniques 
2.6.1 Agarose gel electrophoresis 
TAE-buffer (1x): 
40 mM Tris base, 40 mM glacial acetic acid, 1 mM EDTA 
 
TBE-buffer (1x): 
89 mM Tris base, 89 mM boric acid, 2 mM EDTA 
 
DNA loading buffer (10x): 
15% Ficoll 400, 0.25% Orange G in H2O 
 
DNA loading buffer (5x): 
50% Glycerol, 50% 10x TBE, Bromophenol, Xylene Cyanol FF 
 
Ethidium bromide: 
10 mg/ml in dH2O 
 
Horizontal slab gels were prepared from agarose, electrophoresis grade dissolved in 1x 
TAE or 1x TBE.  Ethidium bromide was added to a concentration of 0.5 µg/ml.  For the 
electrophoretic separation and analysis of linear DNA fragments, superhelical plasmid 
DNA and for the isolation of DNA fragments 0.8 – 2% agarose gels were used.  A 1/10th 
volume of gel loading buffer was added to all DNA samples before loading onto a gel.  A 
100-bp- or 1-kb-size marker was used to define the size of the DNA fragment.  Gel 
electrophoresis was performed in 1x TAE or 1x TBE buffer at a constant voltage of 120 V 
for 30 to 60 min.  Ethidium bromide-stained bands were visualized with a 
White/Ultraviolet Transilluminator (UVP) at 312 nm.  Gel images were captured with a 
CCD video camera module (Kaiser) and reproduced with a Mitsubishi P91 video copy 
processor. 
 
2.6.2 Quantification of DNA 
DNA concentration was estimated by measuring the absorbance of aqueous DNA 
solutions with a Smart Spec 3000 (Bio-Rad) at 260 nm.  Pure DNA at 50 ng/µl has an A260 
of 1.0. 
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2.6.3 Polymerase Chain Reaction (PCR) 
PCR was used to amplify the plasmid DNAs used in this thesis.  PCR reactions were 
performed in a total volume of 50 µl containing 10 ng to 50 ng of plasmid DNA, 5 µl Pwo 
10x PCR buffer (Peqlab), 100 ng forward primer, 100 ng reverse primer, 2 µl dNTPs (10 
nM each) (Roche), 1 µl Pwo-polymerase (1 unit/µl) (Peqlab) and adjusted to 50 µl with 
distilled water.  PCR was performed using a Mastercycler personal (Eppendorf) or 
GeneAmp PCR System 2400 (Perkin Elmer).  Cycle conditions varied between the 
different constructs (see below). 
 
Unr program 
Denaturing: 94°C  3 min 
Denaturing: 94°C  30 sec 
Annealing: 42°C  30 sec        10 cycles 
Elongation: 72°C  2 min 
Denaturing: 94°C  30 sec 
Annealing: 42°C  30 sec        20 cycles 
Elongation: 72°C  2 min 
   + 20 sec / cycle 
Elongation: 72°C  10 min 
hold at 4°C 
 
 
5`UTR ADAM10 program 
Denaturing: 95°C  3 min 
Denaturing: 95°C  30 sec 
Annealing: 50°C  30 sec        35 cycles 
Elongation: 72°C  2 min 
Elongation: 72°C  10 min 
hold at 4°C 
PCR products were analysed by agarose gel electrophoresis (see 2.6.1).  The amplified 
DNA fragments were gel purified (see 2.6.4) and digested with the respective enzymes 
(see 2.6.5).  The resulting fragments were used for further cloning (see 2.6.6). 
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2.6.4 DNA extraction from agarose gels 
DNA was recovered and purified from agarose gels according to the NucleoSpin® 
Extract II kit (Macherey-Nagel) protocol.  Briefly, desired DNA bands were excised from 
the agarose gel with a clean, sharp scalpel blade on a UV screen and weighed in a 1.5 ml 
tube.  Two volumes of buffer NT were added to one volume of gel.  Then the reaction was 
incubated at 50°C for 10 min to solubilize the agarose.  After 10 min, the sample was 
transferred to a NucleoSpin® Extract II column and centrifuged for 1 minute at 13000 rpm 
to bind the DNA.  Then 600 µl of buffer NT3 was added to the NucleoSpin® extract II 
column and centrifuged twice for 1 to 2 min at 13000 rpm.  Finally, the NucleoSpin® 
Extract II column was inserted into a clean 1.5 ml microcentrifuge tube, 15-50 µl elution 
buffer NE was added to the NucleoSpin® Extract II column, incubated for 1 minute at 
room temperature and centrifuged for 1 minute at 13000 rpm to elute DNA. 
 
2.6.5 Restriction enzyme digest 
All restriction enzyme digests were performed with restriction enzymes purchased 
from Fermentas or NEB. 
Analytical restriction enzyme digests after plasmid preparation were carried out in a 
total volume of 20 µl, containing 1 µg DNA, 0.5 µl of the required enzymes and 2 µl of the 
recommended reaction buffer.  Digests were incubated for 1h at 37°C.  Digested DNA 
products were separated by agarose gel electrophoresis (see 2.6.1). 
Preparative restriction enzyme digests for cloning were carried out in a total volume of 
30 µl containing 2-5 µg DNA or the respective PCR product, 1 µl of the required enzymes 
and 3 µl of the recommended reaction buffer.  Digests were incubated for at least 1h or 
overnight at 37°C.  Digested DNA fragments were separated by agarose gel 
electrophoresis and purified as described above (see 2.6.1 and 2.6.4). 
Preparative restriction enzyme digests for in vitro transcription were carried out in a 
total volume of 100 µl, containing 15-30 µg plasmid DNA, 5 µl of the required enzymes 
and 10 µl of the recommended reaction buffer.  Digests were incubated overnight at 37°C.  
The linearised DNA was separated by agarose gel electrophoresis and purified as described 
above (see 2.6.1 and 2.6.4). 
 
2.6.6 Ligation of cDNA fragments into vector DNA 
Agarose gel purified digested DNA was cloned in between the desired restriction sites 
of the respectively digested vector to produce the desired plasmid.  Ligations were carried 
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out in a total volume of 20 µl, containing 2 µl digested DNA, 2 µl vector and 1 µl T4 DNA 
ligase in the supplied T4 ligase buffer.  The mixture was incubated for 1-2 h or overnight at 
room temperature.  In parallel, to control re-ligation of the vector, the vector was incubated 
without insert.  10 µl of the ligation reaction were then used for the transformation of 
competent bacteria of E.coli strain DH5α (see 2.6.8). 
 
2.6.7 Preparation of competent DH5α and BL21 (DE3) cells 
CaCl2-buffer: 
50 mM CaCl2, 10 mM Tris, pH 8.0 in dH20, sterile filtered 
 
LB-Medium: 
1% (w/v) Bacto-Tryptone, 0.5% (w/v) Yeast extract, 0.5% (w/v) NaCl in dH2O, autoclaved 
 
One colony of a freshly struck LB agar plate with DH5α or BL21 (DE3) was picked 
and dispersed in 3 ml LB medium to grow overnight at 37°C.  The 3 ml overnight DH5α 
or BL21 (DE3) culture in LB medium was used to inoculate 300 ml fresh LB medium.  
Bacteria were cultured to a density of OD600 = 0.5 at 37°C by shaking at 200 rpm.  Then 
the culture was collected into 50 ml polypropylene centrifuge tubes (e.g., Falcon tubes) and 
centrifuged at 3000 rpm for 5 min at 4°C.  Each bacterial pellet was resuspended in 17.5 
ml cold CaCl2-buffer, incubated on ice for at least 30 min and centrifuged as before.  The 
bacterial pellets were resuspended in 1 ml CaCl2-buffer, supplemented with 20% glycerol, 
and 100-200 µl aliquots of the suspension were stored at -80°C. 
 
2.6.8 Transformation of DNA constructs into DH5α or BL21 
LB-medium: 
see 2.6.7 
 
LB agar plates: 
LB-medium, 1.5% agar, autoclaved 
 
An aliquot (100 µl) of competent DH5α or BL21 (DE3) cells was thawed on ice, 10 µl 
of the ligation reaction or 50 ng plasmid DNA (re-transformation) was added, mixed gently 
and incubated on ice for 30 min.  After a heat shock at 42°C for 2 min, cells were 
incubated for additionally 2 min on ice.  Then 300 µl of fresh LB medium was added to the 
mixture and bacteria were incubated for 1 h at 37°C with shaking at 750 rpm.  The mixture 
was briefly centrifuged, the pellet resuspended in 100 µl of LB and then plated onto a LB-
agar plate containing the respective antibiotic to select positive clones.  LB-agar plates 
were incubated overnight at 37°C.  Colonies were picked, inoculated into 3 ml fresh LB 
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medium containing the desired antibiotic and incubated overnight at 37°C.  1.5 ml of the 
overnight culture was used for mini prep (see 2.6.9). 
 
2.6.9 Small-scale plasmid preparation (Mini-prep) 
LB-medium: 
see 2.6.7 
 
TENS: 
10 mM Tris, pH 8.0, 1 mM EDTA, pH 8.0, 100 mM NaCl, 0.5% SDS in dH2O 
 
Na-Acetate: 
3 M Na-Acetate, pH 5.2 with acetic acid 
 
RNase – DNase free: 
10 mg/ml RNase in 10 mM Tris, pH 7.5 and 15 mM NaCl, incubation for 15 min at 95°C, slowly cooling 
down at room temperature, store aliquots at -20°C 
 
Plasmid DNA was isolated in smaller amounts (Mini-preps) by the alkaline lysis 
method (Zhou et al., 1990), described as follows: Usually, a volume of 3 ml of LB-media 
supplement with the appropriate antibiotic was inoculated with a single bacterial colony 
and cultured overnight at 37°C and 200 rpm.  The next day, 1.5 ml overnight culture was 
collected into 1.5 ml tube and centrifuged for 1 min at 13000 rpm.  The supernatant was 
gently discarded, leaving 50-100 µl with bacterial pellet and the bacterial pellet 
resuspended in the leftover supernatant by vortexing.  The bacterial cells were lysed in 300 
µl TENS buffer by gently inverting the suspension.  Then the suspension was neutralized 
by adding 150 µl 3 M NaOAc, pH 5.2 by gently inverting the suspension.  Afterwards the 
insoluble fraction (cell debris and chromosomal DNA) was removed by centrifugation at 
13000 rpm for 5 min at room temperature.  The supernatant was transferred into a fresh 1.5 
ml tube containing 900 µl -20°C cold 100% ethanol, mixed well and incubated for at least 
20 min at -80°C.  Plasmid DNA and RNA were precipitated by centrifugation at 13000 
rpm for 2 min at 4°C.  The pellet was rinsed twice with 4°C cold 70% Ethanol and 
centrifuged at 13000 rpm for 2 min at 4°C.  Thereafter, the pellet was dried for 5 min at 
37°C, resuspended in 30 µl dH2O/RNase solution (1 µg/µl) and incubated for 30 min at 
37°C.  To identify positive clones, 5 µl of the mini prep DNA was digested (see 2.6.5) with 
the same restriction enzymes that were used to get sticky ends before ligation and analysed 
by agarose gel electrophoresis (see 2.6.1). 
One of typically several positive clones containing the predicted size of insert cDNA 
fragment was selected and used for medium- or large-scale DNA preparation. 
For directly sequencing, a Mini-prep preparation the DNA was isolated using the 
NucleoBond Plasmid kit according to the manufacturer`s instructions. 
Methods 
48 
2.6.10 Medium-scale plasmid preparation (Midi-prep) 
Plasmid DNA was isolated in medium amounts (Midi-preps) using the NucleoBond 
Xtra Midi kit described as follows: Usually, a volume of 100 ml of LB-medium 
supplemented with the appropriate antibiotic was inoculated with a single bacterial colony 
and cultured overnight at 37°C and 200 rpm.  The next day, the bacteria culture was 
centrifuged in centrifuge bottles at 5000 rpm for 15 min at 4°C.  The supernatant was 
removed and the pellet resuspended in 8 ml of cold resuspension buffer RES + RNase A by 
pipetting the cells up and down.  Afterwards, 8 ml of lysis buffer LYS was added, mixed 
gently by inversion and incubated for 5 min at room temperature.  Next, a NucleoBond® 
Xtra Column together with the inserted column filter was equilibrated with 12 ml 
equilibration buffer EQU by applying the buffer onto the rim of the column filter.  The 
column was allowed to empty by gravity flow.  Then 8 ml of neutralisation buffer NEU 
was added to the suspension and the lysates was immediately mixed gently by inversion.  
The lysates was simultaneously cleared and loaded onto the column and the column was 
allowed to empty by gravity flow.  The NucleoBond® Xtra column filter and column was 
washed with 5 ml equilibration buffer EQU.  The buffer was applied to the funnel shaped 
rim of the filter to make sure that the lysates, which was remaining in the filter, was 
washed out.  Afterwards, the NucleoBond® Xtra column filter was discarded and the 
column was washed with 8 ml wash buffer WASH.  The column was transferred to a 50 ml 
Falcon tube and the plasmid DNA was eluted with 5 ml elution buffer ELU.  To precipitate 
the eluted plasmid DNA, 3.5 ml isopropanol (at room temperature) was added, vortexed 
well and the mixture was left on the bench for 2 min.  Then the plasmid DNA was 
recovered by centrifugation at 6000 rpm for 30 min at 4°C.  Finally, the DNA pellet was 
washed with 2 ml 70% ethanol, dried for at least 10 min at room temperature, before being 
resuspended in 100 to 200 µl distilled water dependent on the pellet size and transferred to 
a 1.5 ml microcentrifuge tube.  5 µl DNA was diluted in 495 µl H2O and used for DNA 
concentration measurement (see 2.6.2).  To control the plasmid DNA, 1 µg DNA was 
digested with the respective enzymes (see 2.6.5) and analysed by agarose gel 
electrophoresis (see 2.6.1). 
 
2.6.11 Large-scale plasmid preparation (Maxi-prep) 
Plasmid DNA was isolated in larger amounts (Maxi-prep) using the NucleoBond 
PC500 kit described as follows: Usually, a volume of 200 ml of LB-media supplemented 
with the appropriate antibiotic was inoculated with a single bacterial colony and cultured 
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overnight at 37°C and 200 rpm.  The next day, the culture was centrifuged in bottles at 
5000 rpm for 15 min at 4°C.  The supernatant was removed and the pellet resuspended in 
10 ml of cold resuspension buffer S1 by pipetting up and down.  Afterwards, 10 ml of lysis 
buffer S2 was added and mixed gently by inversion.  Then 10 ml of neutralisation buffer 
S3 was added, mixed thoroughly by inversion and incubated on ice for 5 min.  Before the 
solution was decanted through a wetted paper filter onto a column, the column was 
moistened with equilibration buffer N2.  The column was filled with wash buffer N3, 
transferred to a 50 ml Falcon tube and the DNA was eluted with 15 ml elution buffer N5.  
Isopropanol (11 ml) was then added to the decanted supernatant, mixed thoroughly by 
inversion and the precipitated plasmid DNA was recovered by centrifugation at 6000 rpm 
for 30 min.  Finally, the DNA pellet was washed with 70% ethanol, dried for at least 10 
min at room temperature before being resuspended in 200 to 400 µl distilled water 
(dependent on the pellet size) and transferred to a 1.5 ml microcentrifuge tube.  5 µl DNA 
was diluted in 495 µl H2O and used for DNA concentration measurement (see 2.6.2).  To 
control the plasmid DNA, 1 µg DNA was digested with the respective enzymes (see 2.6.5) 
and analysed by agarose gel electrophoresis (see 2.6.1). 
 
2.6.12 DNA sequencing 
All cDNA constructs were confirmed by sequencing by GATC Biotech AG 
(Konstanz, Germany).  The constructs were sequenced with the T7 or BGH primer.  For 
UNR, two additional primers were used (see Table 2.3). 
 
Oligonucleotide name Sequence 
Unr 601-620 5`aca atc aag gac aga aat gg`3 
Unr 1201-1220 5`gta gaa aaa gaa gcc act tt`3 
Table 2.3 Oligonucleotides used for sequencing. 
 
Sequencing results were analysed by BLASTN (http://blast.ncbi.nlm.nih.gov) or 
HUSAR Prof Align, a bioinformatics service of the DKFZ (Heidelberg). 
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2.7 RNA techniques 
2.7.1 In vitro transcription of α-32Phosphate-labelled RNA 
The pcDNA6-V5/HisA ADAM10 5`UTR and deletion constructs were linearised with 
HindIII to serve as templates for the synthesis of RNA probes.  The pcDNA3.1(+) Zeo 
BACE1 5`UTR was linearised with EcoRI.  In case of the ADAM10 5`UTR the last 12 
nucleotides of the 5`UTR were removed, resulting in a 5`UTR with a length of 432 
nucleotides instead of 444 nucleotides.  For the BACE1 5`UTR the last 9 nucleotides of the 
5`UTR were removed, resulting in a 5`UTR with a length of 437 nucleotides instead of 446 
nucleotides.  In addition, as the T7 promoter used for the in vitro transcription was not 
directly in front of the 5`end of the two 5`UTRs, the resulting in vitro transcripts for 
ADAM10 and BACE1 5`UTR had a length of 453 nucleotides and 474 nucleotides, 
respectively (Figure 2.1). 
 
 
 
 
 
 
 
Figure 2.1 Representation of the ADAM10 and BACE1 5`UTR constructs. 
The ADAM10 and BACE1 5`UTR used for in vitro transcription are shown.  The bracket shows 
the T7 promoter sequence.  The transcription start (TCS) is highlighted in red.  (A) NheI and 
HindIII are the restriction sites used for cloning the ADAM10 5`UTR.  HindIII was used for 
linearization of the ADAM10 5`UTR.  The black stripped box represents the last 12 nucleotides 
which are missing in the in vitro-transcribed ADAM10 5`UTR.  (B) HindIII and EcoRI were used 
for cloning the BACE1 5`UTR.  The restriction enzyme EcoRI was used for linearization of the 
BACE1 5`UTR.  The black stripped box represents the last 9 nucleotides which are missing in the 
in vitro-transcribed BACE1 5`UTR. 
 
 
In vitro transcription was performed at room temperature.  There is a trade-off 
between synthesis of high specific activity probe and synthesis of full-length probe.  The 
proportion of full-length transcript increases with increasing concentration of limiting 
nucleotide.  However, if unlabelled nucleotide is used to increase the limiting nucleotide 
concentration, it will lower the specific activity of the transcript.  In order to find the 
optimal reaction setup for in-vitro-transcribed RNA with a high proportion of full-length 
transcript combined with a high specific activity, several reaction setups were prepared.  
Therefore, different end concentrations of α32P-CTP (3.125 µM and 0.625 µM) and non-
labelled CTP (0 µM, 10 µM, 50 µM, 100 µM and 500 µM) were tested for the ADAM10 
A 
B 
BACE1 5`UTR
5` 3`
NheI HindIII
ADAM10 5`UTR…….TAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGC
T7 promoter site
…….
3`
…….
EcoRI
5`
HindIII
…….TAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCGTTTAAACTTAAGCTT
T7 promoter site
TCS
1
1
432
437
TCS
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5`UTR.  For the BACE1 5`UTR several reaction setups with different end concentrations 
of non-labelled UTP (0 µM, 10 µM, 50 µM and 100 µM) and 3.125 µM α32P-UTP were 
tested.  In this work, the ADAM10 5`UTR was prepared with 3.125 µM α32P-CTP and 10 
µM CTP and the BACE1 5`UTR with 3.125 µM α32P-UTP and 10 µM UTP. 
According to the MAXIscript® In vitro Transcription Kit – T7 (Ambion) a 20 µl 
reaction, e.g., for the ADAM10 5`UTR, included 4 µl nuclease-free water, 1 µg linearised 
DNA template, 2 µl 10x Transcription buffer, 1 µl 10 mM ATP, 1 µl 10 mM GTP, 1 µl 10 
mM UTP, 2 µl 100 µM CTP, 50 µCi 32P labelled CTP (10 µCi/µl) and 2 µl T7 Enzyme 
mix.  The reaction was mixed by gently flicking the tube and microfuged briefly to collect 
the reaction mixture at the bottom of the tube.  Afterwards, the reaction was incubated for 
1 h at 37°C.  Following the transcription reaction, the template DNA was removed by 
adding 1 µl TURBO DNase 1.  The reaction was mixed well and incubated for an 
additional 15 min at 37°C.  Finally, the reaction was purified according to 2.7.4 and 
analysed according to 2.7.7. 
 
2.7.2 In vitro transcription of RNA 
The pcDNA6-V5/HisA ADAM10 5`UTR and deletion constructs were linearised with 
HindIII to serve as templates for the synthesis of RNA probes.  The pcDNA6-V5/HisA 
APAF-1 5`UTR was linearised with HindIII.  The reactions were set up at room 
temperature according to the MEGAscript® High-Yield Transcription Kit (Ambion).  A 20 
µl reaction included 6 µl Nuclease-free water, 1 µg DNA, 2 µl 75 mM ATP, 2 µl 75 mM 
CTP, 2 µl 75 mM GTP, 2 µl 75 mM UTP, 2 µl 10x Transcription buffer, and 2 µl T7 
Enzyme mix.  The reaction was mixed by gently flicking the tube and microfuged briefly 
to collect the reaction mixture at the bottom of the tube.  Afterwards the reaction was 
incubated for 4 h at 37°C.  Following the transcription reaction, the template DNA was 
removed by adding 1 µl TURBO DNase 1.  The reaction was mixed well and incubated for 
an additional 15 min at 37°C.  Finally, the reaction was purified according to 2.7.5. 
 
2.7.3 In vitro transcription of internally biotinylated RNA 
The pcDNA6-V5/HisA ADAM10 5`UTR was linearised with HindIII to serve as 
templates for the synthesis of RNA probes.  The pcDNA3.1(+) Zeo BACE1 5`UTR was 
linearised with EcoRI.  The reaction was set up at room temperature according to the 
RibomaxTM Large-Scale RNA Production System – T7 (Promega).  A 100 µl sample 
reaction included 20 µl 5x T7 Transcription buffer, 30 µl rNTPs (25 mM ATP, CTP, GTP, 
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UTP), 2.5 µl 10 mM Biotin-14-CTP, 37.5 µl linear DNA template (10 µg total) plus 
Nuclease-free water, 10 µl Enzyme mix and 1 µl RNasin.  The reaction was mixed by 
gently pipetting and incubated at 37°C for 4 h.  To remove the DNA template following 
the transcription reaction, RQ1 RNase-Free DNase was added to a concentration of 1 U/µg 
of template DNA.  The reaction was incubated for 15 min at 37°C.  Additionally, a control 
reaction without 2.5 µl 10 mM Biotin-14-CTP was set up.  Afterwards the transcription 
reaction was purified according to 2.7.5 and analysed according to 2.7.8. 
 
2.7.4 Purification of radiolabelled RNA 
For the purification of radiolabelled RNA from 2.7.1 Quick Spin Columns G-50 
Sephadex Columns for Radiolabelled RNA Purification (Roche Applied Science) were 
used.  For the purification, a column was removed from the storage container and gently 
inverted several times to resuspend the column matrix.  The top cap was removed from the 
column, then the bottom tip was removed and the buffer allowed to drain by gravity and 
discarded.  The column was placed in a collection tube, centrifuged at 1100 x g for 2 min 
and the collection tube with the eluted buffer was discarded.  The column was kept in an 
upright position, the RNA sample was carefully applied to the centre of the column bed 
and the column was placed in a second collection tube.  Finally, the column was 
centrifuged for 4 min at 1100 x g, the column was discarded and the eluate from the second 
collection tube was saved as this contained the purified RNA sample.  The purified RNA 
was analysed according to 2.7.7. 
 
2.7.5 Purification of non-labelled and internally biotinylated RNA 
The in vitro-transcribed RNAs from 2.7.2 and 2.7.3 were purified with the phenol-
chloroform extraction method.  Transcription reactions were brought up to 136 µl with 
Nuclease-free water and 15 µl ammonium acetate stop solution were added and mixed 
thoroughly.  The transcription reaction was extracted with an equal volume (151 µl) of 
phenol-chloroform, mixed and centrifuged at 13000 rpm for 3 min.  The upper phase was 
transferred to a new tube, extracted with an equal volume (115 µl) of chloroform, vortexed 
and centrifuged at 13000 rpm for 3 min.  Then the upper aqueous phase was recovered, 
transferred to a new tube and the RNA was precipitated by adding 1 volume (80 µl) of 
isopropanol and mixed well.  The mixture was chilled overnight at -20°C and centrifuged 
at 4°C for 15 min at 13000 rpm to pellet the RNA.  The pellet was washed 2x with 70% 
ethanol (500 µl) at 13000 rpm for 15 min at 4°C.  Finally, the pellet was dried at room 
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temperature, resuspended in the desired volume of nuclease-free water and the RNA 
concentration was determined (see 2.7.10).  The RNA was stored at -80°C.  The internally 
biotinylated RNA was analysed according to 2.7.8. 
 
2.7.6 Denaturing polyacrylamide gel 
10x TBE: 
0.9 M Tris base, 0.9 M Boric acid, 20 mM EDTA solution in DEPC-H2O 
 
Acrylamide solution: 
40% (w/v) Acrylamide-Bis 37.5:1 
 
APS: 
10% (w/v) Ammoniumpersulfate in dH2O 
 
Mix the following components for a 5% denaturing polyacrylamide / 8 M urea gel 
solution: 
 
for 15 ml Component 
7.2 g Urea 
1.5 ml 10x TBE 
1.9 ml 40% Acrylamide-Bis 
to 15 ml DEPC-H2O 
 
The gel solution was stirred at room temperature until the urea was completely 
dissolved and then the following was added: 
 
120 µl 10% APS 
16 µl TEMED 
 
After the last two ingredients, which catalyse polymerization, were added, the gel 
solution was mixed briefly, and then the gel was poured immediately. 
 
2.7.7 Gel analysis of radiolabelled transcripts 
10x TBE: 
see 2.7.6 
 
The best way to analyse the outcome of a transcription reaction is to run an aliquot on 
a 5% denaturing polyacrylamide / 8 M urea gel (see 2.7.6).  Therefore, 1 µl of the 20 µl 
transcription reaction was mixed with 7 µl Gel Loading buffer II (Ambion) containing 
xylene cyanol and bromophenol blue and heated to 95°C for 2 min.  The sample was 
directly loaded into the freshly rinsed well of the gel and electrophoresed at 200 volts in 1x 
TBE buffer until the bromophenol blue (the faster migrating dye) approached the bottom 
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of the gel.  The loading buffer also served as size marker.  On a 5% denaturing 
polyacrylamide / 8M urea gel xylene cyanol runs around 130 nucleotides and bromophenol 
blue at around 35 nucleotides (Sambrook et al., 1989).  Finally, the gel was removed from 
the glass plates, covered in plastic wrap and exposed to X-ray film. 
 
2.7.8 Analysis of internally biotinylated transcripts 
For the analysis of internally biotinylated transcripts, the BrightStar® BioDetectTM kit 
was used.  A dilution series (1 µg, 100ng, 10 ng, 1 ng, 100 pg, 10 pg, 1 pg) of the 
biotinylated RNA probe (from 2.7.3 and 2.7.5) was spotted on a positively charged nylon 
transfer membrane Hybond-N+ and then detected using the BrightStar® BioDetectTM 
protocol.  First, the membrane was washed 2x 5 min in approximately 1 ml 1x Wash 
Buffer/cm2 membrane.  Afterwards the membrane was incubated 2x 5 min in 
approximately 0.5 ml Blocking Buffer/cm2 membrane followed by a 30 min incubation in 
approximately 1 ml Blocking Buffer/cm2 membrane.  The membrane was incubated for 30 
min in diluted Strep-Alkaline Phosphatase (10 ml Blocking Buffer and 1 µl Strep-Alkaline 
Phosphatase) and after that incubated in 0.5 ml Blocking Buffer/cm2 membrane for 10 min.  
To decrease non-specific background, the membrane was washed 3x 5 min in 
approximately 1 ml Wash Buffer/cm2 membrane.  Finally, the membrane was incubated 2x 
2 min in 0.5 ml 1x Assay Buffer/cm2 membrane and for 5 min in 5 ml CDP-Star.  The 
excess CDP-Star was removed by quickly blotting the membrane on a piece of filter paper 
without letting the membrane dry.  The membrane was wrapped in a single layer of plastic 
and exposed on X-ray film at room temperature. 
 
2.7.9 RNA extraction from cells 
RNA was extracted according to the RNeasy Mini Kit protocol (Qiagen) as follows.  
Cells were harvested with PBS, centrifuged for 5 min at 5000 rpm and the supernatant was 
removed.  The pellet was resuspended in 30 µl H2O and mixed with 600 µl RLT buffer (10 
µl β-mercaptoethanol/ml RLT buffer were freshly added).  The lysate was added to a Qia-
shredder spin column and centrifuged for 2 min at 13000 rpm.  The flow through was 
mixed with 630 µl 70% ethanol (in DEPC-H2O).  700 µl of the lysate were transferred to 
an RNeasy mini column, centrifuged for 15 sec at 10000 rpm and the flow-through was 
discarded.  The procedure was repeated with the remaining sample.  Afterwards 350 µl 
RW1 buffer was added to the column and centrifuged for 15 sec at 10000 rpm to wash the 
spin column membrane.  To eliminate remaining DNA contaminants, 80 µl of a DNaseI 
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mixture (10 µl DNaseI + 70 µl RDD buffer) was added to the RNeasy spin column 
membrane and incubated for 15 min at room temperature.  Then 350 µl RW1 buffer were 
added to the column and centrifuged again for 15 sec at 10000 rpm.  The RNeasy column 
was transferred to a new tube, then 500 µl RPE buffer were added and centrifuged for 15 
sec at 10000 rpm to wash the spin column membrane.  An additional 500 µl RPE buffer 
were added to the column, centrifuged for 2 min at 10000 rpm and again for 1 minute at 
10000 rpm to remove residual ethanol.  Finally, the RNeasy spin column was placed in a 
new 1.5 ml collection tube and the RNA was eluted in 30 µl RNase-free water by 
centrifugation for 1 minute at 10000 rpm.  The concentration and quality of the RNA was 
determined with the Agilent 2100 Bioanalyser (see 2.7.10).  For RNA isolated from 
transiently transfected cells the RNA concentration was first measured with a Jasco 
UV/VIS spectrophotometer V-550 (see 2.7.10).  To remove residual DNA, 10 µg of the 
RNA were treated a second time with DNaseI (DNA-free, Ambion). 
 
2.7.10 RNA concentration and quality determination 
RNA concentration of in vitro-transcribed RNA and RNA isolated from transient 
transfected cells was estimated by measuring the absorbance of aqueous RNA solutions 
with a UV/VIS spectrophotometer V-550 (Jasco). 
RNA concentration and quality of isolated RNA was determined with the Agilent 
2100 Bioanalyser using the Agilent RNA Nano kit according to the manual. 
 
2.7.11 cDNA synthesis 
cDNA synthesis was performed according to the SuperScriptTM First-Strand Synthesis 
System for RT-PCR as follows.  The reaction was set up with 100 ng random primers, 100 
ng isolated RNA, 1 µl dNTP mix (10 mM each) and filled up to 12 µl with RNase-free 
water.  The mixture was then heated to 65°C for 5 min and quickly chilled on ice.  
Afterwards, the content of the tube was collected by brief centrifugation and 4 µl 5x First-
Strand Buffer, 2 µl 0.1 M DTT and 1 µl RNaseOUT (40 units/µl) (optional) were added.  
The content of the tube was mixed gently and incubated at 25°C for 2 min.  Finally, 1 µl 
(200 units) of SuperScriptTM II RT was added and mixed by pipetting gently up and down.  
The tubes were incubated at 25°C for 10 min following incubation at 42°C for 50 min.  
The reaction was inactivated by heating at 70°C for 15 min.  For the cDNA synthesis of 
RNA isolated of transiently transfected cells, the reaction was set up with 500 ng oligo-dT 
primer and 500 ng isolated RNA. 
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2.7.12 qRT-PCR 
For quantitative RT-PCR, the Applied Biosystems 7500 Fast machine was used.  For 
endogenous RNA the reaction was set up as follows: 10 µl TaqMan Buffer, 1 µl TaqMan 
Primer (20x TaqMan Gene Expression Assay Mix) (see Table 2.4), 1 µl cDNA and 8 µl 
RNase-free water. 
Samples were measured in triplicates with the following program: holding stage with 
50°C for 2 min and 95°C for 10 min following the cycling stage with 40 cycles at 95°C for 
15 sec and 60°C for 1 minute. 
 
Gene of interest Primer name   
CSDE1 Hs00200261_m1 Fam/MGB exon-exon 
APP Hs00169098_m1 Fam/MGB exon-exon 
BACE1 Hs00201573_m1 Fam/MGB exon-exon 
ADAM10 Hs00153853_m1 Fam/MGB exon-exon 
GAPDH 4326317E-0509010 VIC-MGB exon-exon 
Table 2.4 List of TaqMan primers used for qRT-PCR. 
 
 
For the detection of transfected constructs, the reaction was set up as follows: 10 µl 2x 
Power SYBR Green PCR Master Mix (Applied Biosystems), 1 µl (1 µM) of each primer 
pair (see Table 2.5), 1 µl cDNA and 8 µl RNase-free water. 
Samples were measured in triplicates with the same program as for endogenous RNA.  
The relative ADAM10 RNA expression was normalised to the ∆∆Ct method. 
 
Gene of interest Primer name Sequence 
V5-tagged 
ADAM10 
constructs 
ADAM10-2228 forward primer 
ADAM10-V5 reverse primer 
5`cat tca gca acc cca gcg tca g`3 
5`atc gag acc gag gag agg gtt 
ag`3 
GAPDH GAPDH forward primer 
GAPDH reverse primer 
5`tca gtg cca ccc aga aga c`3 
5`cag tga gct tcc cgt tca g`3 
Table 2.5 Primers used for qRT-PCR. 
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2.8 Cell lines and cell culture 
2.8.1 Cell lines and cell culture 
PBS buffer (1x, sterile): 
140 mM NaCl, 10 mM Na2HPO4*2H2O, 1.75 mM KH2PO4, 2.7 mM KCl in dH2O, set to pH 7.4 with HCl, 
autoclaved 
 
Trypsin-EDTA: 
0.05% Trypsin-EDTA 
 
Culture medium: 
DMEM + GlutaMAX I (with 4.5 g/l glucose, without pyruvate), 10% FCS, 2 mM L-Glutamine 
 
Selection medium: 
Culture medium supplemented with 50 units/ml penicillin, 50 µg/ml streptomycin and 200 µg/ml Zeocin 
 
Cell lines: 
293E 
293E UnrKO #15 
293E Unr #6 
 
Cell culture 
Human embryonic kidney 293E cells (HEK293E) were cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum, 50U/ml 
penicillin/ 50 µg/ml streptomycin, and as appropriate, 200 µg/ml Zeocin (293E Unr, 293E 
Unr KO). 
All cells were maintained at 37°C in an incubator (Hera Cell, Heraeus) in 5% CO2 
and 95% air humidity.  The cells were grown in cell culture dishes of varying sizes 
depending on the application.  The cells were allowed to grow until a confluency of 90% 
had been reached.  For passage of the cells the medium was removed carefully with a 
sterile pasteur pipette, the cells were washed with 1x sterile PBS and then detached with 
Trypsin-EDTA.  The trypsinised cells were resuspended in medium, transferred to a 15 ml 
tube and centrifuged at 1000 rpm for 5 min.  The cell pellet was resuspended in fresh 
medium and the cells re-plated at the desired density in new cell culture dishes. 
 
2.8.2 Counting of cells 
The cell number was determined using a Neubauer counting chamber. 
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2.8.3 Storage of cells (cryoconservation) 
PBS buffer (sterile): 
see 2.8.1 
 
Trypsin-EDTA: 
see 2.8.1 
 
Culture medium: 
see 2.8.1 
 
Freezing medium: 
90% FCS, 10% DMSO 
 
To prepare cells for storage, confluent cells were washed with 1x PBS, trypsinised and 
resuspended in culture medium.  Cells were then centrifuged at 1000 rpm for 5 min.  The 
medium was removed and the cells resuspended in 1 ml freezing medium and transferred 
into a 1.5 ml cryo tube.  Cells were then transferred to a freeze box that allows a slow and 
defined cooling down at -80°C overnight and finally stored at -80°C or in liquid nitrogen.  
To repropagate cells, the microtubes were removed from -80°C or liquid nitrogen and 
placed at room temperature for thawing.  The cells were then mixed with 9 ml fresh 
medium followed by centrifugation (to remove DMSO) to pellet them before being re-
plated in cell culture dishes in fresh medium. 
 
2.8.4 Coating of cell culture dishes with poly-L-lysine 
Poly-L-Lysine: 
1:100 dilution of 10 mg/ml poly-L-lysine in PBS 
 
PBS: 
see 2.8.1 
 
For some experiments, the cell culture dishes had to be coated with poly-L-lysine to 
get a better adhesion of the cells.  Therefore, cell culture dishes were incubated with poly-
L-lysine for at least 30 min at 37°C in a CO2-incubator and afterwards 2-3x washed with 
dH2O.  Before use, the cell culture dishes were dried under the clean bench. 
 
2.8.5 Transient transfection by LipofectamineTM 2000 
Cells used for transfection were split and re-seeded 24 h before transfection.  Usually, 
transient transfections were performed in either 6 cm or 10 cm cell culture dishes for cell 
lysates.  Transient transfection was performed using LipofectamineTM 2000 (Invitrogen).  
According to the manufacturer’s instructions, 8 µg of plasmid DNA and 20 µl of the 
transfection reagent or 24 µg of plasmid DNA and 60 µl Lipofectamine per reaction were 
mixed separately with either 0.5 ml or 1.5 ml Optimem.  As transfection control, 0.05 µg 
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pEGFP-N1 was added to each transfection reaction.  The reaction was incubated for 5 min, 
and then both solutions were mixed and incubated for 20 min at room temperature. The 
transfection mixture was gently added onto the cells and incubated for 24 h before 
processing for the indicated experiment. 
 
2.8.6 Stable Transfection by LipofectamineTM 2000 
To establish stable cell lines, cells were transfected with cDNA as described above 
with LipofectamineTM 2000 (see 2.8.5).  The cells were re-seeded 1:5 to 1:100 24 h post-
transfection under appropriate antibiotic selection to generate clones.  Single-cell clones 
were picked using 100 µl pipette tips, transferred to 24 well plates and cultured.  The 
clones were screened for expression levels by Western blot and the best clones used for 
further experiments. 
 
2.9 Protein biochemistry methods 
2.9.1 Preparation of cell pellets 
PBS: 
see 2.8.1 
 
The desired confluent cells were placed on ice and the medium was removed.  
Afterwards the cells were washed with 5 ml 1x PBS, 1 ml 1x PBS was added to remove 
the cells from the plate and transferred to a 1.5 ml tube.  Cells were centrifuged for 5 min 
at 5000 rpm, the liquid phase was removed and pellets were stored at -20°C. 
 
2.9.2 Collection of supernatants 
Culture medium: 
see 2.9.1 
 
Culture medium without FCS: 
DMEM + GlutaMAX I (with 4.5 g/l glucose, without pyruvate), 2 mM L-Glutamine 
 
1.8 x 106 cells/6cm dish or 5.4 x 106 cells/10 cm dish of the desired cells were plated 
in culture medium on poly-L-lysine coated plates.  The next day the medium was changed 
and the cells were incubated in 5 ml culture medium containing 10% FCS overnight.  After 
18h, the supernatants were collected, centrifuged for 5 min at 2000 rpm and Aβ levels 
were analysed by ELISA as described in 2.9.12.  After removal of the supernatants for Aβ 
measurement, the plates were 3x washed with 5 ml culture medium without FCS.  The 
cells were then incubated in 5 ml culture medium containing 10 µg/ml fatty-acid-free BSA 
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instead of 10% FCS.  After 4h, the supernatants were collected, centrifuged for 5 min at 
2000 rpm and TCA precipitated as described in 2.9.7.  The TCA precipitates were used for 
the determination of APPst, APPsα and APPsβ.  To ensure equal amounts of protein 
content, the cells were harvested in 1ml PBS and OD600 was determined and all 
supernatants were adjusted with medium to the same OD600 before TCA precipitation or 
Aβ measurement via ELISA. 
 
2.9.3 Cytosolic and nuclear extracts 
PBS: 
see 2.8.1 
 
Buffer A: 
10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, add fresh 0.5 mM DTT 
 
Buffer B: 
0.3 M HEPES, pH 7.9, 1.4 M KCl, 30 mM MgCl2 
 
Buffer C: 
20 mM HEPES, pH 7.9, 25% v/v glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, add fresh 0.5 mM 
PMSF and 0.5 mM DTT 
 
Buffer D: 
20 mM HEPES, pH 7.9, 20% v/v glycerol, 0.1 M KCl, 0.2 mM EDTA, add fresh 0.5 mM PMSF and 0.5 mM 
DTT 
 
Cytosolic and nuclear extracts were prepared according to a protocol of Dignam 
(Dignam et al., 1983).  All steps were done on ice, in the cold room and in cooled 
centrifuges.  Pelleted cells were suspended in 5 volumes of cold PBS and collected by 
centrifugation for 10 min at 2000 rpm.  The cells were then suspended in 5 packed cell 
pellet volumes of buffer A and allowed to stand for 10 min on ice.  The cells were 
collected by centrifugation as before, suspended in 2 packed cell pellet volumes (volume 
prior to the initial wash with buffer A) of buffer A and lysed by 10-20 strokes with a glass 
douncer (Wheaton).  The homogenate was centrifuged for 10 min at 2000 rpm to pellet 
nuclei.  The supernatant was carefully decanted, mixed with 0.11 volumes of buffer B, and 
centrifuged for 60 min at 100000 g.  The high-speed supernatant from this step, designated 
the cytosolic fraction, was dialyzed overnight against buffer D.  The cytosolic extract was 
frozen in liquid nitrogen and stored at -80°C. 
The nuclear extract was prepared as follows.  The pellet obtained from the low-speed 
centrifugation of the homogenate was subjected to a second centrifugation for 20 min at 
25000 g, to remove residual cytoplasmic material.  This pellet was designated as crude 
nuclei.  These crude nuclei were resuspended in 3 ml of buffer C per 109 cells with a glass 
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douncer (Wheaton).  The resulting suspension was stirred gently with a magnetic stirring 
bar for 30 min and then centrifuged for 30 min at 25000 g.  The obtained clear supernatant 
was dialyzed against buffer D overnight.  The dialysate was centrifuged at 25000 g for 20 
min and the resulting precipitate discarded.  The supernatant, designated the nuclear 
extract, was frozen as aliquots in liquid nitrogen and stored at -80°C. 
 
2.9.4 Cytosolic extract from mouse brains 
MC buffer: 
10 mM HEPES(K) pH 7.6, 10 mM K-acetate, 0.5 mM Mg-acetate, 5 mM DTT, 1x protease inhibitor 
 
The brain tissue was washed with PBS (if the tissue was frozen, this step was 
skipped).  The weight of the brain tissue was determined and afterwards was cut into small 
pieces.  2 ml of MC buffer was added per 1 g of brain tissue.  The brain tissue was 
homogenized by 25 strokes with a tight glass douncer (Wheaton).  The homogenate was 
centrifuged for 1 hour at 100000 g at 4°C.  The supernatant was collected and aliquots 
were stored at -80°C. 
 
2.9.5 STEN-Lysates 
STEN-Lysis: 
50 mM Tris pH 7.6, 150 mM NaCl, 2 mM EDTA, 1% Triton-X100, 1:500 PI-mix in dH2O 
 
Pelleted cells were suspended in 300 µl (6 cm dish) or 600 µl (10 cm dish) STEN-
Lysis buffer containing 1:500 PI-mix and incubated for 20 min on ice.  After the 
incubation on ice, the suspension was centrifuged for 20 min at 13000 rpm at 4°C.  The 
supernatant was transferred to a fresh tube and the pellet was discarded.  The concentration 
of the STEN-lysate was measured by the BCA assay as described in 2.9.8 and analysed by 
SDS-PAGE (see 2.9.9) followed by Western blotting (see 2.9.10). 
 
2.9.6 Membrane preparations for ADAM10 
Hypotonic-buffer: 
10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 1:500 PI-mix in dH2O 
 
STEN-Lysis: 
see 2.9.5 
 
Pelleted cells were suspended in 200 µl (6 cm dish) or 400 µl (10 cm dish) hypotonic 
buffer and incubated for 10 min on ice.  Cells were lysed by passing the suspension 
approximately 15 times through a 1 ml syringe (Terumo) with 0.6 mm cannula (Braun).  
The suspension was centrifuged for 45 min at 13000 rpm at 4°C to pellet the nuclear 
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fraction and the membranes.  The supernatant was removed, kept as cytosolic fraction and 
the pellet was resuspended in 100 µl (6 cm dish) or 200 µl (10 cm dish) STEN-Lysis 
buffer.  The suspension was incubated for 20 min on ice and centrifuged for 20 min at 
13000 rpm at 4°C.  The supernatant was transferred to a new tube, designated as nuclear/ 
membrane fraction and the pellet was discarded.  The concentration of the cytosolic 
fraction and the nuclear/ membrane fraction were measured by the BCA assay as described 
in 2.9.8 and analysed by SDS-PAGE (see 2.9.9) followed by Western blotting (see 2.9.10). 
 
2.9.7 TCA precipitation 
TCA: 
6.1 M in dH2O (= 100%) 
 
Acetone: 
100% at -20°C 
 
SDS-sample buffer (2x): 
6.4% upper Tris (4x), 4% (w/v) SDS, 0.4% (w/v) DTT, 20% Glycerol, bromophenolblue 
 
For TCA precipitation of cell supernatants (chapter 2.9.2), several portions of cell 
media were precipitated with 100% TCA.  For this 1 ml of cell media was treated with 113 
µl freshly prepared cold 100% TCA and centrifuged for 4 min at 13000 rpm.  The 
supernatant was removed after each centrifugation step.  Finally, the pellet was washed 
twice with 1 ml acetone (-20°C).  The pellet was dried at 95°C for 2 min and dissolved in 
100 µl 1x SDS-sample buffer. 
For TCA precipitation of eluted proteins (see 2.9.19), 1 volume of 100% TCA was 
added to 4 volumes of protein eluate (e.g., to 1 ml elution fraction add 250 µl TCA).  The 
mixture was incubated on ice for 10 min and centrifuged for 5 min at 10000 rpm.  The 
supernatant was removed leaving the protein pellet intact.  Then the protein pellet was 
washed twice with 200 µl ice-cold acetone and centrifuged at 13000 rpm for 5 min.  The 
protein pellet was dried by placing the tube in a 95°C heating block for 5 min to drive off 
the acetone.  Finally, the protein pellet was dissolved in 30 µl 1x SDS-sample buffer. 
 
2.9.8 Protein quantification 
BSA standard: 
2 mg/ml BSA (Interchim) 
 
Protein concentration of cell lysates was determined using a BCA assay (Interchim).  
Briefly, the standard working solution was prepared by mixing 50 volumes of reagent A 
with 1 volume of reagent B.  Then 200 µl standard working solution was added to 10 µl 
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sample, mixed and incubated for 30 min at 37°C.  Protein concentration was estimated by 
measuring the absorbance at 562 nm with a plate reader Power WaveXS (BioTex 
Instruments) or Smart Spec 3000 (Bio-Rad).  For the preparation of a standard curve, a 
concentration series of BSA from 0 µg/µl to 20µg/µl was used.  All samples and the 
calibration standards were prepared as duplicates. 
 
2.9.9 SDS-polyacrylamide gel electrophoresis 
Lower Tris (4x): 
1.5 M Tris pH 8.8, 0.4% SDS (w/v) in dH2O 
 
Upper Tris (4x): 
0.5M Tris pH 6.8, 0.4% SDS (w/v) in dH2O 
 
Acrylamide solution: 
see 2.8.6 
 
APS: 
see 2.8.6 
 
SDS-sample buffer (5x): 
16% upper Tris (4x), 10% (w/v) SDS, 1% (w/v) DTT, 50% Glycerol, bromophenolblue 
 
Tris-Glycine gel running buffer without SDS (10x): 
250 mM Tris, 1.92 M Glycine, in dH2O 
 
Tris-Glycine gel running buffer (1x): 
25 mM Tris, 192 mM Glycine, 0.1% SDS 
 
To detect different proteins, cell lysates, membrane extracts or cytosolic extracts were 
analysed by immunoblotting.  The gel electrophoresis was done according to Laemmli 
(Laemmli, 1970).  The separation was done in a discontinuous horizontal SDS-
polyacrylamide gel electrophoresis using the gel apparatus Mini-PROTEAN® Cell (Bio-
Rad) filled with Tris-Glycine gel running buffer for gels with a size of 10 x 8 cm.  The gels 
had a thickness of 1.5 mm.  The concentration of the gels ranged from 8 to 15% 
polyacrylamide depending on the protein size (see Table 2.6). 
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 8% 
Separating 
gel 
10% 
Separating 
gel 
12% 
Separating 
gel 
15% 
Separating 
gel 
Stacking 
gel 
H2O 4.4 ml 4.0 ml 3.6 ml 3.2 ml 3.25 ml 
Acrylamide-
Bis (40%) 
1.6 2.0 ml 2.4 ml 2.8 ml 0.5 ml 
Lower Tris 2 ml 2 ml 2 ml 2 ml - 
Upper Tris - - - - 1.25 ml 
TEMED 15 µl 15 µl 15 µl 15 µl 15 µl 
10% APS 15 µl 15 µl 15 µl 15 µl 15 µl 
Table 2.6 Composition of one thick (1.5 mm) mini gel 
 
 
10-30 µg proteins were separated by SDS-PAGE dependent on the protein to be 
detected.  Prior to SDS-PAGE, proteins were denatured by adding SDS-sample buffer and 
boiling for 5 min at 95°C before applying to the gel.  As size marker, 5 µl SeeBlue pre-
stained Protein Standard was loaded.  Electrophoresis was performed at constant voltage at 
70 V until all samples migrated into the stacking gel and then at 120 V.  The separated 
proteins were analysed by Western blotting. 
 
2.9.10 Western blot analysis 
Blotting buffer (1x): 
25 mM Tris, 192 mM Glycine in dH2O 
 
Blocking buffer: 
0.2% I-Block, 0.1% Tween20 in PBS 
 
TBST (10x): 
100 mM Tris pH 7.6, 3 M NaCl, 1% Tween20 in dH2O 
 
TBST (1x): 
10 mM Tris pH 7.6, 300 mM NaCl, 0.1% Tween20 in dH2O 
 
After protein separation, the proteins were transferred from the gel onto a PVDF 
membrane of the size of the separating gel using the Bio-Rad system.  The PVDF transfer 
membrane was soaked in isopropanol, washed with dH2O, and equilibrated in blotting 
buffer.  Gel plates were opened and gels were carefully removed from the plates.  The 
transfer membrane was placed on the gel between blotting buffer, two filter papers soaked 
with blotting buffer and one sponge on both sides. 
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Blotting assembly: 
Anode plate (transparent) 
Sponge equilibrated in blotting buffer 
2 pieces blotting paper equilibrated in blotting buffer 
membrane equilibrated in blotting buffer 
SDS gel 
2 pieces blotting paper equilibrated in blotting buffer 
Sponge equilibrated in blotting buffer 
Cathode plate (black) 
 
The protein transfer was performed at constant current flow of 400 mA for 65 min 
using as blotting device the Mini Trans-Blot® Cell (Bio-Rad) filled with Tris-Glycine 
buffer together with an ice cube block. 
After the transfer, the apparatus was disassembled.  The membrane was removed and 
incubated for at least 1 h in blocking buffer to saturate unspecific protein binding sites.  
Membranes were incubated in the desired primary antibody with appropriate dilution in I-
Block containing 0.02% sodium azide at room temperature for 1 h or overnight at 4°C with 
shaking.  Afterwards the membranes were washed 4x for 15 min in 1x TBST to remove 
unspecific bound antibody.  After washing, the membrane was incubated with the 
appropriate HRP-conjugated secondary antibody at the optimal concentration in blocking 
buffer for 1 h at room temperature.  After extensive washing of the membranes with 1x 
TBST as described above, the protein of interest was detected with the enhanced 
chemiluminescence (ECL) Western blotting detection reagent (Amersham Bioscience) 
according to the manufacturer’s description.  The chemiluminescence signals were 
exposed on X-ray film for an appropriate time, and the films were developed using a 
developer machine. 
For the identification of RNA-binding proteins (see method 2.9.19) via Western 
blotting, the proteins were bound to PVDF membranes as described above (see 2.9.10).  
After the transfer, the proteins were detected via chemiluminescence as described above 
(see 2.9.10). 
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2.9.11 “Stripping” of Western blots 
Strip Buffer: 
2% SDS, 62.5 mM Tris-HCl, pH 6.7, 100 mM β-Mercaptoethanol 
 
The membrane is incubated in Strip-buffer for 1 h at 50°C with shaking.  After 1 h, the 
membrane is washed 2x for 10 min in TBST and incubated in I-Block for 1 h.  Then the 
membrane was processed as described in 2.9.10. 
 
2.9.12 ELISA 
1x Tris wash buffer: 
1:10 dilution of 10x Tris wash buffer (provided by MSD) 
 
1% Blocker A solution: 
1% Blocker A (provided by MSD) in 1x Tris wash buffer 
 
Detection antibody solution: 
1x SULFO-TAG 6E10 antibody (stock provided by MSD), 1x Blocker G (stock provided by MSD) in 1% 
Blocker A solution 
 
2x MSD read buffer T: 
1:2 dilution of 4 MSD read buffer T (provided by MSD) 
 
Calibrator: 
serial dilution of combined Aβ1-38, Aβ1-40 and Aβ1-42 peptide standards in cell culture medium 
 
Aβ levels of supernatants from cells were determined by an enzyme-linked 
immunosorbent assay (ELISA), following the manufacturer`s recommendations.  
Measurements were carried out using the 96-well MULTI-SPOT® Human (6E10) Abeta 
Triplex Assay from MSD.  The 96-well plate was blocked for 1 hour at room temperature 
on a shaker with 150 µl/well 1% Blocker A solution.  Afterwards the plate was washed 3x 
with 1x Tris wash buffer.  25 µl/well of detection antibody solution were added as well as 
25 µl/well of supernatant or calibrator diluted in cell culture medium.  The reaction was 
incubated for 2 hours at room temperature with shaking.  Then, the wells were washed 3x 
with 1x Tris wash buffer.  Finally, 150 µl/well of 2x MSD read buffer T was added and the 
plate immediately measured using the MSD Sector Imager 2400 reader.  The concentration 
of the Aβ peptides were calculated using the MSD Discovery Workbench software. 
 
2.9.13 Purification of GST-fusion protein 
Elution buffer: 10 mM Glutathione in 50 mM Tris-HCl, pH 9.0 
 
In order to generate GST-fusion protein, the DNA of interest was cloned downstream 
of and in frame with the GST gene in the pGEX-5 expression vector (see 2.6.6).  Once 
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sequenced (see 2.6.12) and proven to be correct, the construct was transformed into the 
expression E.coli host strain BL21 (DE3) (see 2.6.8).  A single colony of bacteria was 
grown overnight in 5 ml LB medium supplemented with 100 µg/ml ampicillin (to select 
for plasmid-containing bacteria).  Next morning, the culture was diluted 1:100 with fresh 
LB medium containing 100 µg/ml ampicillin and grown for an additional 2-3 h until OD600 
= 0.5 was reached.  Expression of the GST-fused protein was induced by the addition of 
IPTG to a final concentration of 1 mM and the culture was grown for another 2-3 h at 
37°C.  The cells were harvested by centrifugation at 5000 rpm for 10 min at 4°C.  The 
bacterial pellet was resuspended in 20 ml PBS containing 1:200 PI mix and 200 µl 
lysozyme (10 mg/ml) (10 µl were removed for SDS-PAGE analysis).  The suspension was 
stirred for 30 min on ice before it was sonified (4 min: 20 sec sonification, 20 sec pause; 3 
min: 30 sec sonification, 30 sec pause) (50% Duty, left 5).  After sonification 1% Triton 
and 1:500 PI-mix were added and stirred again for 30 min on ice (10 µl were removed for 
SDS-PAGE analysis).  Cell debris (10 µl were removed for SDS-PAGE analysis) was 
removed by centrifugation at 10000 rpm for 20 min.  The supernatant containing the 
protein (10 µl were removed for SDS-PAGE analysis) was incubated with 600 µl 
Glutathione-sepharose 4B by rotation for 2 h at RT or overnight at 4°C.  Afterwards, the 
suspension was centrifuged for 10 min at 6000 rpm at 4°C and the supernatant (10 µl were 
removed for SDS-PAGE analysis) was discarded.  In order to remove unbound material, 
the sepharose was washed 3 times in PBS containing 0.5% Triton by 5 min centrifugation 
at 6000 rpm at 4°C.  The sepharose was resuspended in 5 ml PBS and loaded on a Poly-
Prep® chromatography column (Bio-Rad).  The column was washed with 10 ml PBS 
before the specific GST fusion protein was eluted by incubation of the beads for 10 min at 
room temperature with 10x 1 ml elution buffer.  SDS-PAGE (see 2.9.9) and subsequent 
Coomassie staining (see 2.9.15) estimated the amount and purity of the isolated protein.  
Usually 20 µl of each fraction were loaded per lane.  The correct fraction were pooled and 
dialysed against PBS. 
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2.9.14 Purification of His-tagged fusion-protein 
Lysis buffer: 20 mM Tris-HCl pH 8.0, 1 M KCl, 0.25% NP40, 1 mM PMSF, 10 µg/ml Leupeptin 
 
Buffer A: 24 mM Tris-HCl pH 8.0, 1.5 mM MgCl2, 1M KCl, 5% glycerol 
 
Buffer B: 1 M KCl, 20 mM Tris-HCl, 5% glycerol, 1 mM EDTA, 1 mM DTT 
 
Elution buffer: buffer A containing 500 mM imidazole 
 
In order to generate His-tagged fusion-protein, the DNA of interest was cloned 
downstream of and in frame with the His-tag in the pET28a expression vector (see 2.6.6).  
Once sequenced (see 2.6.12) and proven to be correct, the construct was transformed into 
the expression E.coli host strain BL21 (DE3) (see 2.6.8).  A single colony of bacteria was 
grown overnight in 5 ml LB medium supplemented with 50 µg/ml kanamycin (to select for 
plasmid-containing bacteria).  Next morning the culture was diluted 1:100 with fresh LB 
medium containing 50 µg/ml kanamycin and grown for an additional 2-3 h until OD600 = 
0.5 was reached. Expression of the His-tagged fusion-protein was induced by the addition 
of IPTG to a final concentration of 1 mM and the culture was grown for another 3 h at 
30°C.  The cells were harvested by centrifugation at 5000 rpm for 10 min at 4°C.  The 
bacterial pellet was resuspended in 5 ml lysis buffer (10 µl were removed for SDS-PAGE 
analysis) and sonified on ice (4 min: 20 sec sonification, 20 sec pause; 3 min: 30 sec 
sonification, 30 sec pause) (50% Duty, left 5).  After sonification, 10 µl were removed for 
SDS-PAGE analysis and cell debris (10 µl were removed for SDS-PAGE analysis) was 
removed by centrifugation at 10000 rpm for 30 min at 4°C.  The supernatant containing the 
protein (10 µl were removed for SDS-PAGE analysis) was incubated with 500 µl Ni-NTA 
agarose (Qiagen) by rotation for 2 h at RT or overnight at 4°C.  The Ni-NTA agarose was 
washed twice with buffer A before the addition of the protein.  In order to remove unbound 
material, the agarose was washed 3 times in buffer A by 5 min centrifugation at 6000 rpm 
at 4°C.  The agarose was resuspended in 5 ml buffer A and loaded on a Poly-Prep® 
chromatography column (Bio-Rad).  The column was washed with 10 ml buffer A before 
the specific His-tagged fusion-protein was eluted by incubation of the beads for 10 min at 
room temperature with 10x 1 ml elution buffer.  The amount and purity of the isolated 
protein was estimated by SDS-PAGE (see 2.9.9) and subsequent Coomassie staining (see 
2.9.15).  Usually 20 µl of each fraction were loaded per lane.  The correct fractions were 
pooled and dialysed against buffer B. 
The group of Ostareck and Ostareck-Lederer has kindly provided recombinant His-hnRNP 
K and His-hnRNP E1 (Ostareck et al., 1997). 
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2.9.15 Coomassie Blue Staining 
Coomassie Brilliant Blue R staining solution: 
25% Isopropanol, 1% acetic acid, 0.1% Coomassie Brilliant Blue R in dH2O 
 
Destaining solution: 
5% Isopropanol, 7% acetic acid in dH2O 
 
Immediately after gel electrophoresis (see 2.9.9), gels were placed into Coomassie 
Brilliant Blue R staining solution and gently shaken at room temperature for 1 h followed 
by destaining in destaining solution until the background was clear. The gels were shortly 
washed with water and then dried for 3 h at 60°C on a gel dryer. 
 
2.9.16 RNA/Protein UV-crosslinking 
β-Mercaptoethanol: 
3 M β-Mercaptoethanol (stock: 14.3 M) 
 
Reaction buffer: 
40 mM Tris pH 7.4, 60 mM KCl, 5 mM MgCl2, 1 mM spermidine 
 
Heparin: 
125 mg/ml 
 
RNase T1: 
10 U/µl 
 
RNase A: 
0.55 U/µl 
 
15 µg cytoplasmic or nuclear extract, prepared from HEK293E cells, were pre-treated 
with 200 mM β-mercaptoethanol at room temperature for 10 min and filled up with H2O to 
a final volume of 15 µl.  The treated extracts were then added to 6 µl reaction buffer 
supplemented with 0.75 mM ATP, 0.75 mM GTP, and the non-specific competitors poly 
d(I-C) (0.1 µg/µl) and tRNA (1 µg/µl), and preincubated at room temperature for 10 min.  
The radiolabelled RNA was then added, and incubation continued for 25 min at room 
temperature to allow the formation of specific RNA-protein complexes.  Subsequently, 5 
mg/ml heparin was added to remove weak and unspecific RNA-protein interactions, and 
the incubation continued for 10 min at room temperature.  The samples were then exposed 
to UV irradiation (254 nm) for 25 min on ice (UVP Ultraviolet products, 8W Model 
UVLMS, 10 cm distance from source).  The crosslinked RNA-protein complex was 
digested with RNase T1 (10 U/µl) and RNase A (0.055 U/µl) at room temperature for 15 
min.  Samples were heated to 95°C in protein sample buffer for 5 min, and resolved by 
SDS-PAGE.  The results were obtained by autoradiography. 
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2.9.17 Non-denaturing 3.5% polyacrylamide gel for RNA-EMSAs 
10x TBE: 
see 2.7.6 
 
Acrylamide solution: 
see 2.7.6 
 
APS: 
see 2.7.6 
 
Mix the following components for a 3.5% polyacrylamide gel solution: 
 
for 15 ml Component 
1.5 ml 10x TBE 
1.3 ml 40% Acrylamide-Bis 
12.2 ml DEPC-H2O 
 
The gel solution was stirred at room temperature until the urea was completely 
dissolved and then the following was added: 
 
120 µl 10% APS 
16 µl TEMED 
 
After addition of the last two ingredients, which catalyse polymerization, the gel 
solution was mixed briefly and poured immediately. 
 
2.9.18 RNA-Electrophoretic mobility shift assay 
Reaction buffer: 
see 2.9.16 
 
Heparin: 
see 2.9.16 
 
TBE (10x): 
see 2.7.6 
 
Non-denaturing polyacrylamide gel (3.5%): 
see 2.9.17 
 
15 µg cytoplasmic or nuclear extract, prepared from HEK293E cells, or 4 µg of 
recombinant protein were pre-treated with 200 mM β-mercaptoethanol at room 
temperature for 10 min and filled up with H2O to a final volume of 15 µl.  The treated 
extract and recombinant protein were then added to 6 µl reaction buffer supplemented with 
0.75 mM ATP, 0.75 mM GTP, and the non-specific competitors poly d(I-C) (0.1 µg/µl) 
and tRNA (1 µg/µl), and preincubated at room temperature for 10 min.  After addition of 
radiolabelled RNA, incubation continued for 25 min at room temperature to allow the 
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formation of specific RNA-protein complexes.  Subsequently, 5 mg/ml heparin was added, 
and the incubation continued for 10 min at room temperature.  Samples were heated to 
95°C in 7 µl Gel Loading Buffer II (Ambion) containing xylene cyanol and bromophenol 
blue for 2 min, and resolved on a non-denaturing 3.5% polyacrylamide gel (2.9.17).  The 
loading buffer served as size marker.  On a 3.5% non-denaturing polyacrylamide gel 
xylene cyanol runs at around 460 nucleotides and bromophenol blue at around 100 
nucleotides (Sambrook et al., 1989).  Electrophoresis was performed in 1x TBE at constant 
voltage at 100 V.  The results were obtained by autoradiography. 
 
2.9.19 Isolation of RNA-binding proteins with biotinylated RNA 
probes 
Protein-binding buffer: 
10% glycerol, 10 mM Hepes pH 7, 50 mM KCl, 1 U/ml RNase Inhibitor, 0.15 µg/ml yeast tRNA, 1 mM 
EDTA, 1 mM DTT, 0.5% Triton X-100 
 
First, 2.5 ml of heparin agarose, type I were prewashed 3x with 5 ml of protein-
binding buffer.  Following the last wash, 4 ml protein-binding buffer and 6 mg cytosolic 
cell extract was added to the heparin agarose and rotated at 4°C for 1 h.  The heparin 
agarose was removed by centrifugation at 2000 rpm for 5 min at 4°C.  The precleared 
extract was incubated with 250 µl streptavidin agarose on a rotator at 4°C for 1 h.  The 
streptavidin agarose was washed 3x with 500 µl of protein-binding buffer before usage.  
After the incubation with the cytosolic extract, the streptavidin agarose was removed by 
centrifugation for 5 min at 2000 rpm at 4°C.  400 pmol biotinylated RNA probe in a final 
volume of 100 µl containing 50 mM KCl was incubated with 100 µl of µMACS 
Streptavidin MicroBeads for 1 h at room temperature.  The reaction mixture was incubated 
with the precleared cytosolic cell extract for 1 h at 4°C on a rocking platform.  Following 
the binding reaction, a µColumn was placed in the magnetic field of the µMACS separator 
and prepared by washing 2x with 100 µl of equilibration buffer for protein applications.  In 
addition, the column was rinsed with 2x 100 µl of protein-binding buffer.  The entire 
binding reaction was added to the column held within a µMACS Separator.  Once the 
entire incubation reaction had flowed through the column, the column was washed 4x with 
200 µl of the protein-binding buffer to remove non-specifically bound molecules.  Bound 
proteins were finally eluted with 200 µl protein-binding buffer supplemented with 1 M 
NaCl.  Finally, eluted proteins were TCA precipitated according to 2.9.7 and loaded onto a 
SDS-gel according to 2.9.9.  Proteins were detected by Western blotting according to 
2.9.10 or by Silver staining according to 2.9.20. 
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2.9.20 Silver Staining 
Sensitizing solution: 
30 ml ethanol, 10 ml Sensitizer, up to 100 ml ultrapure water 
 
Staining solution: 
1 ml Stainer, up to 100 ml ultrapure water 
 
Developing solution: 
10 ml Developer, 1 drop Developer enhancer, up to 100 ml ultrapure water 
 
After electrophoresis, the gel was removed from the cassette, placed in a clean staining 
tray of the appropriate size and silver stained following the SilverQuestTM Silver Staining 
Kit (Invitrogen) protocol.  The gel was briefly rinsed with ultrapure water and fixed in 100 
ml fixative solution in a 15 cm Petri dish for at least 20 min with gentle rotation.  The 
fixative solution was decanted and the gel was washed in 30% ethanol for 10 min, 
followed by 100 ml of sensitizing solution for 10 min.  Afterwards, the gel was washed in 
100 ml of 30% ethanol for 10 min, followed by 100 ml ultrapure water for 10 min.  The gel 
was incubated in 100 ml of staining solution for 15 min.  The staining solution was 
decanted and the gel was washed with 100 ml ultrapure water for 20-60 s.  Then the gel 
was incubated in 100 ml of developing solution for 4-8 min until bands started to appear 
and the desired band intensity was reached.  Once the appropriate staining intensity was 
achieved, 10 ml of stopper solution was added to the gel.  The gel was gently agitated for 
10 min and the colour changes from pink to colourless indicated that the development had 
stopped.  Finally, the stopper solution was decanted, the gel was washed with 100 ml of 
ultrapure water for 10 min and given to mass spectrometry analysis (stored in fresh 
ultrapure water) (refer to 2.9.21). 
 
2.9.21 Mass spectrometry analysis 
After silver staining, mass spectrometry analysis was performed to identify RNA-
binding proteins.  Mass spectrometry analysis was performed by Ignasi Forne at the protein 
analysis unit at the Adolf-Butenandt Institute of the Ludwig-Maximilians-University in 
Munich. 
Gel bands were manually excised and placed in a 96-well digestion plate (Proxeon 
Biosystems).  A multiscreen vacuum manifold (Millipore) was used to digest samples with 
trypsin as described before (Shevchenko et al., 2000; Wilm et al., 1996) with minor 
modifications.  First, gel slices were washed twice with 100 µl of ultrapure H2O, 3 times 
with 100 µl of 25 mM NH4HCO3 and dehydrated by washing them 3 times with 100 µl of 
acetonitrile.  Gel slices were then incubated for 1 h with 50 µl of 10 mM DTT in 25 mM 
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NH4HCO3.  Afterwards slices were incubated for 30 min in a dark place with 50 µl of 55 
mM iodoacetamide in 25 mM NH4HCO3 to carbamidomethylate the reduced cysteines.  
Gel fragments were washed with 100 µl of 25 mM NH4HCO3 and dehydrated again with 
100 µl of acetonitrile.  10 µl of 25 ng/ml trypsin (Promega) dissolved in 25 mM NH4HCO3 
were added to each gel slice, depending on the volume of the excised spot, incubated 45 
min at 4ºC and then the non-absorbed trypsin was removed.  Gel fragments were covered 
with 25 mM NH4HCO3 and digestion took place for 16 h at 30ºC.  For the peptide 
extraction, gel slices were washed twice with 50 µl of acetonitrile/ultrapure H2O 1/1 0.25% 
TFA and twice more with 50 µl of acetonitrile.  The resulting liquid containing the 
digested peptides was totally evaporated.  The peptides were redissolved with 10 µl of 
0.1% formic acid and stored at -20 ºC until further processing.  
For the mass spectrometry analysis, 8 µl were injected in an Ultimate 3000 HPLC 
system (LC Packings) and desalted on-line in a C18 micro column (75 µm i.d. x 15 cm, 
packed with C18 PepMap™, 3 µm, 100 Å by LC Packings).  The desalted sample was then 
separated in a 15 cm analytical column C18 micro column (75 µm i.d., packed with C18 
PepMap™, 3 µm, 100 Å by LC Packings) with a 40 min gradient from 5 to 60% 
acetonitrile in 0.1% formic acid.  The effluent from the HPLC was directly electrosprayed 
into a LTQ-Orbitrap mass spectrometer (Thermo).  The MS instrument was operated in 
data-dependent mode to automatically switch between full scan MS and MS/MS 
acquisition.  Survey full scan MS spectra (from m/z 300 – 2000) were acquired in the 
Orbitrap with resolution R=60000 at m/z 400 (after accumulation to a ‘target value’ of 
500000 in the linear ion trap).  The six most intense peptide ions with charge states 
between 2 and 4 were sequentially isolated to a target value of 10000 and fragmented in 
the linear ion trap by collision-induced dissociation (CID).  All fragment ion spectra were 
recorded in the LTQ part of the instrument.  For all measurements with the Orbitrap 
detector, 3 lock-mass ions from ambient air (m/z=371.10123, 445.12002, 519.13882) were 
used for internal calibration as described before (Olsen et al., 2005).  Typical mass 
spectrometry conditions were: spray voltage of 1.5 kV; no sheath and auxiliary gas flow; 
heated capillary temperature of 200ºC; normalised collision energy of 35% for CID in 
LTQ.  The ion selection threshold was 10000 counts for MS2.  An activation q = 0.25 and 
activation time of 30 ms were used. 
Each individual thermo binary .raw file was searched with Mascot against the 
Swissprot database (versions 52.2-57.10).  Typical search parameters were peptide mass 
tolerance of 10 ppm, fragment tolerance of 0.5 Da, enzyme was set to trypsin (allowing up 
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to two missed cleavages), static modification, carbamidomethylated cysteine (+57.0215 
Da), variable modifications and methionine oxidation (+15.9949 Da).  All searches were 
performed considering a maximum of +3 charges for the precursor ion. 
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3 Results 
3.1 RNA-protein-binding studies 
3.1.1 Electrophoretic Mobility Shift Assay with cytosolic and nuclear 
extract of HEK293E cells 
In initial experiments, in vitro-transcribed ADAM10 5`UTR and BACE1 5`UTR RNA 
(as defined in Figure 2.1) (referred to as ADAM10 5`UTR and BACE1 5`UTR throughout 
this thesis) were used to study RNA-protein interactions, which possibly contribute to the 
regulation of the ADAM10 and/or BACE1 expression.  First, EMSAs were performed to 
detect putative 5´UTR-binding proteins. 
To do so, cytosolic and nuclear extracts from HEK293E cells were prepared according 
to a well-established protocol (Dignam et al., 1983).  To provide conclusive evidence that 
the cytosolic preparation was free of nuclear proteins, the absence of b-Myb, a specific 
nuclear marker (Takemoto et al., 1994), was demonstrated (Figure 3.1).  To control the 
quality of the nuclear extract, the absence of tubulin, a specific cytosolic marker 
(Willingham et al., 1980), was proven (Figure 3.1). 
 
 
 
 
 
 
 
 
 
Figure 3.1 Quality control of nuclear and cytosolic extracts of HEK293E cells. 
Nuclear and cytosolic extracts of HEK293E cells were separated on an 8% SDS gel and analysed 
by Western blot with the anti-b-Myb or anti-tubulin antibody as indicated.  In the upper panel the 
anti-b-myb antibody detects a specific signal in the nuclear extract but not in the cytosolic extract.  
In the lower panel the anti-tubulin antibody detects a specific signal in the cytosolic extract but not 
in the nuclear extract, indicating that the cytosolic fraction is not contaminated with nuclear 
proteins and vice versa. 
 
 
In a next step, ADAM10 5`UTR and BACE1 5`UTR RNA were prepared.  Several 
reactions with different amounts of limiting nucleotide (mixture of labelled and unlabelled 
form of that nucleotide) were setup to find the optimal conditions for the generation of the 
ADAM10 5`UTR and BACE1 5`UTR (refer to 2.7.1).  The loading buffer containing 
xylene cyanol and bromophenol blue served as size marker.  On a 5% denaturing 
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polyacrylamide / 8M urea gel xylene cyanol runs around 130 nucleotides and bromophenol 
blue at around 35 nucleotides (Sambrook et al., 1989). 
The in vitro transcription setup in presence of 3.125 µM α32P-CTP and 10 µM CTP for 
the ADAM10 5`UTR (Figure 3.2A) and of 3.125 µM α32P-UTP and 10 µM UTP for the 
BACE1 5`UTR (Figure 3.2B) were used for further experiments.  These reaction setups 
showed an optimal combination of high specific activity and synthesis of full-length probe. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Effect of limiting nucleotide concentration on ADAM10 5`UTR and BACE1 
5`UTR transcription. 
An aliquot of several reactions of in vitro-transcribed  ADAM10 (A) and BACE1 (B) 5`UTR RNA 
were analysed on 5% denaturing polyacrylamide / 8M urea gels and detected by autoradiography.  
The in vitro-transcribed ADAM10 and BACE1 5`UTR RNA is 453 and 474 nucleotides long, 
respectively (as explained in Figure 2.1).  The xylene cyanol (~ 130 nt) and bromophenol blue (~ 
35 nt) front on the gel served as size marker.  The reaction setup used for further experiments is 
highlighted in red. 
 
 
In order to analyze the effect of the 5`cap on protein binding, EMSAs were performed 
with capped and non-capped 5`UTR.  Capped and non-capped α32P-labelled in vitro 
transcripts of the ADAM10 5`UTR or BACE1 5`UTR (shown in Figure 3.3A) were 
incubated with 15 µg cytosolic extract of HEK293E cells (Figure 3.3B).  Following the 
incubation, 5 µg/µl heparin was added to remove unspecifically bound proteins from the 
RNA.  Heparin is a polyanion that is used to eliminate nonspecfic RNA-protein 
interactions (Tanguay and Gallie, 1996).  Subsequently, the RNA-protein complexes were 
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analysed on a 3.5% non-denaturing polyacrylamide gel and visualized by autoradiography 
(Figure 3.3B).  The loading buffer containing xylene cyanol and bromophenol blue served 
as size marker.  On a 3.5% non-denaturing polyacrylamide gel xylene cyanol runs at 
around 460 nucleotides and bromophenol blue at around 100 nucleotides (Sambrook et al., 
1989). 
The formation of a RNA-protein complex is visible in the gel through a delayed 
running behaviour of this complex (shift) in comparison to the free RNA (Figure 3.3B).  
Figure 3.3B demonstrates that the free labelled probes of ADAM10 and BACE1 5`UTR 
RNA have a faster-running behaviour than the 5`UTRs of ADAM10 and BACE1, which 
were incubated with cytosolic extract.  The results presented in Figure 3.3B suggest that 
proteins may bind to the 5`UTR of ADAM10 and BACE1 mRNA.  The binding was 
independent of the 5`cap.  Hence, future studies were performed without 5`cap. 
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Figure 3.3 Cytosolic proteins bind to the 5`UTRs of ADAM10 and BACE1. 
(A) An aliquot of the in vitro-transcribed α32P-labelled 5`capped or uncapped ADAM10 and 
BACE1 5´UTR RNA was analysed on a 5% denaturing polyacrylamide / 8M urea gel to control the 
quality of the RNA.  The xylene cyanol (~ 130 nt) and bromophenol blue (~ 35 nt) front on the gel 
served as size marker.  (B) 106 cpm α32P-labelled 5`capped or uncapped ADAM10 or BACE1 
5’UTR RNA probe was incubated with 15 µg cytosolic extract from HEK293E cells in binding 
buffer for 30 min at room temperature.  RNA-protein complexes were separated on a 3.5% non-
denaturing polyacrylamide gel and visualized by autoradiography.  The xylene cyanol front (~ 460 
nt) on the gel served as size marker.  Upon incubation of the RNA with the cytosolic extract, a shift 
of the RNA is visible in the gel. 
 
 
In a similar experiment, the ADAM10 5`UTR RNA (shown in Figure 3.4A) was 
incubated with 15 µg cytosolic or nuclear extract in the presence or absence of heparin 
(Figure 3.4B/C).  As expected, the ADAM10 5`UTR also formed an RNA-protein complex 
with the nuclear extract (Figure 3.4C).  Omitting the heparin treatment resulted in a more 
delayed running behaviour because of nonspecific RNA-protein interactions (Figure 
3.4B/C).  Thus, these data indicate that heparin treatment is necessary to avoid unspecific 
binding of cytosolic and nuclear proteins to the 5`UTR of ADAM10. 
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Figure 3.4 Heparin influences the binding of cytosolic proteins to the ADAM10 5`UTR. 
(A) An aliquot of in vitro-transcribed α32P-labelled ADAM10 5´UTR RNA was analysed on a 5% 
denaturing polyacrylamide / 8M urea gel to control for RNA quality.  The xylene cyanol (~ 130 nt) 
and bromophenol blue (~ 35 nt) front on the gel served as size marker.  (B) 106 cpm α32P-labelled 
ADAM10 5`UTR was incubated with 15 µg cytosolic (B) or nuclear (C) cell extract in binding 
buffer for 30 min at room temperature and subsequently treated with 5 µg/µl heparin as indicated.  
RNA-protein complexes were separated on a 3.5% non-denaturing polyacrylamide gel and 
visualized by autoradiography.  The xylene cyanol (~ 460 nt) and bromophenol blue (~ 100 nt) 
front on the gel served as size marker.  The incubation of RNA with cytosolic or nuclear cell 
extracts induced a shift due to cytosolic proteins binding to the ADAM10 5`UTR.  Omitting the 
heparin treatment resulted in a more delayed running behaviour due to unspecifically bound 
proteins. 
 
 
3.1.2 EMSA with cytosolic mouse brain extract 
To provide in vivo evidence, cytosolic brain extract of postnatal-day 30 (P30) was 
prepared to identify possible RNA-binding proteins which bind to the 5`UTR of ADAM10 
and/or BACE1.  To control the quality of the cytosolic extract of P30 mice brains, extracts 
were analysed by Western blot with anti-histone H3, a specific nuclear antibody, and anti-
tubulin antibody.  This analysis revealed that the cytosolic extract was free of nuclear 
proteins and can be used for further experiments (Figure 3.5). 
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Figure 3.5 Quality control of cytosolic extract from brains of P30 mice. 
Cytosolic extract of P30 mice brain was separated on a 15% gel and analysed by Western blot with 
anti-histone H3 or anti-tubulin antibody as indicated.  In the upper panel the tubulin antibody 
detects a specific signal in the cytosolic extract.  In the lower panel the histone H3 antibody reveals 
no signal which shows that the cytosolic extract is not contaminated with nuclear proteins. 
 
 
In analogy to the experiments with the HEK293E cytosolic extract, the labelled in 
vitro transcript of the human ADAM10 5`UTR (Figure 3.6A) was incubated with 15 µg 
cytosolic extract from P30 mice brains (Figure 3.6B).  Subsequently, the RNA-protein 
complex was analysed on a 3.5% non-denaturing polyacrylamide gel and visualized by 
autoradiography.  The formation of an RNA-protein complex of the ADAM10 5`UTR and 
the cytosolic extract from the brains of P30 mice was visible in the gel through a delay in 
the running behaviour in comparison with the free RNA.  Interestingly, the running 
behaviour of the RNA-protein complex from the P30 mice brain cytosolic extract (Figure 
3.6B) differs from the running behaviour of the RNA-protein complex formed with the 
HEK293E cytosolic extract (Figure 3.3).  An explanation for this might be that the protein 
composition binding to the ADAM10 5`UTR differs between the cytosolic extract from 
P30 mice brains and HEK293E cells. 
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Figure 3.6 Cytosolic proteins from brains of P30 mice bind to the ADAM10 5`UTR. 
(A) An aliquot of in vitro-transcribed α32P-labelled ADAM10 5´UTR RNA was analysed on a 5% 
denaturing polyacrylamide / 8 M urea gel to control for RNA quality.  The xylene cyanol (~ 130 nt) 
and bromophenol blue (~ 35 nt) front on the gel served as size marker.  (B) 106 cpm α32P-labelled 
human ADAM10 5’UTR RNA was incubated with 15 µg cytosolic extract from brains of P30 mice 
in binding buffer for 30 min at room temperature.  RNA-protein complexes were separated on a 
3.5% non-denaturing polyacrylamide gel and visualized by autoradiography.  The xylene cyanol (~ 
460 nt) front on the gel served as size marker. 
 
 
3.1.3 Electrophoretic mobility shift assays with ADAM10 5`UTR 
deletion constructs 
Recently, our laboratory could show that deletion of the first half of the ADAM10 
5`UTR (∆1-259) revealed an approximately 100-fold increase in ADAM10 protein 
expression in HEK293E cells while ADAM10 mRNA levels were only slightly increased 
(Lammich et al., 2010).  In contrast to these findings, deletion of the second half of the 
ADAM10 5`UTR (∆251-432) resulted in decreased ADAM10 protein levels accompanied 
by a similar reduction of ADAM10 mRNA levels (Lammich et al., 2010).  These results 
indicate that the first half of the 5`UTR contains inhibitory elements for translation while 
the second half of the 5`UTR of ADAM10 might be important for mRNA stability and 
efficient translation of ADAM10 (Lammich et al., 2010).  RNA-binding proteins might 
bind to these regions and could be involved in this regulation. 
In order to identify possible protein-binding sites within the 5`UTR of ADAM10, 
different parts of the 5`UTR were used in EMSA experiments.  The ADAM10 5`UTR was 
divided into two halves namely ∆1-259 and ∆251-432 (Figure 3.7A).  The formation of a 
RNA-protein complex was observed for the full-length and the ∆251-432 ADAM10 
5`UTR (Figure 3.7C).  In contrast, no RNA-protein complex was formed with the 
ADAM10 5`UTR lacking the first 259 nucleotides (Figure 3.7C).  These data demonstrate 
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that cytosolic proteins bind to the first part of the 5`UTR of ADAM10 mRNA but not to 
the second half. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Binding of cytosolic proteins to the first half of the ADAM10 5`UTR. 
(A) Representation of the ADAM10 deletion constructs.  Schematic representation of the 
ADAM10 5`UTR, the ∆1-259 and the ∆251-432 ADAM10 5`UTR utilized in the EMSA 
experiments.  All ADAM10 5`UTR constructs lack the last 12 nucleotides (see Figure 2.1A).  (B) 
An aliquot of in vitro-transcribed α32P-labelled ADAM10 5´UTR RNA was analysed on a 5% 
denaturing polyacrylamide / 8M urea gel to control for RNA quality.  The xylene cyanol (~ 130 nt) 
and bromophenol blue (~ 35 nt) front on the gel served as size marker.  (C) 106 cpm of 
radiolabelled RNA of full-length, ∆1-259 and ∆251-432 ADAM10 5`UTR was incubated with 15 
µg cytosolic cell extract.  RNA-protein complexes were separated on a 3.5% non-denaturing 
polyacrylamide gel and visualized by autoradiography.  The xylene cyanol (~ 460 nt) and 
bromophenol blue (~ 100 nt) front on the gel served as size marker.  The incubation of the full-
length and the ∆251-432 RNA with cytosolic cell extract induced a shift due to binding of proteins.  
In case of the ∆1-259 ADAM10 5`UTR no protein binding was detectable. 
 
 
3.1.4 UV crosslinking with cytosolic and nuclear extracts 
To provide further evidence that proteins bind to the 5`UTR of ADAM10, a series of 
UV crosslinking studies were performed.  In vitro-transcribed radiolabelled 5’UTR RNA 
of ADAM10 or BACE1 (as control for selectivity) was incubated with 15 µg cytosolic or 
nuclear extract from HEK293E cells.  RNA and cell extract were incubated in the presence 
of an excess of poly d(I-C) and tRNA.  After treatment with 5 µg/µl heparin to remove 
weak and instable unspecific RNA-protein interactions, RNA bound proteins were 
covalently crosslinked with UV light at 254 nm for 25 min on ice.  Subsequently, the 
samples were treated with RNase T1 and RNase A.  RNase T1 cleaves single-stranded 
RNA after G-residues near double-stranded RNA whereas RNase A cleaves single-
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stranded RNA at the 3`end of pyrimidine residues (C or U).  RNA nucleotides that are not 
involved in the RNA-protein complex and therefore not protected by the bound protein 
were removed by this treatment.  RNase-protected RNA-protein complexes were separated 
on an 8% SDS gel and visualized by autoradiography.  Interaction of ADAM10 5`UTR 
with cytosolic proteins resulted in the formation of at least four UV-crosslinked RNA-
protein complexes in the region between 36 and 98 kDa (Figure 3.8A).  For the ADAM10 
5`UTR incubated with nuclear extract at least two protein bands were detected in the 
region of 36 to 64 kDa (Figure 3.8A).  Importantly, all protein bands were only detected in 
the presence of extract and were dependent on UV crosslinking (Figure 3.8A). 
In addition, the BACE1 5`UTR was analysed in an effort to prove the specificity and 
selectivity of the RNA-binding proteins.  The data in Figure 3.8B indicate binding of 
several proteins to the BACE1 5`UTR.  Again, the protein binding is dependent on UV 
irradiation. 
In summary, the results show that several proteins bind to the ADAM10 and BACE1 
5`UTR.  However, the protein band patterns detected differ.  Hence, the detected proteins 
seem to bind in a selective way to the 5`UTRs of ADAM10 and BACE1. 
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Figure 3.8 Crosslinking of cytosolic and nuclear proteins to the ADAM10 5`UTR or 
BACE1 5`UTR. 
UV-crosslinking experiments of 106 cpm radiolabelled in vitro-transcribed 5’UTR mRNA of 
ADAM10 (A) or BACE1 (B) were performed in the presence or absence of HEK293E cytosolic or 
nuclear extract.  After RNase digestion, the protected RNA-protein complexes were separated on 
an 8% SDS gel and visualized by autoradiography.  (A) For the ADAM10 5`UTR incubated with 
15 µg cytosolic extract of HEK293E cells at least 4 protein bands in the region of 36 to 98 kDa 
were detected.  In contrast with nuclear extract, only 2 protein bands in the region of 36 to 64 kDa 
were detected.  (B) The BACE1 5`UTR incubation with cytosolic or nuclear extract of HEK293E 
cells following UV light treatment results in binding of several protein bands.  For (A) and (B) the 
reaction set ups without extract or no UV light treatment revealed no protein bands on the gel.  All 
reactions for ADAM10 5`UTR and cytosolic extract and ADAM10 5`UTR and nuclear extract 
were run on one gel, respectively.  The lanes were separated by other reactions that have been 
removed for this figure.  The reactions for the BACE1 5`UTR with cytosolic extract and nuclear 
extract were run as well on separate gels. 
 
 
To further prove the specificity of the ADAM10 5`UTR RNA-binding proteins, 
competition experiments were performed.  The cytosolic and nuclear extracts were 
preincubated with a 100-fold of in vitro-transcribed ADAM10 5`UTR prior to the addition 
of 106 cpm radiolabelled in vitro-transcribed ADAM10 5`UTR.  The formation of all the 
UV-crosslinked RNA-protein complexes could be specifically competed by unlabelled 
ADAM10 5`UTR RNA (Figure 3.9). 
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Figure 3.9 Displacement of protein binding via excess of non-radioactive-labelled 
ADAM10 5`UTR RNA 
Cytosolic and nuclear extracts were preincubated (right) with an excess of unlabelled in vitro-
transcribed ADAM10 5`UTR.  Following the addition of radiolabelled in vitro-transcribed 
ADAM10 5`UTR, RNA and protein were UV crosslinked at 254 nm for 25 min on ice and RNA 
was digested.  RNase-protected RNA-protein complexes were separated on an 8% SDS gel and 
visualized by autoradiography. 
 
 
The specificity of the ADAM10 5`UTR RNA-binding proteins was proven by the use 
of the reverse ADAM10 5`UTR sequence (Figure 3.10A).  Incubation of the reverse 
ADAM10 5`UTR sequence with either cytosolic or nuclear HEK293E extract following 
UV light treatment resulted in the detection of a slightly different protein band pattern 
(Figure 3.10B).  The slight difference between the proteins binding to the ADAM10 
5`UTR and the reverse ADAM10 5`UTR confirms the specificity of the RNA-binding 
proteins.  Taken together, these data demonstrate that different RNA sequences are 
recognized by different proteins.  However, proteins, which do not bind to specific 
nucleotides but to purine-rich or pyrimidine-rich stretches, can bind to both 5`UTRs.  This 
might explain the similarity of the detected protein pattern. 
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Figure 3.10 Specific binding of proteins to the ADAM10 5`UTR. 
Nuclear and cytosolic extract were incubated with ADAM10 5`UTR RNA or reverse ADAM10 
5`UTR and crosslinked via UV treatment at 254 nm for 25 min.  The RNA-protein complex was 
separated on an 8% SDS gel and visualized by autoradiography.  In the first lane of each gel, the 
same proteins were detected as in Figure 3.8.  Incubation of nuclear and cytosolic extracts with 
reverse ADAM10 5`UTR reveals a changed protein pattern. 
 
 
In summary, the UV-crosslink experiments strongly suggest that the detected RNA-
binding proteins are selectively binding to the ADAM10 5`UTR. 
 
3.1.5 Deletional analysis of ADAM10 5`UTR protein-binding sites 
In the experiment described in 3.1.4, the intact ADAM10 5`UTR was used to detect 
RNA-protein interactions.  To map the region of the RNA sequence/structure involved in 
protein binding, a series of 3` and 5` deletions of the 5`UTR were tested for their ability to 
crosslink to proteins (Figure 3.11A). 
In order to test the RNA-protein interaction of the deletion constructs, UV crosslink 
experiments of the full-length 5`UTR and the 3` and 5` deletions were performed as 
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described in 3.1.4.  For the 3` deletion construct ∆251-432 no reduction but an increased 
intensity in protein bands could be detected after incubation with 15 µg cytosolic extract in 
comparison to the full-length ADAM10 5`UTR (Figure 3.11B).  The formation of a 70-90 
kDa UV-crosslinked RNA-protein complex disappeared for the 5` deletion constructs ∆1-
155 and ∆1-175 when incubated with cytosolic extract.  However, an increased intensity of 
the remaining bands was detected for these constructs, indicating that the remaining 
proteins might bind more efficiently.  Analysis of the 5` deletion construct ∆1-215 revealed 
a reduced number and intensity of detected proteins, suggesting that an important element 
is missing for efficient binding of the remaining proteins.  Furthermore, the deletion of the 
first 259 nt of the 5`UTR nearly completely reduced the number of UV-crosslinked 
proteins (Figure 3.11B).  The results are in agreement with the EMSAs performed for ∆1-
259 and ∆251-432 (Figure 3.7).  The two remaining bands for the ∆1-259 construct in the 
UV-crosslink might be some weak interactors that were stabilized by the covalent binding 
and can therefore not be seen by EMSAs.  Taken together, these data confirm that the 
crosslinked proteins bind to the first half of the 5`UTR.  In addition, it was demonstrated 
that the region between 175 and 259 contains important protein-binding sites. 
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Figure 3.11 Determination of the ADAM10 5`UTR-binding domains required for protein 
binding. 
(A) Schematic representation of the ADAM10 5`UTR deletion constructs.  The complete 
ADAM10 5`UTR (432 nt), the 3` deleted ∆251-432 RNA as well as a series of 5` deleted RNAs 
(∆1-259, ∆1-215, ∆1-175, ∆1-155) were prepared for UV-crosslinking experiments.  All ADAM10 
5`UTR constructs lack the last 12 nucleotides (see Figure 2.1A).  (B) Crosslink experiments with 
full-length and deleted ADAM10 5`UTR constructs were performed in the presence of 15 µg 
cytosolic extract.  For the ∆251-432 construct the same proteins as for the full-length 5`UTR were 
detected, but the intensity of the protein bands increased.  The formation of the 70-90 kDa RNA-
protein complex disappeared upon deletion of the first 155 and 175 nucleotides.  However, the 
other RNA-protein complexes appear with a higher intensity.  The ∆1-215 construct resulted in a 
reduced number of RNA-protein complexes and a decreased intensity of the complexes.  Nearly no 
RNA-protein complexes could be detected with the first half (∆1-259) of the ADAM10 5`UTR. 
 
 
3.2 Data base search for ADAM10 and BACE1 5`UTR-binding 
proteins 
The above described results suggest a specific binding of proteins to the 5`UTR of 
ADAM10 and BACE1.  Therefore a database search was performed to look for potential 
candidate proteins.  The UTR database UTRdb of the Institute for Biomedical 
Technologies (http://utrdb.ba.itb.cnr.it/) (Grillo et al., 2010; Pesole et al., 2000; Pesole et 
al., 1998) was used for the identification of ADAM10 and BACE1 5`UTR-binding 
proteins.  Examination of the BACE1 5`UTR revealed that there was no predicted RNA-
binding protein.  In contrast, for the ADAM10 5`UTR the search revealed two possible 
binding sites for the RNA-binding protein upstream of N-ras (Unr).  These binding sites 
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are located within an 83-nucleotide-long stretch that is composed almost solely of purines 
between nucleotides 164 and 246 of the ADAM10 5`UTR (Figure 3.12). 
 
 
 
 
 
 
Figure 3.12 Representation of the ADAM10 5`UTR sequence and its predicted Unr 
binding sites. 
Shown is the sequence of the ADAM10 5`UTR (Accession number: NT_010194.17, 
GI:224514848).  The 83-nucleotide-long purine stretch is shown in bold.  The two predicted 
optimal Unr binding sites R8AACR3 (R = G or A) within this purine stretch are underlined and 
shown in red (Triqueneaux et al., 1999).  The last 12 nucleotides of the ADAM10 5`UTR, which 
were not included in EMSA, UV-crosslink and purification experiments, are shown in green (see 
Figure 2.1A). 
 
 
Unr is a cytoplasmic RNA-binding protein and contains five cold shock domains 
(CSD) (Jacquemin-Sablon et al., 1994).  Each CSD contains two conserved RNA 
recognition motifs RNP-1 (ribonucleoprotein 1) (amino acids Y/FGFI) and RNP-2 (amino 
acids FFH) that fold in a compact β-barrel and mediate binding to single stranded nucleic 
acids (Figure 3.13) (Brown and Jackson, 2004; Jacquemin-Sablon et al., 1994). 
 
 
 
 
 
 
 
Figure 3.13 Representation of the Unr protein. 
Shown is Unr with its five CSDs, each containing two conserved RNP motifs.  RNP1 consists of 
the amino acids Y/FGFI and RNP2 consists of the amino acids FFH.  Two isoforms of Unr are 
shown: a 767-amino-acid-long isoform lacking exon 5 and a 798 amino acid long isoform 
containing exon 5. 
 
 
Two isoforms of Unr with an open reading frame of 767 or 798 amino acids are 
generated by skipping of exon 5 (Boussadia et al., 1993; Ferrer et al., 1999).  In addition, 
three alternative polyadenylation sites have been described in the Unr gene (Jeffers et al., 
1990). 
1 GCGGCGGCAG GCCUAGCAGC ACGGGAACCG UCCCCCGCGC GCAUGCGCGC GCCCCUGAAG
61 CGCCUGGGGG ACGGGUAGGG GCGGGAGGUA GGGGCGCGGC UCCGCGUGCC AGUUGGGUGC
121 CCGCGCGUCA CGUGGUGAGG AAGGAGGCGG AGGUCUGAGU UUCGAGGGAG GGGGGGAGAG
181 AAGAGGGAAC GAGCAAGGGA AGGAAAGCGG GGAAAGGAGG AAGGAAACGA ACGAGGGGGA
241 GGGAGGUCCC UGUUUUGGAG GAGCUAGGAG CGUUGCCGGC CCCUGAAGUG GAGCGAGAGG
301 GAGGUGCUUC GCCGUUUCUC CUGCCAGGGG AGGUCCCGGC UUCCCGUGGA GGCUCCGGAC
361 CAAGCCCCUU CAGCUUCUCC CUCCGGAUCG AUGUGCUGCU GUUAACCCGU GAGGAGGCGG
421 CGGCGGCGGC AGCGGCAGCG GAAG
CSD CSD CSD CSD CSDNH2 COOH
1 767, 798
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Proteins of the CSD family perform a variety of functions and are thought to behave as 
RNA chaperones, promoting a linear conformation of the mRNA.  Unr was shown to be 
involved in the regulation of mRNA translation and stability by binding to purine-rich sites 
in UTRs (Mihailovich et al., 2010).  Therefore, Unr may be a potential candidate that 
might regulate ADAM10 protein expression by binding to its 5’UTR. 
 
3.3 Affinity purification of RNA-binding proteins 
To prove Unr as a ADAM10 5`UTR-binding protein and to identify and purify other 
ADAM10 5`UTR binding proteins in a large scale, a biotin-streptavidin affinity 
chromatography (based on Miltenyi-Biotech procedures, Figure 3.15), was established.  In 
the original protocol from Miltenyi-Biotech, the in vitro-transcribed RNA was labelled 
with a biotinylated oligonucleotides which must be complementary to the in vitro-
transcribed RNA and should be at least 25 – 30 bases long.  However, with this labelling 
method no specific interaction with proteins was detectable.  Therefore, the protocol was 
optimized with internally biotinylated in vitro-transcribed RNA (refer to 2.7.3).  
Furthermore to reduce possible background binding, two preclearing steps (streptavidin 
agarose and heparin agarose) for the cytosolic extract were introduced (refer to 2.9.19) 
instead of only one optional washing step with heparin agarose in the original protocol 
(www.miltenyibiotec.com/~/media/Images/Products/Import/0002500/IM0002567.ashx). 
For the purification of 5`UTR-binding proteins, 400 pmol internally biotinylated in 
vitro-transcribed ADAM10 or BACE1 5`UTR mRNA (as control for selectivity) (Figure 
3.14) was incubated with paramagnetic micro beads covalently conjugated with 
streptavidin for one hour.  As a control, the same experimental setup was performed with 
the exception that the paramagnetic micro beads were incubated with non-biotinylated in 
vitro-transcribed mRNA (Figure 3.14). 
 
 
 
 
 
Figure 3.14 Control of biotinylated ADAM10 and BACE1 5`UTR 
A dot blot for 1 µg biotinylated and non-biotinylated ADAM10 and BACE1 5`UTR decorated with 
a Streptavidin-Alkaline phosphatase antibody is shown.  
 
 
 
1µg
ADAM10
5`UTR
BACE1
5`UTR ++ Biotin-CTP++
Results 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Schematic representation of the affinity purification method (adapted from 
Miltenyi-Biotech, www.miltenyibiotec.com) 
400 pmol in vitro-transcribed internally biotinylated RNA was incubated with µMACS 
Streptavidin MicroBeads for 1 h at room temperature.  Cytosolic extract was precleared with 
heparin and streptavidin agarose followed by the incubation with the biotinylated RNA-µMACS 
Streptavidin MicroBeads complex for 1 h.  The entire binding reaction was added to an equilibrated 
µColumn in the magnetic field of a µMACS separator.  Once the entire incubation reaction passed 
through the column, the column was washed several times with binding buffer to remove non-
specifically bound molecules.  Bound proteins were finally eluted with binding buffer 
supplemented with 1 M NaCl. 
 
 
The RNA-bead complexes were incubated with 6 mg cytosolic extract from HEK293E 
cells (Figure 3.16A) or cytosolic brain extracts from P30 mice (Figure 3.16B) to allow the 
formation of RNA-protein complexes.  These complexes were separated on a µColumn 
localized in the magnetic field of a µMACS separator.  After stringent washing, the RNA-
binding proteins were eluted with high-salt buffer followed by TCA precipitation.  Finally, 
the RNA-binding proteins were separated on an 8% SDS gel for the HEK293E cytosolic 
extract and on a 10% SDS gel for the cytosolic extract from P30 mice brains.  The gels 
were either stained with silver (Figure 3.16) or blotted onto a membrane (Figure 3.21).  As 
already seen for the results of the UV crosslinking, the protein band patterns for the 
ADAM10 and BACE1 5`UTR differ significantly (Figure 3.16).  Hence, there seems to be 
selective binding of proteins to either of the two 5`UTRs. 
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Figure 3.16 Purification of ADAM10 and BACE1 5`UTR-binding proteins. 
6 mg cytosolic extract was incubated with 400 pmol non-biotinylated and biotinylated ADAM10 or 
BACE1 5`UTR.  RNA-binding proteins were affinity purified in a magnetic field and separated on 
an 8% SDS gel (A) or 10% SDS gel (B), respectively.  The silver-stained protein bands were cut 
out and subjected to LC-MS/MS.  (A) Silver gel for the affinity purified TCA precipitated RNA-
binding proteins from HEK293 cytosolic extract, and (B) for RNA-binding proteins from cytosolic 
extract from P30 mouse brains.  Next to the gel pictures, the cutting paradigm is shown.  Gel (A) 
was cut manually whereas gel (B) was cut with a moulding tool. 
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The silver-stained gels of the affinity purifications (Figure 3.16) comprising the 
complete molecular weight range from 36 kDa to 210 kDa were cut into several pieces (see 
cutting paradigm next to gel pictures).  Each piece was subjected to in-gel trypsin 
digestion.  Peptide mass fingerprints were generated by LC-MS/MS analysis and the 
results analysed by a mascot database search (LC-MS/MS analysis was performed by Dr. 
Ignasi Forne). 
 
3.4 ADAM10 5`UTR RNA-binding proteins 
As expected from the database search, Unr was identified in both affinity purification 
setups for the lane at 98 kDa (refer to Figure 3.16) with a high coverage confirming the 
results of the UTR scan approach.  The mass spectrometry performed on the silver gel 
from the purification with the cytosolic extract from HEK293E cells yielded 14 different 
peptides covering the human Unr protein sequence from the N- to the C-terminus (20% 
peptide coverage) (Figure 3.17, Figure 3.18 and in detail Appendix Figure 6.1).  The 
mascot score, describing the significance of the search result was 193.  The mascot score is 
a measure of the reliability of the identification (Koenig et al., 2008).  Thus, a high score 
represents a reliable identification.  In this work, the significance threshold was set to 100. 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Unr peptides found by mass spectrometry. 
Unr peptides found by mass spectrometry for the purification with cytosolic extract from 
HEK293E cells are shown.  The peptides identified by mass spectrometry are marked in red.  The 
peptides of exon5 which were not identified by mass spectrometry are marked in blue. The mascot 
score and the peptide coverage were 193 and 20%, respectively. 
 
  1 MSFDPNLLHN NGHNGYPNGT SAALRETGVI EKLLTSYGFI QCSERQARLF
 51 FHCSQYNGNL QDLKVGDDVE FEVSSDRRTG KPIAVKLVKI KQEILPEERM
101 NGQVVCAVPH NLESKSPAAP GQSPTGSVCY ERNGEVFYLT YTPEDVEGNV
151 QLETGDKINF VIDNNKHTGA VSARNIMLLK KKQARCQGVV CAMKEAFGFI
201 ERGDVVKEIF FHYSEFKGDL ETLQPGDDVE FTIKDRNGKE VATDVRLLPQ
251 GTVIFEDISI EHFEGTVTKV IPKVPSKNQN DPLPGRIKVD FVIPKELPFG
301 DKDTKSKVTL LEGDHVRFNI STDRRDKLER ATNIEVLSNT FQFTNEAREM
351 GVIAAMRDGF GFIKCVDRDV RMFFHFSEIL DGNQLHIADE VEFTVVPDML
401 SAQRNHAIRI KKLPKGTVSF HSHSDHRFLG TVEKEATFSN PKTTSPNKGK
451 EKEAEDGIIA YDDCGVKLTI AFQAKDVEGS TSPQIGDKVE FSISDKQRPG
501 QQVATCVRLL GRNSNSKRLL GYVATLKDNF GFIETANHDK EIFFHYSEFS
551 GDVDSLELGD MVEYSLSKGK GNKVSAEKVN KTHSVNGITE EADPTIYSGK
601 VIRPLRSVDP TQTEYQGMIE IVEEGDMKGE VYPFGIVGMA NKGDCLQKGE
651 SVKFQLCVLG QNAQTMAYNI TPLRRATVEC VKDQFGFINY EVGDSKKLFF
701 HVKEVQDGIE LQAGDEVEFS VILNQRTGKC SACNVWRVCE GPKAVAAPRP
751 DRLVNRLKNI TLDDASAPRL MVLRQPRGPD NSMGFGAERK IRQAGVID 
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Figure 3.18 Detailed description of Unr peptides from HEK293E cytosolic extract found 
by mass spectrometry. 
Start – End: amino acid number of the peptide in the protein sequence.  Observed: experimental 
mass number / charge number (m/z) value.  Mr(expt): experimental m/z transformed to a relative 
molecular mass.  Mr(calc): relative molecular mass calculated from the matched peptide sequence. 
 
 
For the silver gel from the purification with the cytosolic extract from P30 mouse 
brains, mass spectrometry identified 32 different peptides from the 98 kDa band, which 
matched peptide sequences from mouse Unr (Figure 3.19, Figure 3.20 and in detail 
Appendix Figure 6.2).  The corresponding peptide coverage was 41% and the mascot score 
was 1447. 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Unr peptides found by mass spectrometry. 
Unr peptides found by mass spectrometry for the purification with cytosolic extract from P30 
mouse brains are shown.  The peptides identified by mass spectrometry are marked in red.  The 
peptides of exon5 which were not identified by mass spectrometry are marked in blue.  The mascot 
score and the peptide coverage were 1447 and 41%, respectively. 
  1 MSFDPNLLHN NGHNGYPNGT SAALRETGVI EKLLTSYGFI QCSERQARLF  
 51 FHCSQYNGNL QDLKVGDDVE FEVSSDRRTG KPIAIKLVKI KPEIHPEERM  
101 NGQVVCAVPH NLESKSPAAP GQSPTGSVCY ERNGEVFYLT YTSEDVEGNV  
151 QLETGDKINF VIDNNKHTGA VSARNIMLLK KKQARCQGVV CAMKEAFGFI  
201 ERGDVVKEIF FHYSEFKGDL ETLQPGDDVE FTIKDRNGKE VATDVRLLPQ  
251 GTVIFEDISI EHFEGTVTKV IPKVPSKNQN DPLPGRIKVD FVIPKELPFG  
301 DKDTKSKVTL LEGDHVRFNI STDRRDKLER ATNIEVLSNT FQFTNEAREM  
351 GVIAAMRDGF GFIKCVDRDA RMFFHFSEIL DGNQLHIADE VEFTVVPDML  
401 SAQRNHAIRI KKLPKGTVSF HSHSDHRFLG TVEKEATFSN PKTTSPNKGK  
451 DKEAEDGIIA YDDCGVKLTI AFQAKDVEGS TSPQIGDKVE FSISDKQRPG  
501 QQIATCVRLL GRNSNSKRLL GYVATLKDNF GFIETANHDK EIFFHYSEFS  
551 GDVDSLELGD MVEYSLSKGK GNKVSAEKVN KAHSVNGITE EANPTIYSGK  
601 VIRPLRGVDP TQIEYQGMIE IVEEGDMKGE VYPFGIVGMA NKGDCLQKGE  
651 SVKFQLCVLG QNAQTMAYNI TPLRRATVEC VKDQFGFINY EVGDSKKLFF  
701 HVKEVQDGVE LQAGDEVEFS VILNQRTGKC SACNVWRVCE GPKAVAAPRP  
751 DRLVNRLKNI TLDDASAPRL MVLRQPRGPD NSMGFGAERK IRQAGVID 
Start – End Observed Mr(expt) Mr(calc) Sequence    
  65 – 78    805.3696    1608.7246   1608.7380 VGDDVEFEVSSDRR  
  90 – 99    627.8517    1253.6889   1253.6979 IKQEILPEER   
195 – 202    484.7464      967.4782      967.4763 EAFGFIER   
208 – 217    673.8214    1345.6283   1345.6343 EIFFHYSEFK   
218 – 234    938.9553    1875.8961   1875.9102 GDLETLQPGDDVEFTIK  
247 – 269    858.4576    2572.3509   2572.3425 LLPQGTVIFEDISIEHFEGTVTK
287 – 295    529.8392    1057.6639   1057.6536 IKVDFVIPK    
308 – 317    569.8107    1137.6068   1137.6142 VTLLEGDHVR    
318 – 325    504.7607    1007.5068   1007.5148 FNISTDRR   
331 - 348     1028.0024    2053.9903   2054.0069 ATNIEVLSNTFQFTNEAR  
519 - 527        489.3065       976.5985      976.5957 LLGYVATLK   
601 - 606        377.2598       752.5051      752.5021 VIRPLR    
683 - 696        809.8669    1617.7192   1617.7311 DQFGFINYEVGDSK    
759 - 769     586.7951    1171.5756   1171.5833 NITLDDASAPR   
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Figure 3.20 Detailed description of Unr peptides from mouse brain cytosolic extract found 
by mass spectrometry. 
Start – End: amino acid number of the peptide in the protein sequence.  Observed: experimental 
mass number / charge number (m/z) value.  Mr(expt): experimental m/z transformed to a relative 
molecular mass.  Mr(calc): relative molecular mass calculated from the matched peptide sequence. 
 
 
To prove the result of the mass spectrometry analysis regarding Unr, the TCA 
precipitated RNA-binding proteins from cytosolic extracts of HEK293E cells binding to 
the ADAM10 5`UTR were blotted onto a membrane and decorated with the Unr S23 
antibody (Jacquemin-Sablon et al., 1994) (Figure 3.21).  Unr could be detected in the 
Start – End Observed Mr(expt) Mr(calc) Sequence   
33 – 45  787.3870 1572.7594 1572.7606 LLTSYGFIQCSER   
65 - 78       537.2531   1608.7375   1608.7380 VGDDVEFEVSSDRR 
65 - 78       805.3762   1608.7378   1608.7380 VGDDVEFEVSSDRR 
79 - 86       414.2715   826.5284    826.5276 TGKPIAIK 
90 - 99       416.5660   1246.6762   1246.6669 IKPEIHPEER 
158 - 166      538.7904   1075.5662   1075.5662 INFVIDNNK 
167 - 174      399.7144   797.4142    797.4144 HTGAVSAR 
175 - 180      366.2279   730.4412   730.4411 NIMLLK 
175 - 180      374.2253   746.4360   746.4360 NIMLLK Oxidation (M) 
195 - 202      484.7450    967.4754    967.4763 EAFGFIER 
218 - 236      716.6857   2147.0353   2147.0383 GDLETLQPGDDVEFTIKDR 
237 - 246      544.7883   1087.5620   1087.5622 NGKEVATDVR 
278 - 286      505.7542   1009.4938   1009.4941 NQNDPLPGR 
287 - 295      353.5583   1057.6531   1057.6536 IKVDFVIPK 
287 - 295      529.8340   1057.6534   1057.6536 IKVDFVIPK 
296 - 305      575.2932  1148.5718 1148.5713 ELPFGDKDTK 
306 - 317      451.9200   1352.7382   1352.7412 SKVTLLEGDHVR 
318 - 325      504.7645   1007.5144   1007.5148 FNISTDRR 
349 - 357      489.2491    976.4836    976.4834 EMGVIAAMR 
349 - 357      497.2466    992.4786    992.4783 EMGVIAAMR Oxidation (M) 
349 - 357      505.2438   1008.4730   1008.4732 EMGVIAAMR 2 Oxidation (M) 
358 - 364      392.2054    782.3962    782.3963 DGFGFIK 
416 - 427      456.2130   1365.6172   1365.6174 GTVSFHSHSDHR 
428 - 442      556.6257   1666.8553   1666.8566 FLGTVEKEATFSNPK 
468 - 475      446.2682    890.5218    890.5225 LTIAFQAK 
476 - 496      746.6976   2237.0710   2237.0699 DVEGSTSPQIGDKVEFSISDK 
497 - 508      471.9176   1412.7310   1412.7307 QRPGQQIATCVR 
519 - 527      489.3049    976.5952    976.5957 LLGYVATLK 
601 - 606      377.2585    752.5024    752.5021 VIRPLR 
629 - 642      749.3750   1496.7354   1496.7334 GEVYPFGIVGMANK Oxidation (M) 
683 - 696      809.8754   1617.7362   1617.7311 DQFGFINYEVGDSK 
698 - 703      395.7344    789.4542    789.4538 LFFHVK 
744 - 752      318.1821    951.5245    951.5250 AVAAPRPDR 
744 - 752      476.7696    951.5246    951.5250 AVAAPRPDR 
757 - 769      471.9278   1412.7616   1412.7623 LKNITLDDASAPR 
757 - 769      707.3889   1412.7632   1412.7623 LKNITLDDASAPR 
770 - 774      316.2017    630.3888    630.3887 LMVLR 
770 - 774      324.1990    646.3834    646.3836 LMVLR Oxidation (M) 
778 - 789      619.2672   1236.5198   1236.5193 GPDNSMGFGAER 
778 - 789      627.2643   1252.5140   1252.5143 GPDNSMGFGAER Oxidation (M) 
791 - 798      436.2534    870.4922    870.4923 IRQAGVID 
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Western blot for the purification with the biotinylated ADAM10 5`UTR RNA but not in 
the control lane.  The lower fainter bands detected by the antibody might be degradation 
products of Unr whereas the upper band might be Unr including exon 5. 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 Detection of Unr after affinity purification. 
Affinity purified ADAM10 5`UTR RNA-binding proteins from HEK293E cytosolic extract were 
precipitated with TCA after elution and separated on an 8% SDS gel. Unr was detected by 
immunoblotting with the Unr antibody S23 (Jacquemin-Sablon et al., 1994) at 98 kDa 
(representative Western Blot for n=3 experiments).  Note, in addition to the 98 kDa band, some 
fainter bands, possibly degraded Unr, could be detected. 
 
 
Besides Unr several other RNA-binding proteins could be identified for the ADAM10 
5`UTR, which were not predicted in the UTR database (Table 3.1 and 3.2).  22 gel bands 
from the purification with HEK293E cytosolic extract were analysed by mass 
spectrometry, which identified 90 proteins (Table 3.1).  ADAM10 5`UTR associated 
proteins included 3 RNA transport proteins, 12 proteins involved in protein synthesis, 12 
hnRNPs, 7 RNA helicases, 6 splicing factors, 15 RNA associated proteins (including Unr), 
10 tRNA synthetases, 9 cytoskeletal associated proteins and 16 other known proteins. 
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Function / Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
RNA transport (3) FXR1 400 70 kDa 11, 10, 12 
 FXR2 172 75 kDa 8 
 THOC6 122 38 kDa 18 
Protein synthesis (12) eEF1a1 254 50 kDa 17, 18, 14, 19 
 eEF1a2 145 51 kDa 17 
 eEF1d 181 31 kDa 20 
 eEF1g 299 50 kDa 17 
 eIF2a 636 36 kDa 18, 20, 21 
 eIF2b 148 39 kDa 17 
 eIF2g 380 52 kDa 16, 17 
 eIF3c 116 106 kDa 11 
 eIF3i 120 67 kDa 13 
 IMDH2 219 56 kDa 14, 15 
 RL6 282 33 kDa 18 
 RLA0 171 34 kDa 18 
hnRNP (12) hnRNP A0 145 34 kDa 18 
 hnRNP A1 446 39 kDa 18, 21, 20 
 hnRNP A2/B1 1714 37 kDa 18, 20, 19, 21 
 hnRNP A3 171 40 kDa 18, 20 
 hnRNP C 105 34 kDa 19 
 hnRNP F 318 46 kDa 17, 16, 19, 18 
 hnRNP H1 491 49 kDa 16, 19, 17 
 hnRNP H2 242 50 kDa 16 
 hnRNP H3 171 37 kDa 18 
 hnRNP K 110 51 kDa 13 
 hnRNP Q 128 70 kDa 13 
 hnRNP U 364 91 kDa 10, 4, 11, 9, 8, 12, 13 
RNA helicases (7) DHX9 160 142 kDa 3 
 DHX15 141 92 kDa 10, 8 
 DHX40 114 90 kDa 9 
 Ku70 212 70 kDa 11 
 UAP56 152 49 kDa 17 
 G3BP1 462 52 kDa 13 
 G3BP2 137 54 kDa 14 
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Function / Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
Splicing factors (6) SF3A1 154 89 kDa 4 
 SF3B1 142 146 kDa 4 
 SF3B3 428 136 kDa 3 
 SF3B4 105 44 kDa 17 
 U2AF1 202 28 kDa 18 
 U2AF2 236 54 kDa 13 
Other RNA associated (15) Unr 193 90 kDa 8, 11 
 Nucleolin 567 77 kDa 14, 17, 15, 13, 11, 18, 9, 7, 10, 19, 8 
 FBP1 221 68 kDa 11 
 LA 123 47 kDa 19 
 IMP4 100 34 kDa 21 
 NONO 177 54 kDa 22, 18 
 ILF2 320 43 kDa 19 
 ILF3 466 96 kDa 10, 9 
 NPM 161 33 kDa 18 
 PRP19 107 55 kDa 14 
 PA2G4 398 44 kDa 17 
 CPSF6 243 59 kDa 11 
 SND1 486 103 kDa 5, 6 
 APEX1 102 36 kDa 18 
 LC7L2 145 47 kDa 18 
tRNA synthetases (10) SYC 150 89 kDa 9 
 SYDC 696 57 kDa 15, 16, 14 
 SYEP 318 165 kDa 4, 5, 9, 8, 14, 7 
 SYIC 1060 145 kDa 2, 3, 1 
 SYK 474 68 kDa 11, 12 
 SYLC 964 136 kDa 3, 4 
 SYMC 516 102 kDa 7 
 SYQ 931 89 kDa 8, 13 
 SYRC 916 76 kDa 12, 11, 13 
 SYSC 153 59 kDa 14 
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Function / Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
Cytoskeletal (9) Drebrin 776 72 kDa 4, 5, 7, 10, 11, 6 
 Septin-2 283 42 kDa 19, 18 
 Septin-7 194 51 kDa 17, 18 
 Septin-8 154 56 kDa 15 
 Septin-9 205 66 kDa 13 
 Septin-11 311 50 kDa 16 
 Vimentin 109 54 kDa 14 
 LIMA1 116 86 kDa 10, 13 
 DC1I2 102 69 kDa 10 
Other known proteins (16) LONM 1167 107 kDa 6, 7, 8 
 HSP71 236 70 kDa 11 
 KIAA1967 
homolog 
338 103 kDa 5 
 KCC2B 103 58 kDa 17 
 IQGA1 589 190 kDa 7 
 GTPBP1 191 72 kDa 11 
 GLYM 232 56 kDa 15 
 DRG1 335 41 kDa 19 
 Moesin 137 68 kDa 10 
 MCA1 299 35 kDa 20, 21 
 MCA2 106 36 kDa 21 
 MCM3 146 92 kDa 7 
 MCM5 191 83 kDa 8 
 P5CR2 326 34 kDa 18 
 PP1G 146 38 kDa 18 
 DHB4 275 72 kDa 10 
Table 3.1 ADAM10 5`UTR interacting proteins from cytosolic extract of HEK293E cells 
Cytosolic extract of HEK293E cells was incubated with ADAM10 5`UTR RNA. The RNA binding 
proteins were separated by gel electrophoresis, and 22 bands were analysed with mass 
spectrometry.  The proteins were subdivided in different categories according to their function.  For 
each identified protein the highest mascot score, the molecular weight and the lane(s), where the 
protein was identified, are listed.  The lane number marked in bold corresponds to the mascot 
score.  Only proteins with a mascot score higher than 100 were considered.  The data listed 
represents n=2 experiments.  Proteins colour labelled in blue were detected in the purification with 
cytosolic extract from HEK293E and P30 mice brains. 
 
 
Fewer proteins were identified for the affinity purification with cytosolic extract from 
P30 mouse brains.  The analysis of the 31 gel bands identified 42 proteins including 2 
transcription / RNA transport proteins, 1 protein involved in proteins synthesis, 5 hnRNPs, 
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6 RNA associated proteins (including Unr) and 19 cytoskeletal associated proteins as well 
as 9 other known proteins (Table 3.2). 
 
Function / Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
Transcription / Pur-alpha 865 35 kDa 13, 12, 11 
RNA transport (2) Pur-beta 1224 34 kDa 11, 12 
Protein synthesis (1) eEF1a2 115 51 kDa 15 
hnRNP (5) hnRNP A1 158 34 kDa 9 
 hnRNP F 687 46 kDa 15, 14, 16 
 hnRNP H1 1042 49 kDa 16, 15, 14 
 hnRNP H2 906 49 kDa 16 
 hnRNP Q 118 70 kDa 19 
Other RNA associated (6) Unr 1447 90 kDa 23, 22 
 Unrip 753 39 kDa 11 
 Nucleolin 563 77 kDa 23, 20 
 FBP1 344 68 kDa 20 
 PABP 106 32 kDa 16 
 SART-3 135 110 kDa 25 
Cytoskeletal (19) MAP1A 117 301 kDa 30 
 MAP2 7553 199 kDa 29, 30, 28, 31, 27 
 MAP6 651 97 kDa 25 
 Coronin-2A 113 60 kDa 18 
 Coronin-2B 174 55 kDa 17 
 Drebrin 1100 78 kDa 25, 24 
 Tau 153 76 kDa 15 
 Spectrin ( chain 280 285 kDa 28 
 Spectrin ( chain 111 275 kDa 28 
 Synapsin-1 1269 74 kDa 21, 19, 20 
 Synapsin-2 376 64 kDa 17 
 Synapsin-3 124 64 kDa 19 
 DC1I1 329 71 kDa 21 
 DC1I2 125 69 kDa 21 
 DC1L1 217 57 kDa 17 
 DYHC1 2293 534 kDa 29, 30, 31 
 DYN1 3227 98 kDa 23, 22 
 DYN2 738 98 kDa 23 
 DYN3 846 98 kDa 23 
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Function / Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
Other known proteins (9) EFHD2 352 27 kDa 8, 7 
 HS71L 195 71 kDa 20 
 HSP72 229 70 kDa 20 
 HSP7C 373 71 kDa 20 
 SYNJ1 101 174 kDa 26 
 BASP1 115 22 kDa 16 
 NCAN 105 139 kDa 30 
 G3P 110 36 kDa 10 
 KIAA1967 
homolog 
229 104 kDa 25 
Table 3.2 Potential ADAM10 5`UTR interacting proteins from cytosolic extract of P30 
mice brains identified by mass spectrometry. 
Cytosolic extract of P30 mice brains was incubated with ADAM10 5`UTR RNA. The RNA 
binding proteins were separated by gel electrophoresis, and 31 bands were analysed with mass 
spectrometry.  The proteins were subdivided in different categories according to their function.  For 
each identified protein the highest mascot score, the molecular weight and the lane(s), where the 
protein was identified, are listed.  The lane number marked in bold corresponds to the mascot 
score.  Only proteins with a mascot score higher than 100 were considered.  The data listed 
represents n=1 experiment due to limited amount of cytosolic extract from P30 mice brains.  
Proteins colour labelled in blue were detected in the purification with cytosolic extract from 
HEK293E and P30 mice brains. 
 
 
Interestingly, besides the total number of identified proteins also the kind of proteins 
identified largely differed (compare Table 3.1 and 3.2). 
Comparison of the proteins identified with the cytosolic extract of HEK293E cells and 
the cytosolic extract of P30 mice brains implies that there are a couple of different proteins 
identified (compare Table 3.1 and 3.2).  However, several of the proteins identified, such 
as Unr, Nucleolin, hnRNP A1 and hnRNP H/F, were found in both purifications (identical 
protein colour labelled in Table 3.1 and 3.2 and summarized in Table 3.3). 
Interestingly, only for the purification with HEK293E cytosolic extract RNA 
helicases, splicing factors and tRNA synthetases were pulled down (compare Table 3.1 and 
3.2).  For the purification with mice brain cytosolic extract an increasing number of  
cytoskeleton-associated proteins was pulled down (compare Table 3.1 and 3.2).  
Furthermore, the identified RNA transport proteins differed between the two purifications 
(refer to Table 3.3). 
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Function / Type (number) Protein name Molecular weight (kDa) 
Protein synthesis (1) eEF1a1 50 kDa 
RNA transport (4) FXR1 1 70 kDa 
 FXR2 1 75 kDa 
Pur-alpha 2 35 kDa 
 Pur-beta 2 34 kDa 
hnRNP (7) hnRNP A1 39 kDa 
 hnRNP A2/B1 1 37 kDa 
 hnRNP F 46 kDa 
 hnRNP H1 49 kDa 
 hnRNP H2 50 kDa 
 hnRNP Q 70 kDa 
 hnRNP U 1 91 kDa 
Other RNA associated (5) Unr 90 kDa 
 Nucleolin 77 kDa 
 FBP1 68 kDa 
 PABP 2 32 kDa 
 Unrip 2 39 kDa 
Cytoskeletal (2) Drebrin 72 kDa 
DC1I2 69 kDa 
Other known proteins (1) KIAA1967 homolog 103 kDa 
Table 3.3 Summary of potential ADAM10 5`UTR interacting proteins from cytosolic 
extract of HEK293E cells and P30 mice brains identified by mass spectrometry. 
Cytosolic extracts of HEK293E cells and P30 mice brains were incubated with ADAM10 5`UTR 
RNA. The RNA binding proteins were separated by gel electrophoresis, and the slices were 
analysed with mass spectrometry.  The proteins were subdivided in different categories according 
to their function.  The RNA-binding proteins, which were identified in both purifications with a 
mascot score higher than 100 are listed.  RNA-binding proteins marked with a 1 were only 
identified with cytosolic extract of HEK293E cells and proteins marked with a 2 came up only in 
the purification with mouse cytosolic extract. 
 
 
Interestingly, some of the proteins identified were described to interact with Unr.  The 
protein hnRNP Q (Grosset et al., 2000), which was identified in both purifications, belongs 
to the proteins interacting with Unr.  hnRNP U, which has only been identified in the 
purification with HEK293E cytosolic extract was described to play a role in mRNA 
stabilisation together with hnRNP Q (Weidensdorfer et al., 2009).  Two other proteins, 
which have been described to interact with Unr in an RNA independent-manner, namely 
Unrip (Hunt et al., 1999; Mitchell et al., 2003) and PABP (Chang et al., 2004; Duncan et 
al., 2009; Grosset et al., 2000; Patel et al., 2005), have only been identified for the 
purification with P30 mice brain cytosolic extract.  Moreover, FBP1 was identified in both 
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purifications.  This protein is closely related to FBP2, which interacts with Unr (Dinur et 
al., 2006; Nechama et al., 2008; Nechama et al., 2009). 
 
3.4.1 Electrophoretic mobility shift assay with recombinant Unr 
The UTR database search and the biotin-streptavidin affinity purification have 
revealed that Unr is an ADAM10 5`UTR RNA-binding protein.  In the next step, this result 
was further confirmed by EMSAs with recombinant Unr.  Recombinant Unr was prepared 
by the Glutathione S-transferase (GST) Gene Fusion System (Figure 3.22).  In addition, 
GST and a gene associated with Parkinson`s disease and which was reported to interact 
with RNA, GST-DJ1 (Blackinton et al., 2009; Hod et al., 1999; van der Brug et al., 2008), 
were used as negative controls (Figure 3.22). 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Quality control of purified recombinant GST fusion proteins. 
Recombinant proteins were analysed on a 10% SDS gel.  A Coomassie stained SDS gel is shown 
for recombinant GST-Unr (lane1), GST (lane 2) and GST-DJ1 (lane3), respectively.  1 µg of each 
recombinant protein was loaded. 
 
 
To analyse the ability of Unr to bind specifically to the ADAM10 5`UTR RNA, 106 
cpm 32P-labelled ADAM10 5’UTR was incubated with recombinant GST-Unr.  As positive 
control a cytosolic extract of HEK293E cells was incubated with ADAM10 5`UTR.  GST-
DJ1 and GST served as negative control.  Figure 3.23 demonstrates that recombinant Unr 
binds to the 5’UTR of ADAM10, while GST-DJ1 or GST alone do not.  Specificity of the 
binding of GST-Unr to radiolabelled ADAM10 5`UTR was determined by competition 
with non-radioactive in vitro-transcribed ADAM10 5`UTR.  Binding of GST-Unr to the 
radiolabelled ADAM10 5`UTR was prevented by the addition of an excess of unlabelled 
ADAM10 5`UTR (100-fold).  Moreover, it was described that Unr can bind to the Apaf-1 
5`UTR (Mitchell et al., 2001).  Therefore, the Apaf-1 5`UTR was used as an additional 
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control to analyse the specificity of GST-Unr binding to the ADAM10 5`UTR.  Addition 
of an excess of Apaf-1 5`UTR (100-fold) abolished the binding of the ADAM10 5´UTR to 
GST-Unr.  In summary, the observed effects confirmed that Unr specifically binds to the 
ADAM10 5`UTR. 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 GST-Unr binds to the ADAM10 5`UTR. 
106 cpm of 32P-labelled ADAM10 5’UTR RNA was incubated either with 15 µg HEK293E cell 
extract or with 4 µg of the indicated recombinant proteins in binding buffer for 30 min at room 
temperature.  RNA-protein complexes were separated on a 3.5% non-denaturing polyacrylamide 
gel and visualized by autoradiography.  The xylene cyanol (~ 460 nt) front on the gel served as size 
marker.  Competition studies were performed by addition of an excess of unlabelled ADAM10 
5`UTR (+1) or Apaf-1 5`UTR (+2) as indicated.  The incubation of RNA with cytosolic extract or 
GST-Unr induced a shift, whereas no shift was observed for GST or GST-DJ1.  Addition of 
unlabelled ADAM10 5`UTR (+1) or Apaf-1 5`UTR (+2) abrogates the binding of cytosolic extract 
and GST-Unr. 
 
 
3.4.2 Binding of Unr to the mouse 5`UTR 
In chapter 3.3, the affinity purification of RNA-binding proteins was performed with 
cytosolic extract of mouse brains.  In comparison to the human ADAM10 5`UTR, the 
mouse 5`UTR is shorter as it lacks the first 150 nucleotides, however, the Unr binding site 
appears to be evolutionary conserved (Figure 3.24). 
To demonstrate the binding of proteins to the mouse ADAM10 5`UTR, radiolabelled 
mouse ADAM10 5`UTR (Figure 3.25A) was incubated with cytosolic extract of P30 mice 
brains (Figure 3.25B).  The formation of a complex demonstrates that proteins bind to the 
mouse ADAM10 5`UTR (Figure 3.25B). 
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mouse             ------------------------------------------------------------ 
human             GCGGCGGCAGGCCTAGCAGCACGGGAACCGTCCCCCGCGCGCATGCGCGCGCCCCTGAAG 60 
                                                                             
 
mouse             ------------------------------------------------------------ 
human             CGCCTGGGGGACGGGTATGGGCGGGAGGTAGGGGCGCGGCTCCGCGTGCCAGTTGGGTGC 120 
                                                                             
 
mouse             ------------------------------AGGGCCGCGGCTCAGGGAAGGGGCTGAGAC 30 
human             CCGCGCGTCACGTGGTGAGGAAGGAGGCGGAGGTCTGAGTTTCGAAGGAGGGGGGGAGAG 180 
                                                *** * * *  **   * *****  ****  
 
mouse             CAGGCGAA--GAGCGAGGGCAGGGAAGCGGGGAAGGGAGGAAGGAAGAGGCCGAGGGGGA 88 
human             AAGAGGGAACGAGCAAGGGAAGGAAAGCGGGGAAAGGAGGAAGGAAACGAACGAGGGGGA 240 
                   **  * *  **** **** *** ********** ***********  *  ********* 
 
mouse             GGGAGGGCCCTGTTTTGGCGGAGCAGGGCGCGCGGCTGGGCCCCTGAAGTGGAGCGAGAG 148 
human             GGGAGGTCCCTGTTTTGGAGGAGCTAGGAGCGTTGCCGG-CCCCTGAAGTGGAGCGAGAG 299 
                  ****** *********** *****  ** ***  ** ** ******************** 
 
mouse             GGAGGCGCTTCGCCGGGTGCCACTGCCGGGGAGGCTCG----------------TCGGGA 192 
human             GGAGGTGCTTCGCCGTTTCTCCTGCCAGGGGAGGTCCCGGCTTCCCGTGGAGGCTCCGGA 359 
                  ***** *********  *  *    * *******  *                 ** *** 
 
mouse             CCCAGCGCCGGTCGCGGCTCCCTCAGGATCGATGCACCGCGGTTAACCCGTGAGGAGGCG 252 
human             CCAAGCCCCTTCAGCTTCTCCCTCCGGATCGATGTGCTGCTGTTAACCCGTGAGGAGGCG 419 
                  ** *** **    **  ******* *********  * ** ******************* 
 
mouse             GCGGCCGGGGAAG------------ 265 
human             GCGGCGGCGGCAGCGGCAGCGGAAG 444 
                  ***** * ** **         
Figure 3.24 Alignment of the human and mouse ADAM10 5`UTR sequence. 
The ADAM10 5`UTR is conserved in human and mouse.  Nucleotides shown in red are part of the 
purine-rich sequence.  The stars below the nucleotides show the conserved residues between mouse 
and human ADAM10 5`UTR.  The mouse 5`UTR was isolated from P5 brain mRNA via 5`RACE 
(data provided by Dr. Lammich).  The alignment was done with Clustal. 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.25 Cytosolic proteins from mice brains bind to the mouse ADAM10 5`UTR. 
(A) An aliquot of in vitro-transcribed α32P-labelled mouse ADAM10 5´UTR RNA was analysed on 
a 5% denaturing polyacrylamide / 8 M urea gel to control for RNA quality.  The xylene cyanol (~ 
130 nt) and bromophenol blue (~ 35 nt) front on the gel served as size marker.  (B) 106 cpm α32P-
labelled mouse ADAM10 5’UTR was incubated with 15 µg cytosolic extract of P30 mice brains in 
binding buffer for 30 min at room temperature.  RNA-protein complexes were separated on a 3.5% 
non-denaturing polyacrylamide gel and visualized by autoradiography.  The xylene cyanol (~ 460 
nt) and bromophenol blue (~ 100 nt) front on the gel served as size marker.  Upon incubation of the 
RNA with the cytosolic extract, a shift of the RNA is visible in the gel. 
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To further confirm that Unr is a binding partner of the murine ADAM10 5`UTR, 
EMSAs were performed.  Radiolabelled murine ADAM10 5’UTR (Figure 3.25A) was 
either incubated with cytosolic extract of HEK293E cells or with recombinant GST-Unr.  
Since mouse and human Unr have a very high sequence homology (98% identity), the 
human protein was used for this analysis.  GST-DJ1 or GST served as negative controls 
(Figure 3.26).  In line with the findings of the EMSAs with the human ADAM10 5`UTR, 
cytosolic extract and GST-Unr could bind in vitro to the mouse 5’UTR of ADAM10.  The 
interaction of the radiolabelled mouse ADAM10 5`UTR with cytosolic extract or GST-Unr 
could be inhibited by the addition of an excess of unlabelled mouse ADAM10 5`UTR 
(100-fold) (Figure 3.26).  In summary, these results demonstrate that Unr binds to both the 
human and the mouse ADAM10 5`UTR. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 Recombinant Unr binds to the mouse ADAM10 5`UTR. 
Radiolabelled mouse ADAM10 5’UTR (1x 106 cpm) was incubated either with 15 µg cytosolic 
extract of HEK293E cell or with 4 µg of the indicated recombinant proteins in binding buffer for 
30 min at room temperature.  RNA-protein complexes were separated on a 3.5% non-denaturing 
polyacrylamide gel and visualized by autoradiography.  The xylene cyanol (~ 460 nt) and 
bromophenol blue (~ 100 nt) front on the gel served as size marker.  Competition studies were 
performed by the addition of unlabelled mouse ADAM10 5`UTR (100-fold excess).  The 
incubation of RNA with cytosolic or GST-Unr induced a shift due to cytosolic proteins or GST-
Unr binding to the RNA.  The two negative controls GST or GST-DJ1 showed no binding to the 
ADAM10 5`UTR.  The addition of unlabelled mouse ADAM10 5`UTR to the reaction abrogates 
the binding of cytosolic extract and GST-Unr. Note, in the lane with GST-Unr some degradation is 
visible. 
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selection experiments (SELEX) it was shown that Unr preferentially binds to purine-rich 
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that there are two optimal Unr binding sites within the purine-rich stretch of the human 
ADAM10 5`UTR.  The first Unr binding site is located between nucleotides 180-193 and 
the second Unr binding site between nucleotides 218-231 (compare Figure 3.12).  To 
confirm that these regions within the long purine stretch are part of the Unr binding site, 
several 5`deletions of the ADAM10 5`UTR RNA were analysed by EMSA (Figure 3.27).  
As expected, the full-length ADAM10 5`UTR and the first half (∆251-432) of the 
ADAM10 5`UTR bind proteins of the cytosolic extract as well as GST-Unr (Figure 3.27) 
in agreement with the previous results.  However, for the second half (∆1-259) of the 
ADAM10 5`UTR, lacking the entire purine-rich stretch, neither binding of cytosolic 
proteins nor binding of GST-Unr was detectable (see Figure 3.27: highlighted with a red 
box).  To explore the importance of this purine-rich sequence, the ∆1-163/247-342, ∆164-
246, ∆164-204 and ∆201-246 probes were analysed.  Interestingly, cytosolic extract and 
recombinant GST-Unr bind to the ∆1-163/247-342 construct that extends over the entire 
purine-rich sequence, indicating that Unr binds to the purine-rich stretch of the ADAM10 
5`UTR as predicted by the UTR database search and SELEX experiments (Triqueneaux et 
al., 1999). 
Moreover, proteins of the cytosolic extract and recombinant GST-Unr still bind to the 
∆164-204 and ∆201-246 probes of the ADAM10 5`UTR, where only one half of the 
purine-rich sequence is present.  In contrast, the binding of Unr was diminished when the 
complete purine-rich stretch (∆164-246) was deleted (Figure 3.27, highlighted with an 
yellow box).  Importantly, the ∆164-246 ADAM10 5`UTR was still capable of binding 
proteins of the cytosolic extract (Figure 3.27, highlighted with an orange box).  This 
observation suggests that Unr is not the only protein that interacts with the ADAM10 
5`UTR.  However, Unr was able to bind to the ∆164-204 and ∆201-246 ADAM10 5`UTR, 
supporting the prediction that there are at least two potential Unr binding sites within the 
purine-rich sequence 164-246 of the ADAM10 5`UTR. 
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Figure 3.27 Unr binds to the purine stretch of the ADAM10 5`UTR. 
(A) Schematic representation of the ADAM10 5`UTR deletion constructs lacking the predicted 
binding sites for Unr.  Depicted are the 5`UTR and the 5`UTR deletion constructs used for EMSA.  
All ADAM10 5`UTR constructs lack the last 12 nucleotides; so that, e.g., the used full-length 
5`UTR is only 432 nt instead of 444 nt long (compare Figure 2.1 and Figure 3.12).  (B) 106 cpm 
32P-labelled full-length ADAM10 5`UTR and ADAM10 5’UTR deletion constructs were incubated 
either with 15 µg HEK293E cytosolic cell extract (upper panel) or with 4 µg of recombinant GST-
Unr (lower panel) in binding buffer for 30 min at room temperature. RNA-protein complexes were 
separated on a 3.5% non-denaturing acrylamide gel and visualized by autoradiography.  The xylene 
cyanol (~ 460 nt) and bromophenol blue (~ 100 nt) front on the gel served as marker.  Incubation of 
full-length and ∆251-432 ADAM10 5`UTR with either cytosolic or GST-Unr resulted in a shift.  
However, no shift was observed with ∆1-259 ADAM10 5`UTR incubated with either cytosolic 
extract or GST-Unr (highlighted with a red box).  The purine-rich sequence 164-246 as well as the 
deletion constructs ∆164-204 and ∆201-246 form complexes with proteins of the cytosolic extract 
and GST-Unr.  Importantly, the deletion construct ∆164-246 ADAM10 5`UTR induced no shift 
with recombinant Unr but formed a complex with cytosolic extract (highlighted with an yellow or 
orange box). 
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3.4.4 Expression analysis of ADAM10 5`UTR deletion constructs 
In the previous chapter, Unr has been shown to bind to the purine-rich sequence of the 
ADAM10 5`UTR (3.4.3).  In a next step, it was addressed whether deletion of this purine-
rich sequence affects ADAM10 expression at the translational level.  Therefore, various 
5`UTR deletion constructs in front of the ADAM10 ORF were transfected in HEK293E 
cells and expression levels of ADAM10 were analysed by immunoblotting (Figure 3.28A).  
As described previously, deletion of the first 215 and 259 nucleotides resulted in 30- and 
70- to 100-fold increase of ADAM10 expression, respectively (Lammich et al., 2010).  
Deletion of the first half of the purine-rich stretch (nucleotides 164-201) or deletion of the 
second half of the purine-rich stretch (nucleotides 204-246) resulted in a 2.5- and 4.5-fold 
increase of ADAM10 expression, respectively.  However, omission of the complete 
purine-rich sequence (nucleotides 164-246) resulted in an 11-fold increase of ADAM10 
expression (Figure 3.28B), suggesting that the purine-rich stretch is a strong translational 
inhibitory RNA element.  Nevertheless, the constructs missing the first 215 and 259 
nucleotides of the ADAM10 5`UTR resulted even in a stronger increase of ADAM10 
expression, indicating that in addition to the purine-rich stretch there is another strong 
translational inhibitory RNA element within the first 259 nucleotides of the ADAM10 
5`UTR.  These results are consistent with the binding studies (3.4.3) demonstrating that 
there are several proteins which could bind to the ADAM10 5`UTR (Figure 3.27). 
In addition, the mRNA levels of these deletion constructs were analysed to 
demonstrate that the observed effect on the protein expression is independent from an 
increase in transcription.  The mRNA levels only increased 1.2-, 1.4- and 2.8-fold for the 
ADAM10 5`UTR deletions 164-201, 204-246 and 164-246, respectively (Figure 3.28B).  
For the constructs missing the first 215 and 259 nucleotides of the ADAM10 5`UTR the 
mRNA levels increased 3- and 4.9-fold, respectively, as described before (Lammich et al., 
2010), suggesting that deletion of the first 215 and 259 nucleotides could contribute to 
mRNA stability.  However, the robust effects on protein synthesis are unlikely to emerge 
solely from mRNA stability.  Instead, these findings suggest that there is a very strong 
translational inhibitory RNA element within the first 259 nucleotides of the ADAM10 
5`UTR.  Taken together, the Unr binding studies and ADAM10 expression data may 
suggest that Unr is involved in the translational repression of ADAM10. 
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Figure 3.28 Effects of 5`UTR deletions on ADAM10 expression. 
HEK293E cells were transfected with the indicated 5`UTR ADAM10 cDNA constructs.  (A) 
Representative Western blots for V5-tagged ADAM10 and (B) Quantification of ADAM10 signals 
from cells transfected with ADAM10 cDNA constructs lacking parts of the 5`UTR are shown in 
black.  The values were normalised to β-actin and GFP levels.  The signal for ADAM10 with 
5`UTR was set to 1.  The results are expressed as the mean ± standard deviation of six independent 
experiments.  Quantification of ADAM10 mRNA by quantitative real-time RT-PCR from cells 
transfected with ADAM10 cDNA constructs lacking parts of the 5`UTR are shown in grey.  
ADAM10 mRNA levels were normalised to GAPDH mRNA levels.  The values are the mean ± 
standard deviation of at least two different experiments measured in triplicates and the signal of the 
5`UTR ADAM10 mRNA is set to 1. 
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3.5 Effect of Unr on ADAM10 and APP processing 
3.5.1 Unr knockdown 
Based on the hypothesis that the proteins binding to the ADAM10 5`UTR could 
contribute to the regulation of ADAM10 expression at the translational level, the 
functional relationship between endogenous Unr and ADAM10 in HEK293E cells was 
analysed.  HEK293E cells stably expressing shRNA (short hairpin RNA) against Unr were 
generated.  To determine the level of Unr and ADAM10 protein levels in Unr knockdown 
(Unr KD) cells, cytosolic extract and membrane preparations were separated by SDS-
PAGE and analysed by immunoblotting.  Unexpectedly, Unr knockdown in HEK293E 
cells resulted in a significant decrease in Unr levels, accompanied by a significant decrease 
in the expression of ADAM10 protein (Figure 3.29), suggesting that Unr is indeed 
important for regulating ADAM10 synthesis although an increase of ADAM10 expression 
was expected.  To control equal loading of protein, actin and calnexin were used as loading 
controls.  In addition, it was shown that Unr knockdown has no general effect on protein 
expression, since expression of endogenous APP was not altered upon Unr knockdown. 
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Figure 3.29 Endogenous ADAM10 levels were reduced in cells with decreased expression 
of Unr 
Cytosolic extracts of HEK293E Unr knockdown cells were prepared to analyse the levels of Unr 
and β-actin as loading control by Western blot.  Membranes were prepared to analyse the levels of 
ADAM10, APP and loading control calnexin.  ADAM10 protein levels were reduced in cells that 
have low levels of Unr.  In contrast, APP protein levels were unaffected. 
 
 
To further analyse the consequences of Unr knockdown on ADAM10 expression, the 
processing of APP, an ADAM10 substrate, was analysed.  Shedding of APP by ADAM10 
results in APPsα and CTFα.  Therefore, a change in ADAM10 expression levels should 
consequently lead to a change in the production of APPsα.  Supernatants of HEK293E 
cells and HEK293E Unr KD cells were analysed for APPsα levels.  As expected, reduced 
ADAM10 levels in the HEK293E Unr KD cells resulted in reduced APPsα levels 
compared to HEK293E cells (Figure 3.30) although APPsβ and Aβ levels did not change.  
The drop of total APPs levels (APPst) is due to the reduced levels of APPsα. 
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Figure 3.30 Reduced APP processing in Unr KD cells 
(A-C) Representative Western blots for APPsα (A), APPsβ (B) and APPst (C) in stable HEK293E 
Unr knockdown (KD) cells are shown.  (D-F) Quantification of APPsα (D), APPsβ (E) and APPst 
(F) signals from Unr KD cells.  The APPsα, APPsβ, APPst and Aβ signal for HEK293E was set to 
100%.  Results are expressed as the mean ± standard deviation of at least six independent 
experiments.  (G) Aβ levels were determined by ELISA (performed by Brigitte Nuscher).  The Aβ 
signal for HEK293E was set to 100%.  Results are expressed as the mean ± standard deviation of at 
least three independent experiments. 
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ADAM10 protein expression upon deletion of the Unr binding sites (purine-rich stretch) 
(refer to Figure 3.28).  Therefore, it was expected that Unr plays a role in the translational 
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ADAM10 mRNA.  Therefore, RNA levels of Unr and ADAM10 were analysed by 
quantitative real-time PCR in these cells.  The mRNA levels of Unr in the Unr knockdown 
cells were reduced to 15% (+/- 4.5%) (Figure 3.31).  Importantly, the ADAM10 mRNA 
levels were reduced by 45% (+/- 10%) (Figure 3.31).  This finding indicated that Unr is 
either essential for the stabilisation of the ADAM10 mRNA or has an effect on the 
ADAM10 transcription.  Considering that, Unr is a cytosolic protein (Jacquemin-Sablon et 
al., 1994), which is not found in the nucleus, a transcriptional effect could be ruled out as 
transcription occurs in the nucleus. 
 
 
 
 
 
 
 
Figure 3.31 RNA levels for Unr KD cells. 
Quantification of endogenous Unr (A) and ADAM10 (B) mRNA isolated from HEK293E cells and 
HEK293E Unr KD cells by quantitative  real-time PCR with TaqMan probes.  Unr and ADAM10 
mRNA levels were normalised to endogenous GAPDH mRNA levels using the 2-∆∆CT method.  
Values are expressed as the mean ± standard deviation of at least nine different experiments 
measured in triplicates. ADAM10 mRNA level and Unr mRNA level isolated from HEK293E cells 
were set to 100%. 
 
 
3.5.2 Unr overexpression 
Unr knockdown in HEK293E cells resulted in decreased ADAM10 protein expression 
accompanied by a decrease in ADAM10 mRNA levels.  To examine the functional 
relationship between overexpressed Unr and endogenous ADAM10 in HEK293E cells, 
myc-tagged Unr was stably expressed in HEK293E cells.  Cytosolic extract and membrane 
preparations of HEK293E cells overexpressing Unr-myc were analysed for ADAM10 
expression by Western blotting.  To control equal loading of protein, actin and calnexin 
were used as loading control.  Unr-myc overexpression in HEK293E cells resulted in a 
replacement of the endogenous Unr levels, accompanied by a minor decrease of immature 
ADAM10 levels (Figure 3.32).  Replacement of endogeneous Unr might be due to that Unr 
forms a complex with other proteins.  In addition, it was shown that Unr overexpression 
has no general effect on protein expression by analysing the expression of APP, since the 
expression of APP was not altered upon Unr overexpression. 
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Figure 3.32 Overexpression of Unr results in a minor decrease of endogenous immature 
ADAM10. 
Representative Western blots for Unr, ADAM10 and APP in stably Unr overexpressing HEK293E 
cells.  β-actin as a cytosolic protein and calnexin as a membrane protein were used as loading 
controls.  HEK293E cells with overexpressed Unr show a small decrease in immature ADAM10 
protein levels.  In contrast, APP protein levels were unaffected. 
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HEK293E cells (Figure 3.33).  Surprisingly, APPsβ as well as Aβ levels increased upon 
overexpression of Unr, whereas APPst levels were more or less unaffected.   
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Figure 3.33 Change in APP processing in Unr overexpressing cells. 
Supernatants were collected to assess the levels of APPsα (A), APPsβ (B) and APPst (C) by 
Western blotting.  The signals of APPsα (D), APPsβ (E) and APPst (F) were quantified and 
represented as mean ± standard deviation of at least six independent experiments.  Aβ levels (G) 
were determined by ELISA.  The signals for APPsα, APPsβ, APPst and Aβ in HEK293E cells 
were set to 100%. 
 
 
A decrease of ADAM10 levels upon Unr overexpression in HEK293E cells was 
expected from the previous results of the ADAM10 5`UTR deletion constructs in 
HEK293E cells shown in Figure 3.28.  Since the HEK293E Unr knockdown cells showed 
reduced ADAM10 protein and mRNA levels (Figure 3.31), it might be possible that Unr is 
involved in the stabilisation of ADAM10 mRNA (3.5.1).  To test the involvement of Unr 
in ADAM10 mRNA stabilisation, the RNA levels of Unr overexpressing cells were 
analysed by quantitative real-time PCR.  Quantitative real-time PCR revealed that 
ADAM10 mRNA level did not change in response to increased Unr levels.  The mRNA 
level of Unr in Unr overexpressing cells was increased by a factor of 4 (Figure 3.34). 
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Figure 3.34 RNA levels for Unr overexpression 
Quantification of Unr (A) and ADAM10 (B) mRNA isolated from HEK293E cells and HEK293E 
Unr overexpressing cells by quantitative real-time PCR with TaqMan probes.  Unr and ADAM10 
mRNA levels were normalised to endogenous GAPDH mRNA levels using the 2-∆∆CT method.  
Values are expressed as the mean ± standard deviation of at least four different experiments made 
in triplicate.  ADAM10 mRNA level and Unr mRNA level isolated from HEK293E cells were set 
to 100% 
 
 
In summary, the analysis of the functional relationship between endogenous Unr and 
ADAM10 in HEK293E cells resulted in some interesting findings (summarized in Figure 
3.35). 
  
 
 
 
 
 
 
 
 
 
Figure 3.35 A schematic diagram depicting the major findings of the functional 
relationship between Unr, ADAM10 and APP processing 
(A) Downregulation of Unr leads to reduced ADAM10 mRNA and protein levels as well as 
reduced secretion of APPsα.  (B) The overexpression of Unr leads to a replacement of endogenous 
Unr protein complexes.  Moreover a small decrease of immature (imm.) ADAM10 was observed.  
In addition, the levels of APPsβ and Aβ are increased. 
 
 
Upon Unr downregulation, ADAM10 protein and mRNA levels were reduced.  
Consistent with these findings, the generation of APPsα was reduced (Figure 3.35A).  The 
levels for APPsβ, APPst and Aβ remained unchanged.  Upon overexpression of Unr in 
HEK293E cells, endogenous Unr was downregulated thereby the ADAM10 protein levels 
were hardly affected and no change was observed for ADAM10 mRNA levels, APPsα and 
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APPst.  However, the most significant finding was that Unr overexpression results in 
increased levels of APPsβ consistently with increased Aβ (Figure 3.35B). 
Hence, these results suggest that Unr influences the stability of the ADAM10 mRNA 
and surprisingly has an effect on the generation of APPsβ and Aβ. 
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4 Discussion 
This PhD thesis deals with the translational control of ADAM10 expression.  The 
regulation of ADAM10 expression might be critical for the development of AD.  An 
increase in α-secretase cleavage can be considered as a therapeutic approach for AD 
(Endres and Fahrenholz, 2010; Fahrenholz, 2007).  Consistent with this hypothesis, it was 
recently shown that ADAM10 expression in mice potentiates hippocampal neurogenesis 
(Suh et al., 2013).  Moreover, mutations in the ADAM10 prodomain reduced α-secretase 
activity, increased β-secretase activity, enhanced Aβ plaque load as well as reactive gliosis 
and cosegregate with late onset AD (Suh et al., 2013).  Therefore, it is important to 
understand how the expression of ADAM10 is regulated.  Several studies addressed the 
regulation of ADAM10 expression at the level of transcription (Donmez et al., 2010; 
Prinzen et al., 2005; Tippmann et al., 2009).  In addition to transcription, post-
transcriptional mechanisms play an important role in the control of ADAM10 expression. 
The ADAM10 5`UTR has been shown to be involved in the translational regulation 
(Lammich et al., 2010; Lammich et al., 2011), but the exact mechanism mediating this 
effect is unknown.  Therefore, the possibility that 5`UTR RNA-binding proteins regulate 
ADAM10 expression was explored in this work.  To search for such factors forming 
complexes with RNA, in vitro binding experiments were carried out by EMSAs, UV 
crosslinking and affinity purification.  Beyond that the functional relationship between one 
of these factors and ADAM10 expression was analyzed in this work. 
 
4.1 Unr as potential regulator of ADAM10 expression 
To identify potential ADAM10 5`UTR binding proteins a database search was 
performed.  This search revealed Unr as potential binding protein of ADAM10 5´UTR.  
Interestingly, Unr was shown to be involved in the regulation of mRNA translation and 
stability by binding to sites generally located in UTRs (Mihailovich et al., 2010). 
 
4.1.1 Unr binds to a purine-rich region in the ADAM10 5`UTR 
To confirm the result of the database search, binding of Unr to ADAM10 was 
analysed by EMSAs with recombinant Unr.  EMSAs suggest that Unr indeed binds 
specifically to the human and mouse ADAM10 5`UTR.  In a next step, the exact region of 
Unr binding to the ADAM10 5`UTR was investigated.  By in vitro selection experiments 
(SELEX) it was shown previously that Unr preferentially binds to purine-rich sequences 
(Triqueneaux et al., 1999).  Unr binds preferentially to two related consensus sequences, 
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R5AAGUAR and R8AACR3 (R = G or A) with a Kd of 10-25 nM (Triqueneaux et al., 
1999).  Single base changes of purines to pyrimidine have limited effect on Unr-RNA 
recognition and the purines downstream of the pyrimidine in these motifs seem to be 
unimportant for efficient binding (Triqueneaux et al., 1999).  Interestingly, two such 
R8AACR3 motifs can be found in the 83-nucleotide-long purine-rich stretch of the 
ADAM10 5`UTR (Figure 3.12).  The two Unr binding sites within this purine-rich stretch 
are predicted to be between nucleotides 180-193 and 218-231 (Figure 3.12).  The binding 
of Unr is indeed dependent on the 83-nucleotide-long purine-rich sequence located 
between nucleotides 164-246 of the ADAM10 5’UTR since the binding of Unr is lost 
when this region is deleted.  Moreover, deletion of this purine-rich sequence results in an 
11-fold increase of ADAM10 expression after overexpression of ADAM10 cDNA (Figure 
3.28).  That means, upon deletion of the Unr binding site, the ADAM10 mRNA could be 
translated more efficiently resulting in an increase in protein expression.  Hence, Unr 
might be a translational repressor of ADAM10 protein expression.  Deletion of the first 
155, 175 or 215 nucleotides, where the purine stretch is intact or partially deleted, leads to 
a 8-fold, 28-fold or 40-fold increase in ADAM10 expression, respectively (refer to Figure 
3.28) (Lammich et al., 2010).  However, deletion of the purine-rich stretch together with 
the first 163 nucleotides results in a 70-100-fold increase of ADAM10 expression levels 
compared to the construct with full-length 5`UTR (refer to Figure 3.28) (Lammich et al., 
2010).  Thus, there might be other translational inhibitory RNA elements in the first part of 
the 5´UTR.  Interestingly, Lammich and colleagues could recently show that the ADAM10 
5`UTR contains a G-quadruplex secondary structure close to the 5`end that represses 
ADAM10 translation (Lammich et al., 2011).  Upon deletion of the G-quadruplex and the 
purine-rich sequence, the same increase of ADAM10 expression level can be observed as 
for deletion of the first 259 nucleotides (Dr. S. Lammich, personal communication).  G-
quadruplexes are four-stranded structures formed by guanine-rich sequences (Gellert et al., 
1962; Sen and Gilbert, 1992). 
 
4.1.2 Identification of Unr by affinity chromatography followed by 
mass spectrometry 
The database search result and EMSAs could be confirmed by affinity purification 
followed by mass spectrometry.  Since two different isoforms of Unr were described 
(Boussadia et al., 1993; Ferrer et al., 1999), the question which of these two isoforms binds 
to the ADAM10 5`UTR came up.  The two isoforms result from an exon-skipping 
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mechanism.  Therefore, the protein encoded by the open reading frame is either 767- or 
798-amino-acid-long with a predicted molecular weight of either 85 or 88 kDa.  The Unr 
sequences that are shown in Figure 3.17 represent the longer isoform of Unr including 
exon 5 (exon 5 marked in blue).  The longer message containing exon 5 represents only a 
small fraction of Unr messages in all tissues except for the brain (Boussadia et al., 1993).  
In the brain, both types of messages are equally abundant.  However, the mass 
spectrometry results did not reveal which of the two Unr proteins binds to the ADAM10 
5`UTR (refer to chapter 3.4) as none of the identified peptides corresponds to exon 5.  The 
alternative splicing that leads to a difference of 31 amino acids near the N-terminus of the 
Unr protein does not disrupt any of the five cold shock protein motifs present in the 
protein.  Hence, it is not clear which isoform of Unr binds to the ADAM10 5`UTR.  Since 
the RNA recognition motifs ribonucleoprotein RNP-1 (amino acids Y/FGFI) and RNP-2 
(amino acids FFH) are conserved in both Unr isoforms (Boussadia et al., 1993; Ferrer et 
al., 1999), it is likely that both isoforms are involved in ADAM10 5`UTR binding. 
 
4.2 Other potential regulators of ADAM10 expression 
As mentioned above, the affinity purification followed by mass spectrometry was 
conducted to confirm Unr as ADAM10 5`UTR binding protein.  In addition, the affinity 
purification approach from cytosolic extract of HEK293E cells and from mouse brain 
cytosolic extract identified a large number of other proteins binding to the ADAM10 
5`UTR. 
 
4.2.1 Comparison of results from UV crosslink and affinity 
purification 
Several of the hnRNPs identified by affinity purification in this work, such as hnRNP A1 
and hnRNP A2/B1, are also involved in nuclear-cytoplasmic shuttling (Allemand et al., 
2005; Borer et al., 1989; Nichols et al., 2000).  Furthermore, nucleolin, which was 
identified as potential ADAM10 5`UTR binding protein by affinity purification, is known 
to shuttle between the nucleus and cytosol (Borer et al., 1989).  These shuttle proteins 
could first bind to the ADAM10 5`UTR in the nucleus and then continue their function in 
the cytosol to regulate the ADAM10 mRNA expression.  This would also explain the 
results from the UV crosslinking experiments with cytosolic and nuclear extract which 
show protein bands of the same molecular weight (refer to Figure 3.8).  The protein bands 
in the cytosolic and nuclear fraction with a molecular weight above 36 kDa could be 
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hnRNP A1 and hnRNP A2/B1.  Since these proteins are primarily localized in the nucleus, 
the protein band of the UV crosslink is more pronounced in the nuclear fraction.  The 
protein band around 80 kDa, which is more pronounced in the cytosolic fraction, could be 
nucleolin.  Preliminary results from EMSAs could confirm the binding of recombinant 
hnRNP A1 and hnRNP B1 to the ADAM10 5`UTR (data not shown).  Therefore, they 
likely play a role in the translational control of the ADAM10 expression.  Most 
interestingly, hnRNP A2/B1 has been implicated in AD and its expression is altered in the 
hippocampi of patients at different stages of disease (Mizukami et al., 2005). 
 
4.2.2 Specificity and selectivity of identified proteins 
To prove the specificity of the RNA-binding proteins, competition experiments were 
conducted via UV crosslinking.  Since the RNA-protein complexes could be competed 
with excess of non-labelled ADAM10 5`UTR, RNA-protein binding seems to be specific.  
The selectivity of the RNA-binding proteins was analyzed by the use of a second unrelated 
5`UTR, more precisely the BACE1 5`UTR.  The protein band patterns from the UV-
crosslink (3.1.4) and affinity chromatography (3.3) experiments for the ADAM10 5`UTR 
and BACE1 5`UTR, respectively, are different, strongly suggesting that the detected RNA-
binding proteins were selective for the ADAM10 5`UTR.  Also the mass spectrometry 
results from the affinity purification of both 5`UTRs confirm the difference of proteins 
identified. 
 
4.2.3 Potential role of the other identified proteins on ADAM10 
expression 
Many of the identified proteins are known to influence different aspects of mRNA 
metabolism, including translational control, splicing, transport and stability (Carpenter et 
al., 2006; Glisovic et al., 2008; Krecic and Swanson, 1999).  Since the first part of the 
5`UTR also seems to have a translational inhibitory function, these proteins might bind to 
this part.  As mentioned above, Lammich and colleagues could show that the ADAM10 
5`UTR contains a G-quadruplex secondary structure close to the 5`end that represses 
ADAM10 translation.  Interestingly, several of the purified RNA-binding proteins, such as 
nucleolin, the hnRNP F/H family and hnRNP A family have been reported to interact with 
G-rich sequences (Abdelmohsen et al., 2011; Dominguez et al., 2010; Khateb et al., 2007; 
Khateb et al., 2004).  They can either bind to G-quadruplex structures in DNA or RNA 
promoting its formation, and/or stabilizing the final structure or unwind this stable 
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secondary structure, thus facilitating transcription or translation (Brooks and Hurley, 2010; 
Dominguez et al., 2010; Gonzalez et al., 2009; Khateb et al., 2007; Khateb et al., 2004).  
For example, nucleolin is involved in the formation and stabilisation of the c-myc DNA G-
quadruplex structure.  Nucleolin thereby blocks the transcription of c-myc (Brooks and 
Hurley, 2010; Gonzalez et al., 2009; Gonzalez and Hurley, 2010).  hnRNP F/H can prevent 
G-quadruplex structure formation by binding single-stranded RNA (Dominguez et al., 
2010).  In addition, hnRNP A2 and hnRNP A1 have been reported to destabilize G-
quadruplexes in both DNA and RNA (Khateb et al., 2004).  hnRNP A2 relieves the 
translational block of FMR1 mRNA that results from G-quadruplex formation and thereby 
enhancing translation (Khateb et al., 2007).  Also preliminary results from EMSAs resulted 
in binding of recombinant hnRNP A1, hnRNP A2 and hnRNP B1 to the ADAM10 5`UTR 
(data not shown), it was not yet tested if binding occurs at the G-rich region.  Therefore, 
these proteins might be involved in the translational repression of ADAM10 by binding to 
its G-quadruplex.  Admittedly, the influence of these proteins on the ADAM10 5`UTR G-
quadruplex has not been analysed so far. 
 
4.3 Functional relationship of Unr and ADAM10 expression 
4.3.1 Influence of Unr on ADAM10 expression levels 
As mentioned above, the expression of the ADAM10 5`UTR deletion constructs 
lacking the Unr binding site resulted in a tremendous increase in ADAM10 expression 
(Figure 3.28) (Lammich et al., 2010).  Therefore, a decrease of ADAM10 levels upon Unr 
overexpression and an increase of ADAM10 levels upon Unr knockdown was expected.  
Normally translational repression can be reversed, and this is generally achieved by 
removal of the repressor from its binding site on the mRNA or by remodelling of the 
repressor complex (Abaza and Gebauer, 2008; Cao and Richter, 2002; Klausner et al., 
1993; Ostareck-Lederer et al., 2002; Thomas et al., 2008).  However, stable knockdown of 
Unr resulted in a strong decrease of ADAM10 mRNA and protein levels in HEK293E cells 
(summarized in Figure 3.35).  In line with reduced ADAM10 levels, APPsα levels were 
reduced in the HEK293E Unr KD cells.  However, APPsβ and Aβ levels did not change.  
These findings are in line with the recently published data from Kuhn et al. and Colombo 
et al. (Colombo et al., 2012; Kuhn et al., 2010).  They had demonstrated the same 
phenomenon that upon ADAM10 knockdown APPsα is decreased, however APPsβ and 
Aβ were not increased (Colombo et al., 2012; Kuhn et al., 2010).  As discussed in these 
two publications, the results can be explained by different scenarios.  One possibility is that 
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the cellular APP levels may not be rate limiting for α- and β-secretase cleavages in 
HEK293E cells and therefore the reduction of one cleavage does not increase the other 
cleavage.  Another possibility is that the α- and β-secretase cleavages occur at different 
cellular compartments in HEK293 cells.  This means that reduced α-secretase cleavage of 
APP at the plasma membrane does not increase the endosomal APP available for β-
secretase cleavage. 
An increase in Unr concentration in HEK293E cells does not change ADAM10 
mRNA levels and hardly affects protein levels (summarized in Figure 3.35).  Since 
endogenous levels of Unr were replaced upon Unr overexpression and Unr overexpression 
shows no effect on mRNA and protein levels of ADAM10, a possible explanation for this 
observation might be that a multiprotein complex is necessary for obtaining a change in 
ADAM10 expression.  Furthermore, it is quite common that multiple proteins are involved 
in the translational regulation as mRNA-specific regulation by single proteins (e.g. IRP) is 
more an exception (Gebauer and Hentze, 2004).  Several studies indeed have shown that 
Unr is part of a protein complex that regulates translation and mRNA stability.  Some of 
the identified proteins, like hnRNP Q, PABP, FBP and Unrip are already described to form 
a multiprotein complex together with Unr (Abaza et al., 2006; Chang et al., 2004; Dinur et 
al., 2006; Duncan et al., 2006; Duncan et al., 2009; Grosset et al., 2000; Hunt et al., 1999; 
Mitchell et al., 2003; Nechama et al., 2008; Patel et al., 2005).  Grosset et al. and Chang et 
al., for example, could show that Unr forms a complex with PABP, PAIP1, hnRNP D and 
hnRNP Q to control the translationally coupled mRNA turnover of the c-fos mRNA 
(Chang et al., 2004; Grosset et al., 2000).  In addition, Bannai et al. showed that hnRNP Q 
interacts in HEK293E cells with PABP1, nucleolin as well as several hnRNPs such as 
hnRNP A2/B1, hnRNP F/H and hnRNP U (Bannai et al., 2004) which have been identified 
as binding partners for the ADAM10 5`UTR.  Furthermore, in another study, it was shown 
that Unr can form a complex with PABP and IMP-1 at the 5`UTR of the PABP mRNA to 
repress the translation of PABP mRNA (Patel et al., 2005).   
Such complex components could be the limiting factor for obtaining a change in 
ADAM10 expression and will be discussed in the proposed model for ADAM10 
regulation. 
 
4.3.2 Proposed model for ADAM10 regulation 
In this work, it was shown that Unr overexpression has no effect on ADAM10 mRNA 
levels (refer to Figure 3.34) and ADAM10 mRNA translation stays unchanged (refer to 
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Figure 3.32).  However, Unr overexpression resulted in reduced levels of endogeneous 
Unr.  A possible explanation could be that Unr forms a complex with other proteins as 
mentioned above.  Therefore, overexpression of Unr together with other RNA-binding 
proteins could result in stabilization of ADAM10 mRNA.  Upon Unr knockdown, the 
ADAM10 mRNA is reduced (refer to Figure 3.31) with the consequence of reduced 
ADAM10 protein expression (refer to Figure 3.29).  This observation is depicted in the 
proposed model (Figure 4.1): upon expression of Unr and other RNA-binding proteins 
ADAM10 mRNA might be stabilized and protein translation might then be increased.  
However, it might be also possible that the mRNA is stabilized while the protein 
translation might be not increased since efficient ribosome recruitment is blocked.  Upon 
Unr knockdown, Unr and other RNA-binding proteins are released from the ADAM10 
5`UTR.  Following the release of these proteins, another RNA-binding protein could bind 
to the purine-rich stretch and recruits the degradation machinery to the 5`UTR thereby 
mediating the mRNA turnover. 
This model would also explain why deletion of the purine-rich stretch results in an 
increase in ADAM10 expression.  Upon deletion of the purine-rich stretch, neither Unr nor 
the protein recruiting the degradation machinery could bind anymore.  As a consequence 
the RNA could be translated more efficiently, along with ADAM10 mRNA stabilisation.  
Thus, depletion of both proteins should result in an increase in ADAM10 expression and a 
stabilisation of ADAM10 mRNA. 
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Figure 4.1 Proposed model for the regulation of ADAM10 mRNA stability. 
Unr together with some other RNA-binding proteins (W, X, Z) binds to the 5`UTR of ADAM10 
thereby blocking the recruitment of degrading enzymes.  Upon deletion of Unr another RNA-
binding protein (Y) can bind to the ADAM10 5`UTR that recruits nucleases to the mRNA. 
 
 
There are several different mechanisms of eukaryotic mRNA decay described (Day 
and Tuite, 1998). 
The first example of mRNA decay can occur via the 5´end.  Binding of Unr may 
prevent binding of decapping enzymes and RNA degrading enzymes to the cap structure.  
However, when Unr is depleted mRNA decay is accelerated and mRNA stabilization is 
abrogated.  This means, displacement of Unr makes the 5`cap accessible to degradative 
enzymes, such as Dcp1/Dcp2 and Xrn1.  Dcp1 and Dcp2 are decapping enzymes that 
remove the mRNA cap and renders the 5`end of the mRNA accessible to the Xrn1 
exonuclease (Amrani et al., 2006).  Interestingly, it was reported that Xrn1 exhibits a 
substrate preference for G-quadruplex RNA (Bashkirov et al., 1997).  Recently, Lammich 
and colleagues could show that the 5`UTR contains a G-quadruplex close to the 5`end 
(Lammich et al., 2011) and might therefore be a good binding site for Xrn1. 
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The second example would be endonucleolytic cleavage within the gene while it is 
actively engaged by translating ribosomes (Dodson and Shapiro, 2002).  Three mRNA 
endonucleases have been linked to specific decay pathways: polysomal ribonuclease 1 
(PMR1) (Chernokalskaya et al., 1998), G3BP (Gallouzi et al., 1998) and IRE-1 (Hollien 
and Weissman, 2006).  Endonucleolytic cleavage of some mRNAs is regulated by RNA-
binding proteins that bind near the cleavage site(s) and render them inaccessible to 
nucleolytic attack.  The c-myc mRNA is an example of an eukaryotic mRNA that is 
degraded by endonucleolytic cleavage before deadenylation (Barnes et al., 2009; 
Sparanese and Lee, 2007). 
The third example is based on the regulatory mechanism of the parathyroid hormone 
(PTH) mRNA where Unr binds to the PTH mRNA and stabilise the PTH mRNA (Dinur et 
al., 2006).  Most interestingly, PTH gene expression is regulated post-transcriptionally 
through the binding of the trans-acting proteins FBP2, Unr and hnRNP D to an AU-rich 
element (ARE) element in PTH mRNA 3`UTR (Dinur et al., 2006; Nechama et al., 2008; 
Nechama et al., 2009; Sela-Brown et al., 2000).  While Unr together with hnRNP D 
stabilizes PTH mRNA, FBP2 promotes PTH mRNA decay (Dinur et al., 2006; Nechama et 
al., 2008).  Calcium depletion increases the association of hnRNP D and/or Unr with the 
PTH mRNA ARE and decreases FBP2 binding to the ARE resulting in mRNA 
stabilization (Nechama et al., 2008).  In transfected cells, overexpression of FBP2 
destabilizes the PTH mRNA and this is mediated by the PTH mRNA ARE (Nechama et 
al., 2008).  FBP2-PTH mRNA interaction is prevented by overexpression of HNRNP D 
and/or Unr.  Overexpression of HNRNP D and/or Unr also attenuates the FBP2-mediated 
destabilization of PTH mRNA in transfected cells (Dinur et al., 2006; Nechama et al., 
2008).  In contrast, knockdown of Unr and/or hnRNP D led to a decrease in the expression 
of PTH (Dinur et al., 2006).  FBP2 is described to recruit labile mRNAs to the exosome 
and was proposed to compete with RNA-binding proteins that promote mRNA stability 
(Briata et al., 2005; Chen et al., 2001).  For mRNAs recruited to the exosome by FBP2, the 
activity of deadenylase is also required for transcript decay, suggesting that FBP2 delivers 
the factors, necessary for both deadenylation and exosome-mediated degradation, onto 
target mRNAs (Gherzi et al., 2004; Lai et al., 2003).  In this example, FBP2 interacts with 
the exosome in a phosphorylation-dependent manner and recruits the degradation 
machinery to the PTH mRNA thereby mediating the mRNA turnover (Gherzi et al., 2004).  
In addition, FBP2 recruits the endonuclease PMR1 to the PTH mRNA.  Upon FBP2 
binding to the PTH mRNA, PMR1 cleaves the PTH mRNA and PTH mRNA decay can 
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proceed through exonucleolytic cleavage of both fragments (Gherzi et al., 2004; Nechama 
et al., 2009).  The binding of Unr and/or HNRNP D to the PTH mRNA blocks the binding 
of FBP2 to the PTH mRNA (Nechama et al., 2008). 
A similar mechanism as the third example of mRNA decay could control the 
ADAM10 mRNA.  However, instead of FBP2, FBP1 might play a role in here.  As long as 
Unr could bind to the ADAM10 5`UTR, binding of FBP1 and recruitment of the 
degradation machinery might be blocked.  Upon the deletion of Unr, FBP1 might bind to 
the ADAM10 5`UTR and could recruit the degradation machinery to the ADAM10 mRNA 
thereby mediating the ADAM10 mRNA turnover.  So far, only the binding of Unr to the 
5`UTR of ADAM10 and deletion of Unr leading to ADAM10 mRNA destabilization has 
been demonstrated.  The binding of FBP1 to the ADAM10 5`UTR has to be proven. 
Yet, it is important to know that several of the identified ADAM10 5`UTR act 
together with FBP1 or FBP2 on the translational control of different genes.  For example, 
FBP1 together with hnRNP A2/B1, another identified ADAM10 5`UTR RNA-binding 
protein, was shown to interact specifically with the 3' UTR of nucleophosmin (NPM) to 
repress translation (Olanich et al., 2011). 
 
4.4 Influence of Unr on BACE1 expression 
Although overexpression of Unr had no effect on ADAM10 and APPsα levels, 
surprisingly APPsβ as well as Aβ levels increased significantly upon overexpression of 
Unr.  Since Unr was not identified by the affinity purification with the BACE1 5`UTR 
(refer to Appendix Table 5.1 and 5.2), Unr seems not to bind to the 5`UTR of BACE1.  A 
possible explanation could be that Unr binds to the BACE1 3`UTR since this was predicted 
by the UTR database UTRdb of the Institute for Biomedical Technologies 
(http://utrdb.ba.itb.cnr.it/) (Grillo et al., 2010; Pesole et al., 2000; Pesole et al., 1998).  Unr 
binding to the 3`UTR of BACE1 could result in an increase in BACE1 protein expression 
thereby inducing an enhanced production of APPsβ and Aβ.  If Unr overexpression 
influences the BACE1 expression via its 3`UTR has to be analysed in future studies.  So 
far, there is no data available showing an influence of the BACE1 3`UTR on BACE1 
expression.  Another possibility is that Unr acts as a stress sensor / mediator (Dormoy-
Raclet et al., 2007; Tinton et al., 2005) and thereby upregulates BACE1 expression.  
O’Connor and colleagues showed that during energy deprivation eIF2α is phosphorylated 
and results in increased BACE1 mRNA translation (O'Connor et al., 2008).  Interestingly, 
Tinton et al. demonstrated that eIF2α phosphorylation and Unr expression occur at the 
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same time in the cell cycle (G2/M stage) (Tinton et al., 2005).  Hence, there might be a 
direct link between Unr expression and phosphorylated eIF2α resulting in increased 
expression of BACE1. 
 
4.5 Conclusion 
In summary, the results demonstrate that Unr is not responsible for translational 
repression but rather is responsible for ADAM10 mRNA stabilisation.  Unr has been 
characterised as a regulatory protein that binds specifically to the c-fos and PTH mRNA 
and influences their stability (Chang et al., 2004; Grosset et al., 2000; Patel et al., 2005).  
The rate of mRNA decay is regulated by the interaction of cis-acting elements in the 
transcripts and sequence-specific RNA-binding proteins (Hollams et al., 2002).  The 
presented effect of Unr on ADAM10 expression might be explained by the same 
mechanism as described for PTH mRNA (Dinur et al., 2006). 
 
4.6 Outlook 
This work describes the RNA-binding protein Unr for the ADAM10 5`UTR and 
shows that Unr has the potential to regulate the synthesis of the ADAM10 protein at the 
level of mRNA stability.  The RNA-binding protein Unr provides a potential mechanism 
for suppression of translation of ADAM10 as well as for the stability of the ADAM10 
mRNA.  However, additional work is needed to obtain a detailed characterization of the 
physiological and pathophysiological role of Unr and possible other ADAM10 5`UTR-
binding proteins in controlling ADAM10 translation.  Previous results have shown that 
Unr is an essential gene (Boussadia et al., 2003).  The homozygous knockout of Unr is 
embryonic lethal in mice around embryonic day E10, which implies that Unr is not 
essential for general cell viability and cell division, but must be essential for certain stages 
in differentiation (Boussadia et al., 1997; Dormoy-Raclet et al., 2007).  Interestingly, the 
ADAM10 homozygous knockout, showing a notch phenotype, is also embryonic lethal in 
mice around the same embryonic day due to major developmental defects (Hartmann et al., 
2002).  Therefore, it might be interesting to analyse in particular the homozygous and 
heterozygous Unr knockout in more detail as there might be a direct link to the ADAM10 
knockout.  So far, the phenotype of Unr knockout mice has not been described.  Further 
examination of the in vivo activities of Unr on the ADAM10 5`UTR should provide 
important information about the mechanism of ADAM10 translation.  On the other hand, it 
will be important to determine whether and how the activity of Unr is regulated in the cell.  
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In this regard, it will be also interesting to find out which role Unr plays in the generation 
of APPsβ and Aβ. 
In addition to Unr, a variety of other candidate RNA-binding proteins were identified 
for the ADAM10 5`UTR.  Taken together, the finding that the ADAM10 5`UTR associates 
with factors that have a potentially regulatory function suggests that translation of the 
ADAM10 5`UTR is subject to complex regulatory mechanisms.  In addition, there is the 
possibility that some of the detected proteins were co-purified as a complex via Unr`s 
interaction with the purine-rich stretch of the ADAM10 5`UTR.  Therefore, it will be 
important to proof their binding capabilities and to analyse their effect on the translation of 
ADAM10.  Future studies, similar to the ones performed for Unr, are required to analyse 
the relevance of the RNA-binding proteins in more detail. 
In general, this study supports the notion that RNA-binding proteins of the 5`UTR can 
control translation and in particular begins to provide a molecular basis for translational 
regulation of ADAM10.  Further investigations are necessary to positively identify the 
exact mechanism of the RNA-binding proteins interacting with the 5`UTR.  Identification 
of the functions of these proteins may lead to a greater understanding of translational 
regulation of ADAM10 and eventually to the development of novel drug targets in the 
treatment of AD. 
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6 Appendix 
Function /Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
Protein synthesis (4) eEF1a1 185 50 kDa 17, 18 
 eEF1a2 107 51 kDa 17 
 eIF2a 139 36 kDa 20 
 eIF2b 220 39 kDa 17 
hnRNP(4) hnRNP K 110 51 kDa 18, 19, 1 
 hnRNP E1 304 38 kDa 19, 20 
 hnRNP E2 288 39 kDa 19 
 hnRNP U 202 91 kDa 9, 3/4, 1 
Other RNA associated (5) ILF2 115 43 kDa 19 
 ILF3 201 96 kDa 9 
 PA2G4 347 44 kDa 17 
 SFPQ 203 76 kDa 18 
 YBOX1 176 36 kDa 17 
tRNA synthetases (6) SYEP 569 165 kDa 1, 3/4 
 SYIC 794 146 kDa 1 
 SYLC 616 136 kDa 1, 3/4 
 SYMC 309 102 kDa 7, 6 
 SYQ 653 89 kDa 8 
 SYRC 179 76 kDa 1 
Cytoskeletal (6) Drebrin 1051 78 kDa 3/4, 5, 1, 7, 6, 8, 19, 9 
 LIMA1 125 86 kDa 9 
 Spectrin α chain 106 285 kDa 1 
 Septin-2 118 74 kDa 1, 19 
 Septin-7 169 64 kDa 17 
 TMOD3 191 40 kDa 19 
Other known proteins (2) LONM 641 107 kDa 6, 5 
 MCA1 331 35 kDa 20 
Appendix Table 6.1 Potential BACE1 5`UTR interacting proteins from cytosolic extract of 
HEK293E cells identified by mass spectrometry. 
Cytosolic extract of HEK293E cells was incubated with BACE1 5`UTR RNA. The RNA binding 
proteins were separated by gel electrophoresis, and 13 slices were analysed with mass 
spectrometry.  The proteins were subdivided in different categories according to their function.  For 
each identified protein the highest mascot score, the molecular weight and the lane(s), where the 
protein was identified, are listed.  The lane number marked in bold corresponds to the mascot 
score.  Only proteins with a mascot score higher than 100 were considered. 
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Function / Type (number) Protein name Mascot 
score 
Molecular 
weight (kDa) 
Lane 
Protein synthesis (2) eEF1a1 157 50 kDa 14 
 eEF1a2 157 51 kDa 14, 15 
hnRNP (4) hnRNP K 705 51 kDa 18 
 hnRNP E1 2294 38 kDa 11, 12, 13, 10, 6 
 hnRNP E2 1451 39 kDa 12, 11, 13, 10, 6, 9, 15, 16, 7 
 hnRNP E3 948 36 kDa 12, 11, 13 
Cytoskeletal (10) MAP2 5905 199 kDa 29, 30, 28, 31, 27 
 Drebrin 521 78 kDa 25 
 Tau 169 77 kDa 15, 14 
 Spectrin α chain 270 285 kDa 28 
 Synapsin-1 654 74 kDa 21, 20 
 Synapsin-2 183 64 kDa 17 
 DYHC1 981 534 kDa 29, 30 
 DYN1 616 98 kDa 23 
 DYN2 144 98 kDa 23 
 DYN3 148 98 kDa 23 
Other known proteins (3) EFHD2 244 27 kDa 7 
 FIBB 173 55 kDa 8 
 FIBG 174 50 kDa 8 
Appendix Table 6.2 Potential BACE1 5`UTR interacting proteins from cytosolic extract of 
P30 mice brains identified by mass spectrometry. 
Cytosolic extract of P30 mice brains was incubated with BACE1 5`UTR RNA. The RNA binding 
proteins were separated by gel electrophoresis, and 31 bands were analysed with mass 
spectrometry.  Only proteins with a mascot score higher than 100 were considered.  The proteins 
were subdivided in different categories according to their function.  For each identified protein the 
highest mascot score, the molecular weight and the lane(s), where the protein was identified, are 
listed.  The lane number marked in bold corresponds to the mascot score 
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Appendix Figure 6.1 Unr peptides from HEK293E cytosolic extract found by mass spectrometry. 
Start – End: amino acid number of the peptide in the protein sequence.  Observed: experimental mass number / charge number (m/z) value.  Mr(expt): experimental 
m/z transformed to a relative molecular mass.  Mr(calc): relative molecular mass calculated from the matched peptide sequence.  ppm: difference (error) between the 
experimental and calculated masses. Miss: Number of missed cleavage sites.  Sequence: identified peptide sequence.  The point shows the cleavage site.  Ion score: 
the ions score for an MS/MS match is based on the calculated probability, P, that the observed match between the experimental data and the database sequence is a 
random event. The reported score is -10Log(P). 
 
 
Start – End Observed Mr(expt) Mr(calc)  ppm Miss Sequence   Ion score 
  65 – 78  805.3696   1608.7246   1608.7380          -8      1   K.VGDDVEFEVSSDRR.T    12 
  90 – 99  627.8517   1253.6889   1253.6979          -7      1   K.IKQEILPEER.M    40 
195 – 202  484.7464    967.4782    967.4763            2      0   K.EAFGFIER.G    30 
208 – 217  673.8214   1345.6283   1345.6343         -4      0   K.EIFFHYSEFK.G   16 
218 – 234  938.9553   1875.8961   1875.9102          -8      0   K.GDLETLQPGDDVEFTIK.D 11 
247 – 269  858.4576   2572.3509   2572.3425           3      0   R.LLPQGTVIFEDISIEHFEGTVTK.V   12 
287 – 295  529.8392   1057.6639   1057.6536          10     1   R.IKVDFVIPK.E     46 
308 – 317  569.8107   1137.6068   1137.6142          -7      0   K.VTLLEGDHVR.F    44 
318 – 325  504.7607   1007.5068   1007.5148          -8      1   R.FNISTDRR.D     19 
331 - 348     1028.0024   2053.9903   2054.0069          -8      0   R.ATNIEVLSNTFQFTNEAR.E   52 
519 - 527      489.3065    976.5985    976.5957           3      0   R.LLGYVATLK.D    15 
601 - 606      377.2598    752.5051    752.5021            4      0   K.VIRPLR.S    9 
683 - 696      809.8669   1617.7192   1617.7311          -7      0   K.DQFGFINYEVGDSK.K    28 
759 - 769     586.7951   1171.5756  1171.5833         -7     0  K.NITLDDASAPR.L 68
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Start – End Observed Mr(expt) Mr(calc)  ppm Miss  Sequence   Ion Score 
33 – 45  787.3870  1572.7594 1572.7606 -1 0 K.LLTSYGFIQCSER.Q  70 
65 – 77  727.3258  1452.6370 1452.6369            0      0 K.VGDDVEFEVSSDR.R    56 
65 – 77  727.3262   1452.6378   1452.6369            1     0   K.VGDDVEFEVSSDR.R    36 
65 - 77      727.3264   1452.6382   1452.6369            1      0   K.VGDDVEFEVSSDR.R    63 
65 - 78       537.2531   1608.7375   1608.7380          -0      1   K.VGDDVEFEVSSDRR.T    16 
65 - 78       537.2532   1608.7378   1608.7380          -0      1   K.VGDDVEFEVSSDRR.T    37 
65 - 78       805.3762   1608.7378   1608.7380          -0     1   K.VGDDVEFEVSSDRR.T    17 
65 - 78       805.3764   1608.7382   1608.7380           0      1   K.VGDDVEFEVSSDRR.T    11 
65 - 78       537.2534   1608.7384   1608.7380            0      1   K.VGDDVEFEVSSDRR.T    42 
65 - 78       805.3777   1608.7408   1608.7380            2      1   K.VGDDVEFEVSSDRR.T    17 
79 - 86       414.2715   826.5284    826.5276            1      0   R.TGKPIAIK.L    24 
90 - 99       416.5660   1246.6762   1246.6669            7      0   K.IKPEIHPEER.M    17 
158 - 166      538.7904   1075.5662   1075.5662           0      0   K.INFVIDNNK.H     40 
167 - 174      399.7144   797.4142    797.4144          -0      0   K.HTGAVSAR.N    10 
167 - 174      399.7146   797.4146    797.4144            0      0   K.HTGAVSAR.N    17 
175 - 180      366.2274   730.4402   730.4411          -1      0   R.NIMLLK.K    6 
175 - 180      366.2279   730.4412   730.4411            0      0   R.NIMLLK.K    17 
175 - 180      366.2280   730.4414   730.4411            0      0   R.NIMLLK.K    8 
175 - 180      374.2253   746.4360   746.4360            0      0   R.NIMLLK.K Oxidation (M)  23 
175 - 180      374.2255   746.4364   746.4360            1      0   R.NIMLLK.K Oxidation (M)  22 
175 - 180      374.2256    746.4366   746.4360            1      0   R.NIMLLK.K Oxidation (M)   26 
175 - 180      374.2258    746.4370    746.4360            1      0   R.NIMLLK.K Oxidation (M)   17 
195 - 202      484.7450    967.4754    967.4763          -1      0   K.EAFGFIER.G    26 
195 - 202      484.7451    967.4756    967.4763          -1      0   K.EAFGFIER.G    24 
195 - 202      484.7458    967.4770    967.4763            1      0   K.EAFGFIER.G    27 
195 - 202      484.7460    967.4774    967.4763            1      0   K.EAFGFIER.G    33 
218 - 236      716.6857   2147.0353   2147.0383          -1      1   K.GDLETLQPGDDVEFTIKDR.N 12 
237 - 246      544.7883   1087.5620   1087.5622          -0      1   R.NGKEVATDVR.L    23 
278 - 286      505.7532   1009.4918   1009.4941          -2      0   K.NQNDPLPGR.I     26 
278 - 286      505.7541   1009.4936   1009.4941         -0      0   K.NQNDPLPGR.I     15 
278 - 286      505.7542   1009.4938   1009.4941          -0      0   K.NQNDPLPGR.I     38 
278 - 286      505.7546   1009.4946   1009.4941            1      0   K.NQNDPLPGR.I     25 
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Start – End Observed Mr(expt) Mr(calc)  ppm Miss  Sequence   Ion Score 
287 - 295      353.5583   1057.6531   1057.6536          -0      1   R.IKVDFVIPK.E     37 
287 - 295      529.8340   1057.6534   1057.6536         -0      1   R.IKVDFVIPK.E     25 
287 - 295      529.8340   1057.6534   1057.6536          -0      1   R.IKVDFVIPK.E     59 
287 - 295      353.5585   1057.6537   1057.6536            0      1   R.IKVDFVIPK.E     31 
287 - 295      353.5589   1057.6549   1057.6536            1      1   R.IKVDFVIPK.E     28 
287 - 295      529.8348   1057.6550   1057.6536            1      1   R.IKVDFVIPK.E     28 
296 - 305      575.2932   1148.5718   1148.5713            0      1   K.ELPFGDKDTK.S    6 
296 - 305      575.2944   1148.5742   1148.5713            3      1   K.ELPFGDKDTK.S    17 
306 - 317      451.9200   1352.7382   1352.7412          -2      1   K.SKVTLLEGDHVR.F    38 
306 - 317      451.9207   1352.7403   1352.7412          -1      1   K.SKVTLLEGDHVR.F    41 
308 - 317      380.2118   1137.6136   1137.6142          -1      0   K.VTLLEGDHVR.F    28 
308 - 317      569.8143   1137.6140   1137.6142          -0      0   K.VTLLEGDHVR.F    36 
308 - 317      569.8144   1137.6142   1137.6142            0      0   K.VTLLEGDHVR.F    20 
308 - 317      569.8144   1137.6142   1137.6142            0      0   K.VTLLEGDHVR.F    26 
308 - 317      380.2121   1137.6145   1137.6142            0      0   K.VTLLEGDHVR.F    24 
308 - 317      380.2123   1137.6151   1137.6142            1      0   K.VTLLEGDHVR.F    20 
308 - 317     380.2124   1137.6154   1137.6142            1      0   K.VTLLEGDHVR.F    22 
318 - 324      426.7135    851.4124    851.4137          -2      0   R.FNISTDR.R   32 
318 - 324      426.7140    851.4134    851.4137          -0      0   R.FNISTDR.R    17 
318 - 325      04.7645    1007.5144   1007.5148          -0      1   R.FNISTDRR.D     4 
318 - 325      504.7647   1007.5148   1007.5148            0      1   R.FNISTDRR.D     16 
318 - 325      336.8456   1007.5150   1007.5148            0      1   R.FNISTDRR.D     15 
318 - 325      504.7652   1007.5158   1007.5148            1      1   R.FNISTDRR.D     10 
349 - 357      489.2487    976.4828    976.4834          -1      0   R.EMGVIAAMR.D   10 
349 - 357      489.2491    976.4836    976.4834            0      0   R.EMGVIAAMR.D   20 
349 - 357      489.2491    976.4836    976.4834            0      0   R.EMGVIAAMR.D   18 
349 - 357      497.2466    992.4786    992.4783            0      0   R.EMGVIAAMR.D Oxidation (M)  36 
349 - 357      497.2466    992.4786    992.4783            0      0   R.EMGVIAAMR.D Oxidation (M) 30 
349 - 357      497.2466    992.4786    992.4783            0      0   R.EMGVIAAMR.D Oxidation (M) 23 
349 - 357      505.2438   1008.4730   1008.4732          -0      0   R.EMGVIAAMR.D  2 Oxidation (M) 17 
358 - 364      392.2054    782.3962    782.3963          -0      0   R.DGFGFIK.C   36 
358 - 364      392.2055    782.3964    782.3963            0      0   R.DGFGFIK.C    29 
358 - 364      392.2057    782.3968    782.3963             1      0   R.DGFGFIK.C   16 
358 - 364      392.2059    782.3972    782.3963            1      0   R.DGFGFIK.C   21 
358 - 364      392.2062    782.3978    782.3963            2      0   R.DGFGFIK.C   41 
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Start – End Observed Mr(expt) Mr(calc)  ppm Miss  Sequence   Ion Score 
416 - 427      456.2130   1365.6172   1365.6174           -0      0   K.GTVSFHSHSDHR.F    2 
416 - 427      456.2131   1365.6175   1365.6174            0      0   K.GTVSFHSHSDHR.F    8 
428 - 434      397.2259    792.4372    792.4382          -1      0   R.FLGTVEK.E    11 
428 - 434      397.2263    792.4380    792.4382          -0      0   R.FLGTVEK.E   20 
428 - 434      397.2264    792.4382    792.4382            0      0   R.FLGTVEK.E   12 
428 - 434      397.2265    792.4384    792.4382            0      0   R.FLGTVEK.E   34 
428 - 434      397.2266    792.4386    792.4382            1      0   R.FLGTVEK.E   12 
428 - 434      397.2272    792.4398    792.4382            2      0   R.FLGTVEK.E   19 
428 - 434      397.2277    792.4408    792.4382            3      0   R.FLGTVEK.E   9 
428 - 442      556.6257   1666.8553   1666.8566          -1      1   R.FLGTVEKEATFSNPK.T    7 
435 - 442      447.2216    892.4286    892.4290          -0      0   K.EATFSNPK.T   10 
435 - 442      447.2218    892.4290    892.4290            0      0   K.EATFSNPK.T   24 
435 - 442      447.2218    892.4290    892.4290            0      0   K.EATFSNPK.T   8 
435 - 442      447.2220    892.4294    892.4290            0      0   K.EATFSNPK.T   14 
468 - 475      446.2682    890.5218    890.5225          -1      0   K.LTIAFQAK.D   17 
468 - 475      446.2684    890.5222    890.5225          -0      0   K.LTIAFQAK.D   26 
468 - 475      446.2687    890.5228    890.5225            0      0   K.LTIAFQAK.D    17 
476 - 488      666.8168   1331.6190   1331.6205          -1      0   K.DVEGSTSPQIGDK.V    90 
476 - 488      666.8174   1331.6202   1331.6205          -0      0   K.DVEGSTSPQIGDK.V    53 
476 - 488      666.8176   1331.6206   1331.6205            0      0   K.DVEGSTSPQIGDK.V    60 
476 - 488      666.8180   1331.6214   1331.6205            1      0   K.DVEGSTSPQIGDK.V    56 
476 - 496      746.6976   2237.0710   2237.0699            0      1   K.DVEGSTSPQIGDKVEFSISDK.Q   13 
476 - 496      746.6979   2237.0719   2237.0699            1      1   K.DVEGSTSPQIGDKVEFSISDK.Q   23 
497 - 508      471.9176   1412.7310   1412.7307            0      0   K.QRPGQQIATCVR.L    18 
497 - 508      471.9176   1412.7310   1412.7307            0      0   K.QRPGQQIATCVR.L    16 
497 - 508      707.3730   1412.7314   1412.7307            1      0   K.QRPGQQIATCVR.L    10 
519 - 527      489.3045    976.5944    976.5957          -1      0   R.LLGYVATLK.D   11 
519 - 527      489.3049    976.5952    976.5957          -0      0   R.LLGYVATLK.D   22 
519 - 527      489.3051    976.5956    976.5957          -0      0   R.LLGYVATLK.D   44 
519 - 527     489.3056    976.5966    976.5957            1      0   R.LLGYVATLK.D   47 
601 - 606      377.2585    752.5024    752.5021           0      0   K.VIRPLR.G   9 
601 - 606      377.2585    752.5024    752.5021           0      0   K.VIRPLR.G   8 
629 - 642      749.3750   1496.7354   1496.7334           1      0   K.GEVYPFGIVGMANK.G  (M) 22 
683 - 696      809.8754   1617.7362   1617.7311           3      0   K.DQFGFINYEVGDSK.K    54 
683 - 696      809.8787   1617.7428   1617.7311           7      0   K.DQFGFINYEVGDSK.K    62 
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Appendix Figure 6.2 Unr peptides from mouse brain cytosolic extract found by mass spectrometry. 
Start – End: amino acid number of the peptide in the protein sequence.  Observed: experimental mass number / charge number (m/z) value.  Mr(expt): experimental 
m/z transformed to a relative molecular mass.  Mr(calc): relative molecular mass calculated from the matched peptide sequence.  ppm: difference (error) between the 
experimental and calculated masses. Miss: Number of missed cleavage sites.  Sequence: identified peptide sequence.  The point shows the cleavage site.  Ion score: 
the ions score for an MS/MS match is based on the calculated probability, P, that the observed match between the experimental data and the database sequence is a 
random event. The reported score is -10Log(P) 
Start – End Observed Mr(expt) Mr(calc)  ppm Miss  Sequence   Ion Score 
698 - 703      395.7344    789.4542    789.4538           1     0   K.LFFHVK.E   6 
698 - 703      395.7346    789.4546    789.4538           1      0   K.LFFHVK.E   9 
744 - 752      318.1821    951.5245    951.5250           -1      0   K.AVAAPRPDR.L   12 
744 - 752      476.7696    951.5246    951.5250          -0      0   K.AVAAPRPDR.L   36 
744 - 752      476.7697    951.5248    951.5250          -0      0   K.AVAAPRPDR.L   11 
744 - 752      476.7698    951.5250    951.5250           0      0   K.AVAAPRPDR.L   19 
744 - 752      476.7699    951.5252    951.5250           0      0   K.AVAAPRPDR.L   16 
744 - 752      318.1824    951.5254    951.5250           0      0   K.AVAAPRPDR.L   17 
744 - 752      318.1824    951.5254    951.5250           0      0   K.AVAAPRPDR.L   19 
744 - 752      318.1824    951.5254    951.5250           0      0   K.AVAAPRPDR.L   12 
757 - 769      471.9278   1412.7616   1412.7623          -1      1   R.LKNITLDDASAPR.L    38 
757 - 769      471.9281   1412.7625   1412.7623           0      1   R.LKNITLDDASAPR.L    42 
757 - 769      471.9282   1412.7628   1412.7623           0      1   R.LKNITLDDASAPR.L    39 
757 - 769      707.3889   1412.7632   1412.7623           1      1   R.LKNITLDDASAPR.L    31 
757 - 769      707.3891   1412.7636   1412.7623           1      1   R.LKNITLDDASAPR.L    38 
759 - 769      586.7985   1171.5824   1171.5833          -1      0   K.NITLDDASAPR.L    25 
759 - 769      586.7991   1171.5836   1171.5833           0      0   K.NITLDDASAPR.L    51 
759 - 769      586.7999   1171.5852   1171.5833           2      0   K.NITLDDASAPR.L    57 
759 - 769      586.7999   1171.5852   1171.5833           2      0   K.NITLDDASAPR.L    39 
759 - 769      586.8008   1171.5870   1171.5833           3      0   K.NITLDDASAPR.L    56 
770 - 774      316.2017    630.3888    630.3887           0      0   R.LMVLR.Q   19 
770 - 774      316.2021    630.3896    630.3887           2      0   R.LMVLR.Q   12 
770 - 774      324.1990    646.3834    646.3836          -0      0   R.LMVLR.Q Oxidation (M)  20 
770 - 774      324.1992    646.3838    646.3836           0      0   R.LMVLR.Q Oxidation (M)  26 
778 - 789      619.2672   1236.5198   1236.5193           0      0   R.GPDNSMGFGAER.K    44 
778 - 789      619.2679   1236.5212   1236.5193           2      0   R.GPDNSMGFGAER.K    31 
778 - 789      627.2643   1252.5140   1252.5143          -0      0   R.GPDNSMGFGAER.K  (M)  64 
778 - 789      627.2646   1252.5146   1252.5143           0      0   R.GPDNSMGFGAER.K  (M)  56 
778 - 789      627.2650   1252.5154   1252.5143           1      0   R.GPDNSMGFGAER.K  (M)  46 
778 - 789      627.2661   1252.5176   1252.5143           3      0   R.GPDNSMGFGAER.K  (M)   49 
791 - 798      436.2534    870.4922    870.4923          -0      1   K.IRQAGVID.-     0 
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